Gabriel N. Hortobagyi, M.D., FACP

Peer-Reviewed Articles

1. Pusztai L, Hoag JR, Albain KS, Barlow WE, Stemmer SM, Meisner A, Hortobagyi GN, Shak S, Rae JM, Baehner R, Sharma P, Kalinsky KM. Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer. J Clin Oncol:JCO2401507, 2024. e-Pub 2024. PMID: 39621968.
2. Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Hortobagyi GN, Pusztai L, Kalinsky K. Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial. J Natl Cancer Inst, 2024. e-Pub 2024. PMID: 39656951.
3. Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol, 2024. e-Pub 2024. PMID: 39442617.
4. Yam C, Patel M, Hill HA, Sun R, Bassett RL, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the EGFR Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer – A Phase II Study 4(10):2823-2834. e-Pub 2024. PMID: 39356138.
5. Tarantino P, Hortobagyi G, Tolaney SM, Mittendorf EA. Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review. JAMA Oncol 10(11):1578-1584. e-Pub 2024. PMID: 39264638.
6. Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopoulou E, Wendt AG, Carney JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy +/- 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer. J Clin Oncol 42(25):3012-3021, 2024. e-Pub 2024. PMID: 38833643.
7. Chen CS, Zirpoli G, Budd GT, Barlow WE, Pusztai L, Hortobagyi GN, Albain KS, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, Hertz DL. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy +/- 1 Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive, Early-Stage Breast Cancer. J Clin Oncol 42(25):3012-3021, 2024. e-Pub 2024. PMID: 38814643.
8. Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Razaq W, O’Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopoulou E, Wendt AG, Carney JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy +/- 1 Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive, Early-Stage Breast Cancer. J Clin Oncol 42(25):3012-3021. e-Pub 2024.
9. Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G. Ribociclib Plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 390(23):2221-2222, 2024. e-Pub 2024. PMID: 38507751.
10. Conforti F, Pala L, De Pas T, Zattarin E, Catania C, Cocorocchio E, Rossi G, Laszlo D, Colleoni M, Zambelli A, Hortobagyi GN, Cortes J, Piccart MJ, Dowsett M, Gelber RD, Viale G. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. Clin Cancer Res 30(6):1093-1103, 2024. e-Pub 2024. PMID: 37906083.
11. Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Razaq W, O’Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopoulou E, Baar J, Wendt AG, Carney JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. Results from a Phase III Randomized, Placebo-controlled Clinical Trial Evaluating Adjuvant Endocrine Therapy. Journal of Clinical Oncology (Oral presentation), 2024. e-Pub 2024.
12. Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R, Schwartzberg L, Broder MS. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ Breast Cancer 10(1):12, 2024. e-Pub 2024. PMID: 38297009.
13. Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Bertucci F, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz C. Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun 4(1):236, 2024. e-Pub 2024. PMID: 38282551.
14. Chen CS, Zirpoli G, Barlow WE, Budd GT, McKiver B, Pusztai L, Hortobagyi GN, Albain KS, Damaj MI, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, Hertz DL. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. J Natl Compr Canc Netw 21(11):1172-1180.e3, 2023. e-Pub 2023. PMID: 37935109.
15. André F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, Bardia A, Tripathy D, Lu YS, Lteif A, Taran T, Babbar N, Slamon D, Arteaga CL. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol. e-Pub 2023. PMID: 37673211.
16. Chen CS, Zirpoli G, Thomas Budd G, Barlow WE, Pusztai L, Hortobagyi GN, Albain KS, Godwin AK, Thompson A, Lynn Henry N, Ambrosone CB, Stringer KA, Hertz DL. Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221. Res Sq 21(11):1172-1180, 2023. e-Pub 2023. PMID: 37693586.
17. Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Logan GE, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes DF, Sharma P. Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. JCO Precis Oncol 7:e2300197, 2023. e-Pub 2023. PMID: 37972336.
18. Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, Layman RM. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer 191:113250, 2023. e-Pub 2023. PMID: 37573674.
19. Rutherford DV, Medley S, Henderson NC, Gersch CL, Vandenberg TA, Albain KS, Dakhil SR, Tirumali NR, Gralow JR, Hortobagyi GN, Pusztai L, Mehta RS, Hayes DF, Kidwell KM, Henry NL, Barlow WE, Rae JM, Hertz DL. Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226. Pharmacogenomics 24(12):665-673, 2023. e-Pub 2023. PMID: 37615099.
20. Jagsi R, Barlow WE, Woodward WA, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein SR, Zeidan Y, Zhang H, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncol 9(8):1083-1089, 2023. e-Pub 2023. PMID: 37410451.
21. Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]. Ann Oncol 34(7):630, 2023. e-Pub 2023. PMID: 36564285.
22. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
23. Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz C. Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun 3(6):1078-1092, 2023. e-Pub 2023. PMID: 37377604.
24. Fanucci KA, Bai Y, Pelekanou V, Nahleh ZA, Shafi S, Burela S, Barlow WE, Sharma P, Thompson AM, Godwin AK, Rimm DL, Hortobagyi GN, Liu Y, Wang L, Wei W, Pusztai L, Blenman KRM. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. NPJ Breast Cancer 9(1):38, 2023. e-Pub 2023. PMID: 37179362.
25. Plichta JK, Thomas SM, Hayes DF, Chavez-MacGregor M, Allison K, de Los Santos J, Fowler AM, Giuliano AE, Sharma P, Smith BD, van Eycken E, Edge SB, Hortobagyi GN. Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer. J Clin Oncol 41(14):2546-2560, 2023. e-Pub 2023. PMID: 36944149.
26. Cannioto RA, Attwood KM, Davis EW, Mendicino LA, Hutson A, Zirpoli GR, Tang L, Nair NM, Barlow W, Hershman DL, Unger JM, Moore HCF, Isaacs C, Hobday TJ, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. JAMA Netw Open 6(5):e2311673, 2023. e-Pub 2023. PMID: 37140922.
27. Bergqvist M, Nordmark A, Williams A, Paoletti C, Barlow W, Cobain EF, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Thymidine kinase activity levels in serum can identify HR+?metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Biomarkers 28(3):1-10, 2023. e-Pub 2023. PMID: 36647745.
28. Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol 41(10):JCO2201499, 2023. e-Pub 2023. PMID: 36649570.
29. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol 41(10):1809-1815, 2023. e-Pub 2023. PMID: 36989609.
30. Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol 9(2):197-205, 2023. e-Pub 2023. PMID: 36454580.
31. Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 24(2):162-174, 2023. e-Pub 2023. PMID: 36623515.
32. Nanou A, Miao J, Coumans FAW, Dolce EM, Darga E, Barlow W, Smerage JB, Paoletti C, Godwin AK, Pusztai L, Sharma P, Thompson A, Hortobagyi GN, LWMM T, Hayes DF. Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. JCO Precis Oncol 7:e2200372, 2023. e-Pub 2023. PMID: 36634296.
33. Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib?+?endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol 15:17588359231178125, 2023. e-Pub 2023. PMID: 37275963.
34. Wang YN, Lee HH, Jiang Z, Chan LC, Hortobagyi GN, Yu D, Hung MC. Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation. Int J Biol Sci 19(10):2957-2973, 2023. e-Pub 2023. PMID: 37416781.
35. Kantor O, Burstein HJ, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Winer EP, Korde LA, Sparano JA, Mittendorf EA. ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol 29(13):8024-8025, 2022. e-Pub 2022. PMID: 35902504.
36. Kantor O, Burstein HJ, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Winer EP, Korde LA, Sparano JA, Mittendorf EA. Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol 29(13):8016-8023, 2022. e-Pub 2022. PMID: 35900648.
37. Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, Cortes J, Piccart M, Wolff AC, Viale G, Gelber RD. Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations. JAMA Oncol 8(11):1668-75, 2022. e-Pub 2022. PMID: 36201176.
38. Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-27, 2022. e-Pub 2022. PMID: 36253486.
39. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
40. Cha JH, Chan LC, Wang YN, Chu YY, Wang CH, Lee HH, Xia W, Shyu WC, Liu SP, Yao J, Chang CW, Cheng FR, Liu J, Lim SO, Hsu JL, Yang WH, Hortobagyi GN, Lin C, Yang L, Yu D, Jeng LB, Hung MC. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem 298(4):101817, 2022. e-Pub 2022. PMID: 35278434.
41. Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol 33(3):321-329, 2022. e-Pub 2022. PMID: 34954044.
42. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 386(10):942-950, 2022. e-Pub 2022. PMID: 35263519.
43. Moore HCF, Barlow WE, Somlo G, Gralow JR, Schott AF, Hayes DF, Kuhn P, Hicks JB, Welter L, Dy PA, Yeon CH, Conlin AK, Balcueva E, Lew DL, Tripathy D, Pusztai L, Hortobagyi GN. A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. Clin Cancer Res 28(4):611-617, 2022. e-Pub 2022. PMID: 34844978.
44. Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Reply to A. Pfob and C. Sidey-Gibbons. JCO Clin Cancer Inform 6:e2100171, 2022. e-Pub 2022. PMID: 35175860.
45. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 385(25):2336-2347, 2021. e-Pub 2021. PMID: 34914339.
46. Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst 113(12):1744-1750, 2021. e-Pub 2021. PMID: 34010423.
47. Damodaran S, Hortobagyi GN. Estrogen Receptor: A Paradigm for Targeted Therapy. Cancer Res 81(21):5396-5398, 2021. e-Pub 2021. PMID: 34725132.
48. Paoletti C, Barlow WE, Cobain EF, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial. Clin Cancer Res 27(22):6115-6123, 2021. e-Pub 2021. PMID: 34521624.
49. He X, Ji J, Dai X, Qdaisat AZ, Esteva FJ, Hortobagyi GN, Yeung SJ. Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. Clin Cancer Res 27(19):5343-5352, 2021. e-Pub 2021. PMID: 34117035.
50. Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
51. Weng JK, Lei X, Schlembach P, Bloom ES, Shaitelman SF, Arzu IY, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys 111(2):360-370, 2021. e-Pub 2021. PMID: 33992718.
52. Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clin Cancer Inform 5:789-804, 2021. e-Pub 2021. PMID: 34351787.
53. Staquicini FI, Hajitou A, Driessen WH, Proneth B, Cardó-Vila M, Staquicini DI, Markosian C, Hoh M, Cortez M, Hooda-Nehra A, Jaloudi M, Silva IT, Buttura J, Nunes DN, Dias-Neto E, Eckhardt B, Ruiz-Ramírez J, Dogra P, Wang Z, Cristini V, Trepel M, Anderson R, Sidman RL, Gelovani JG, Cristofanilli M, Hortobagyi GN, Bhujwalla ZM, Burley SK, Arap W, Pasqualini R. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. Elife 10, 2021. e-Pub 2021. PMID: 34060472.
54. Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, Hsu JL, Shen J, Ye Y, Wu X, Hou MF, Tseng LM, Wang SC, Pan MR, Yang CH, Wang YL, Yamaguchi H, Pang D, Hortobagyi GN, Yu D, Hung MC. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun 12(1):2788, 2021. e-Pub 2021. PMID: 33986289.
55. Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow WE, Hortobagyi GN, Gralow JR. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer 29(5):2509-2517, 2021. e-Pub 2021. PMID: 32929540.
56. Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, Hsu JM, Chan LC, Hortobagyi GN, Yang L, Lin C, Yu D, Hung MC. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest 131(8), 2021. e-Pub 2021. PMID: 33855973.
57. George B, Pillai PM, Paul AM, Amjesh R, Leitzel K, Ali SM, Sandiford O, Lipton A, Rameshwar P, Hortobagyi GN, Pillai MR, Kumar R. Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics. Cells 10(2), 2021. e-Pub 2021. PMID: 33670680.
58. Cannioto RA, Hutson A, Dighe S, McCann W, McCann SE, Zirpoli GR, Barlow W, Kelly KM, DeNysschen CA, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. J Natl Cancer Inst 113(1):54-63, 2021. e-Pub 2021. PMID: 32239145.
59. Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel) 12(11), 2020. e-Pub 2020. PMID: 33114311.
60. de Melo Gagliato D, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, Chavez-MacGregor M. Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. Oncologist 25(9):749-757, 2020. e-Pub 2020. PMID: 32431013.
61. Hortobagyi GN. Breast Cancer: 45 Years of Research and Progress. J Clin Oncol 38(21):JCO2000199, 2020. e-Pub 2020. PMID: 32255711.
62. Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst 112(7):698-707, 2020. e-Pub 2020. PMID: 31693129.
63. Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, Kelly KM, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol 38(8):JCO1901203, 2020. e-Pub 2020. PMID: 31855498.
64. Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 9(3):1025-1032, 2020. e-Pub 2020. PMID: 31849202.
65. Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, Huo L, Ko HW, Lin WC, Yamaguchi H, Hsu JM, Yang Y, Pan DN, Hsu JL, Kleer CG, Davidson NE, Hortobagyi GN, Hung MC. Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun 11(1):673, 2020. e-Pub 2020. PMID: 31996688.
66. Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncol. e-Pub 2020. PMID: 31917424.
67. Hortobágyi GN. Bernard Fisher: A Pioneer Moves On. Oncologist 25(1):89-90, 2020. e-Pub 2020. PMID: 31943569.
68. Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res 10(2):648-661, 2020. e-Pub 2020. PMID: 32195033.
69. Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Hess KR, Barcenas CH, Valero V, Carlson RW, Tripathy D, Hortobagyi GN. Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer 6:11, 2020. e-Pub 2020. PMID: 32219153.
70. Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. J Clin Oncol 37(36):3484-3492, 2019. e-Pub 2019. PMID: 31657982.
71. He X, Ji J, Tian M, Esteva FJ, Hortobagyi GN, Yeung SJ. Long-term survival analysis of adjuvant chemotherapy with or without trastuzumab in patients with T1, node-negative HER2-positive breast cancer. Clin Cancer Res 25(24):7388-7395, 2019. e-Pub 2019. PMID: 31515457.
72. Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, Huo L, Ko HW, Lin WC, Yamaguchi H, Hsu JM, Yang Y, Pan DN, Hsu JL, Kleer CG, Davidson NE, Hortobagyi GN, Hung MC. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun 10(1):5114, 2019. e-Pub 2019. PMID: 31704972.
73. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 30(11):1842, 2019. e-Pub 2019. PMID: 31407010.
74. El-Saghir N, Aderson BO, Gralow JR, Lopes G, Shulman LN, Yu PP, Hortobagyi GN. Impact of Merit-based Immigration Policies on “Brain Drain” from Low and Middle Income Countries. J Global Oncol, 2019. e-Pub 2019.
75. Paoletti C, Miao J, Dolce EM, Darga EP, Repollet MI, Doyle GV, Gralow JR, Hortobagyi GN, Smerage JB, Barlow WE, Hayes DF. Circulating Tumor Cell Clusters in Metastatic Breast Cancer Patients: a SWOG S0500 Translational Medicine Study. Clin Cancer Res 25(20):6089-6097, 2019. e-Pub 2019. PMID: 31358544.
76. Woodward WA, Barlow WE, Jagsi R, Buchholtz TA, Shak S, Baehner F, Yoshizawa CN, Whelan TJ, Davisdon NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814. JAMA, 2019. e-Pub 2019.
77. Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. Clin Breast Cancer 19(4):225-235.e2, 2019. e-Pub 2019. PMID: 30928413.
78. Yardley DA, Hart L, Favret A, Blau S, Diab S, Richards D, Sparano J, Beck JT, Richards P, Ward P, Ramaswamy B, Tsai M, Blackwell K, Pluard T, Tolaney SM, Esteva FJ, Truica CI, Alemany C, Volas-Redd G, Shtivelband M, Purkayastha D, Dalal AA, Miller M, Hortobagyi GN. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. Clin Breast Cancer 19(4):268-277.e1, 2019. e-Pub 2019. PMID: 31160171.
79. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 2019. e-Pub 2019. PMID: 31277699.
80. Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol 20(7):835-851, 2019. e-Pub 2019. PMID: 31160797.
81. Prat A, Brase JC, Cheng Y, Nuciforo P, Paré L, Pascual T, Martínez D, Galván P, Vidal M, Adamo B, Hortobagyi GN, Baselga J, Ciruelos E. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. Oncologist 24(7):893-900, 2019. e-Pub 2019. PMID: 30679318.
82. Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts anti-PD-1/PDL1 Therapeutic Efficacy. Cancer Cell. e-Pub 2019. PMID: 31327656.
83. Paoletti C, Miao J, Dolce EM, Darga EP, Repollet M, Doyle GV, Gralow JJ, Hortobagyi GN, Smerage JB, Barlow WE, Hayes DF. Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer Starting First Line Chemotherapy: A Correlative Study of SWOG Study S0500. Clin Cancer Res, 2019. e-Pub 2019.
84. Xing Y, Lin NU, Mauer MA, Chen H, Mahvash A, Sahin AA, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-McGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall DL, Eterovioc AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer ES, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Berstam F. Phase II Trial of AKT Inhibitor MK2206 in Patients with Advanced Breast Cancer Who Have Tumors with PIK3CA or AKT Mutations, and/or PTEN Loss/PTEN Mutation. Breast Cancer Res, 2019. e-Pub 2019.
85. Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA. Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol. e-Pub 2019. PMID: 30973611.
86. Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh ZA, Hayes DF, Hortobagyi GN, Barlow WE, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. J Immunother Cancer 7(1):88, 2019. e-Pub 2019. PMID: 30967156.
87. Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs 37(2):345-351, 2019. e-Pub 2019. PMID: 30610588.
88. Edge SB, Hortobagyi GN, Giuliano AE. New and important changes in breast cancer TNM: incorporation of biologic factors into staging. Expert Rev Anticancer Ther 19(4):1-10, 2019. e-Pub 2019. PMID: 30759347.
89. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. N Engl J Med 380(13):1226-1234, 2019. e-Pub 2019. PMID: 30917258.
90. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst 111(2):210-213, 2019. e-Pub 2019. PMID: 30371800.
91. Hortobagyi GN, Zheng M, Mohanlal R. Indirect Evaluation of Bone Saturation With Zoledronic Acid After Long-Term Dosing. Oncologist 24(2):178-184, 2019. e-Pub 2019. PMID: 30297386.
92. Hart Y, Vavret A, Blau S, Diab S, Richards D, Sparano J, Beck JT, Richards P, Ward P, Ramaswamy B, Tsai M, Blackwell K, Pluard T, Tolaney S, Esteva F, Tan-Chiu E, Truicia C, Alemany C, Volas RD, Shtivelband M, Tk S, Purkayastha D, Delal AA, Miller M, Gb <. Efficacy and Safety of Ribociclib Plus Letrozole in US Patients Enrolled in the MONALEESA-2 Study. Clin Breast Cancer. e-Pub 2019.
93. Han Y, Chen MK, Wang HL, Hsu JL, Li CW, Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. Am J Cancer Res 9(3):608-618, 2019. e-Pub 2019. PMID: 30949414.
94. Kumar R, Murad F, Bogler O, O'Malley BW, Hortobagyi GN. John Mendelsohn: A visionary scientist, oncologist and leader. Genes Cancer 10(5-6):109-118, 2019. e-Pub 2019. PMID: 31798764.
95. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-beta. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
96. Mongiovi JM, Zirpoli GR, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Thomas Budd G, Albain KS, Ambrosone CB, McCann SE. Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20(1):146, 2018. e-Pub 2018. PMID: 30486865.
97. Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN. Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases. Oncologist 23(11):1282-1288, 2018. e-Pub 2018. PMID: 30120166.
98. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
99. Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, Buchholz D, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Amaya DN, Shen Y, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol 36(35):JCO1800317, 2018. e-Pub 2018. PMID: 30379626.
100. Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res 20(1):123, 2018. e-Pub 2018. PMID: 30340505.
101. Yam C, Hung MC, Hortobagyi GN. CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. Oncotarget 9(76):34193-34195, 2018. e-Pub 2018. PMID: 30344934.
102. Hortobagyi GN, Pyle D, Cazap EL, El Saghir NS, Shulman LN, Lyman GH, Schnipper LE, Adebamowo CA, Gandara DR, Vose J, Wong SL, Yu P. American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions. J Glob Oncol(4):1-8, 2018. e-Pub 2018. PMID: 30241187.
103. Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oko O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN. Three-Year Outcomes With Hypofractionated (HF) Versus Conventionally Fractionated (CF) Whole Breast Irradiation (WBI). J Clin Oncol, 2018. e-Pub 2018.
104. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomer HL, Vallejos CS, Partridge AH, Dakhil SR< Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Jr, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS). JNCI, 2018. e-Pub 2018.
105. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29(7):1541-1547, 2018. e-Pub 2018. PMID: 29718092.
106. Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol 25(7):1783-1785, 2018. e-Pub 2018. PMID: 29671136.
107. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer 124(11):2299-2305, 2018. e-Pub 2018. PMID: 29579338.
108. Pelekanou V, Barlow WE, Nahleh ZA, Wasserman B, Lo YC, von Wahlde MK, Hayes D, Hortobagyi GN, Gralow J, Tripathy D, Porter P, Szekely B, Hatzis C, Rimm DL, Pusztai L. Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial. Mol Cancer Ther 17(6):1324-1331, 2018. e-Pub 2018. PMID: 29588392.
109. Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN. Prognostic factors iin metastatic breast cancer patients with bone only metastases. The Oncologist, 2018. e-Pub 2018.
110. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A Phase II Study of Tipifarnib and Gemcitabine in Metastatic Breast Cancer. Invest New Drugs 36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
111. Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313). Ann Oncol 29(3):654-660, 2018. e-Pub 2018. PMID: 29293876.
112. Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncol 4(2):203-209, 2018. e-Pub 2018. PMID: 29222540.
113. Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. e-Pub 2018. PMID: 29470805.
114. Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics 28(2):49-55, 2018. e-Pub 2018. PMID: 29278617.
115. Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell 33(2):187-201.e10, 2018. e-Pub 2018. PMID: 29438695.
116. O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 168(1):127-134, 2018. e-Pub 2018. PMID: 29164421.
117. Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, Hortobagyi GN, Valero V. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118(1):17-23, 2018. e-Pub 2018. PMID: 29235566.
118. Hung MC, Yamaguchi H, Nakai K, Ding M, Chang SS, Hsu J, Wei Y, Nie L, Chang WC, Chen CH, Yu Y, Hortobagyi G, Du Y, Jiao S, Yao J. EZH2 Contributes to the Response to PARP Inibitors Through Its PARP Mediated Poly ADP Ribosylation in Breast Cancer. Oncogene 2017, 2018. e-Pub 2018.
119. Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene 37(2):208-217, 2018. e-Pub 2018. PMID: 28925391.
120. Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, Hortobagyi GN. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4:2, 2018. e-Pub 2018. PMID: 29387785.
121. Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS, Ambrosone CB. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study. J Natl Cancer Inst 109(12), 2017. e-Pub 2017. PMID: 29546345.
122. Masuda H, Qi Y, Liu S, Hayashi N, Kogawa T, Hortobagyi GN, Tripathy D, Ueno NT. Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. Oncotarget 8(41):70481-70495, 2017. e-Pub 2017. PMID: 29050296.
123. Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT. EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget 8(40):67904-67917, 2017. e-Pub 2017. PMID: 28978083.
124. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290-303, 2017. e-Pub 2017. PMID: 28294295.
125. Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol 3(7):906-912, 2017. e-Pub 2017. PMID: 28125763.
126. Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer 123(13):2422-2431, 2017. e-Pub 2017. PMID: 28199747.
127. Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat 164(1):57-67, 2017. e-Pub 2017. PMID: 28417335.
128. Whitman GJ, Hortobagyi GN. Ultrasound Molecular Imaging: A Good Start. J Clin Oncol 35(19):2101-2102, 2017. e-Pub 2017. PMID: 28498783.
129. Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN. Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. J Natl Cancer Inst 109(7), 2017. e-Pub 2017. PMID: 28376179.
130. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23(14):3711-3720, 2017. e-Pub 2017. PMID: 28167507.
131. Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res 23(12):2991-3002, 2017. e-Pub 2017. PMID: 27881578.
132. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget 8(22):35656-35668, 2017. e-Pub 2017. PMID: 27374101.
133. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol 35(10):JCO2015631010, 2017. e-Pub 2017. PMID: 28135148.
134. Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, Baselga J, Chandarlapaty S. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2. Br J Cancer 116(6):726-730, 2017. e-Pub 2017. PMID: 28183140.
135. Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT. Bone Metastasis-related Signaling Pathways in Breast Cancers Stratified by Estrogen Receptor Status. J Cancer 8(6):1045-1052, 2017. e-Pub 2017. PMID: 28529618.
136. Lim B, Hortobagyi GN. Current challenges of metastatic breast cancer. Cancer Metastasis Rev 35(4):495-514, 2016. e-Pub 2016. PMID: 27933405.
137. Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. e-Pub 2016. PMID: 27866850.
138. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 375(18):1738-1748, 2016. e-Pub 2016. PMID: 27717303.
139. Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WH, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci U S A. e-Pub 2016. PMID: 27791177.
140. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 22(10):1192, 2016. e-Pub 2016. PMID: 27711065.
141. Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol 2(10):1310-1315, 2016. e-Pub 2016. PMID: 27532364.
142. Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME. ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. JAMA Oncol, 2016. e-Pub 2016. PMID: 27532364.
143. Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 159(2):367-74, 2016. e-Pub 2016. PMID: 27522517.
144. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7:12632, 2016. e-Pub 2016. PMID: 27572267.
145. Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159(1):87-95, 2016. e-Pub 2016. PMID: 27475087.
146. Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158(3):485-95, 2016. e-Pub 2016. PMID: 27393622.
147. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat 158(1):67-77, 2016. e-Pub 2016. PMID: 27287781.
148. Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. Br J Clin Pharmacol 81(6):1134-41, 2016. e-Pub 2016. PMID: 26859101.
149. Rosenstock AS, Lei X, Tripathy D, Hortobagyi GN, Giordano SH, Chavez-MacGregor M. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat 157(2):339-50, 2016. e-Pub 2016. PMID: 27146586.
150. Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin Cancer Res. e-Pub 2016. PMID: 27166393.
151. Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol 2(4):1-9, 2016. e-Pub 2016. PMID: 26720612.
152. Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. e-Pub 2016. PMID: 26986538.
153. Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, Wang Y, Chou CK, Hsu JM, Lai YJ, LaBaff AM, Ding Q, Ko HW, Tsai FJ, Tsai CH, Hortobagyi GN, Hung MC. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation. Cancer Res 76(6):1451-62, 2016. e-Pub 2016. PMID: 26759241.
154. Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res 76(5):1284-96, 2016. e-Pub 2016. PMID: 26759242.
155. Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, Motzer R. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 27(3):519-25, 2016. e-Pub 2016. PMID: 26759276.
156. Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol 34(5):419-26, 2016. e-Pub 2016. PMID: 26503204.
157. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 22(2):194-201, 2016. e-Pub 2016. PMID: 26779812.
158. Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res. e-Pub 2016. PMID: 26896384.
159. Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist 21(1):21-7, 2016. e-Pub 2016. PMID: 26659222.
160. Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia 30(1):242-7, 2016. e-Pub 2016. PMID: 25975189.
161. Chae YK, Gagliato Dde M, Pai SG, Carneiro B, Mohindra N, Giles FJ, Ramakrishnan-Geethakumari P, Sohn J, Liu S, Chen H, Ueno N, Hortobagyi G, Gonzalez-Angulo AM. The association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer. PLoS One 11(4):e0152585, 2016. e-Pub 2016. PMID: 27055285.
162. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer 7(9):1095-104, 2016. e-Pub 2016. PMID: 27326253.
163. Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor Activity of KW-2450 Against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther 14(12):2687-99, 2015. e-Pub 2015. PMID: 26443806.
164. Le Du F, Gonzalez-Angulo AM, Park M, Liu DD, Hortobagyi GN, Ueno NT. Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. Clin Breast Cancer 15(6):458-66, 2015. e-Pub 2015. PMID: 26233757.
165. Karuturi M, Abderrahman B, Hortobagyi GN, Jordan VC. Oral Pure Anti-estrogens as a Solution to Acquired Drug Resistance to Aromatase Inhibitors. Future Medicine Breast Cancer Management 4(6). e-Pub 2015.
166. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer 15(5):325-31, 2015. e-Pub 2015. PMID: 25913905.
167. Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez-MacGregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 153(2):417-23, 2015. e-Pub 2015. PMID: 26272743.
168. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc 90(8):996-1000, 2015. e-Pub 2015. PMID: 26211600.
169. Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, Chronowski GM, Dvorak T, Grade E, Hoffman KE, Kelly P, Ludwig M, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Baumann D, Thompson AM, Amaya D, Davis T, Guerra W, Hamblin L, Hortobagyi G, Hunt KK, Buchholz TA, Smith BD. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol 1(7):931-941. e-Pub 2015. PMID: 26247543.
170. Chavez-MacGregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi GN, Giordano SH. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol 33(19):2176-83, 2015. e-Pub 2015. PMID: 25964256.
171. Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol 47(1):262-8, 2015. e-Pub 2015. PMID: 25975349.
172. Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JK. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist 20(6):593-7, 2015. e-Pub 2015. PMID: 25948675.
173. Smerage JB, Barlow WE, Hortobagyi GN, Hayes DF. Reply to f.-C. Bidard et Al. J Clin Oncol 33(14):1623, 2015. e-Pub 2015. PMID: 25870090.
174. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clin Breast Cancer 15(2):153-60, 2015. e-Pub 2015. PMID: 25454687.
175. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS, Investigators P. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372(10):923-32, 2015. e-Pub 2015. PMID: 25738668.
176. Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost 113(2):593-8, 2015. e-Pub 2015. PMID: 25373787.
177. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 6(5):2604-14, 2015. e-Pub 2015. PMID: 25605252.
178. Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez-MacGregor M. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer 112(4):630-5, 2015. e-Pub 2015. PMID: 25584488.
179. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res 17(1):2, 2015. e-Pub 2015. PMID: 25572591.
180. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. J Clin Oncol 33(1):58-64, 2015. e-Pub 2015. PMID: 25422488.
181. Yang CC, LaBaff A, Wei Y, Nie L, Xia W, Huo L, Yamaguchi H, Hsu YH, Hsu JL, Liu D, Lang J, Du Y, Lien HC, Li LY, Deng R, Chan LC, Yao J, Kleer CG, Hortobagyi GN, Hung MC. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res 7(6):1009-20, 2015. e-Pub 2015. PMID: 26279746.
182. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer 6(4):310-8, 2015. e-Pub 2015. PMID: 25767600.
183. Shaitelman SF, Buchholz TA, Hunt KK, Hortobagyi GN, Schlembach P, Arzu I, Bloom E, Chronowski G, Dvorak T, Grade E, Hoffman KE, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Smith BD. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole breast irradiation: results of a randomized trial. Int J Radiat Oncol Biol Phys 90(5):1264, 2014. e-Pub 2014. PMID: 25539386.
184. Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, Rimes SA, Hortobagyi GN, Valero V, Litton JK. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res 16(6):500. e-Pub 2014. PMID: 25547133.
185. Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25(12):2357-62, 2014. e-Pub 2014. PMID: 25231953.
186. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Accompanied by an editorial: Bardia A, Haber DA: Solidifying Liquid Biopsies: Can Circulating Tumor Cell Monitoring Guide Treatment Selection in Breast Cancer? J Clin Oncol 32(31):3470-3472, 2014. doi: 10.1200/JCO.2014.57.1505. [Epub ahead of print on July 14, 2014] PMID:25024075. J Clin Oncol 32(31):3483-9, 2014. e-Pub 2014. PMID: 24888818.
187. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing. Ann Surg Oncol 21(11):3466-72, 2014. e-Pub 2014. PMID: 24796968.
188. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32(29):3307-29, 2014. e-Pub 2014. PMID: 25185096.
189. Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res 20(20):5265-71, 2014. e-Pub 2014. PMID: 25172932.
190. Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther 31(9):1008-9, 2014. e-Pub 2014. PMID: 25209875.
191. Hayashi N, Manyam GC, Gonzalez-Angulo AM, Niikura N, Yamauchi H, Nakamura S, Hortobágyi GN, Baggerly KA, Ueno NT. Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. Oncologist 19(9):909-14, 2014. e-Pub 2014. PMID: 25117064.
192. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 74(17):4822-35, 2014. e-Pub 2014. PMID: 24970481.
193. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 16(5):440. e-Pub 2014. PMID: 25223629.
194. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobágyi GN, Arun B, Peterson SK, Profato J, Litton JK. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804, 2014. e-Pub 2014. PMID: 24951607.
195. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat 146(3):477-86, 2014. e-Pub 2014. PMID: 25038877.
196. Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, Present, and Future Challenges in Breast Cancer Treatment. J Clin Oncol 32(19):1979-86, 2014. e-Pub 2014. PMID: 24888802.
197. Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, Hortobagyi GN, Smith BD, Giordano SH. Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer. J Clin Oncol 32(19):2010-7, 2014. e-Pub 2014. PMID: 24868022.
198. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 2014. e-Pub 2014. PMID: 24677057.
199. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Transl Med 3(7):849-56, 2014. e-Pub 2014. PMID: 24833589.
200. Campos-Gomez S, Valero V, Flores-Arredondo JH, Isassi-Chapa A, Rangel-Rodríguez I, Hortobagyi GN, Gonzalez-Angulo AM. Breast Cancer Subtype and Baseline Characteristics from Diabetic Breast Cancer Patients are Not Different from Nondiabetics. Breast J 20(4):434-6, 2014. e-Pub 2014. PMID: 24862358.
201. Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Fraser Symmans W, Lee MH, Yeung SC. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst 106(7), 2014. e-Pub 2014. PMID: 24957076.
202. Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat 146(2):259-72, 2014. e-Pub 2014. PMID: 24916181.
203. Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14(3):241-7, 2014. e-Pub 2014. PMID: 23999597.
204. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional Recurrence Risk for Patients with T1,2 Breast Cancer with 1-3 Positive Lymph Nodes Treated with Mastectomy and Systemic Treatment. Int J Radiat Oncol Biol Phys 89(2):392-8, 2014. e-Pub 2014. PMID: 24721590.
205. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
206. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 25(5):1004-11, 2014. e-Pub 2014. PMID: 24562447.
207. Gyorffy B, Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. Mol Oncol 8(3):508-19, 2014. e-Pub 2014. PMID: 24462521.
208. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer 120(9):1319-28, 2014. e-Pub 2014. PMID: 24510381.
209. Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Kwiatkowski DN, Hortobagyi GN. Effect of Age and Race On Quality of Life in Young Breast Cancer Survivors. Clin Breast Cancer 14(2):e21-31, 2014. e-Pub 2014. PMID: 24461458.
210. Eckmann K, Michaud LB, Rivera E, Madden TL, Esparza-Guerra L, Kawedia J, Booser DJ, Green MC, Hortobagyi GN, Valero V. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. J Oncol Pharm Pract 20(2):120-9, 2014. e-Pub 2014. PMID: 23676510.
211. Henry LN, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. J Natl Cancer Inst 106(4):dju034, 2014. e-Pub 2014. PMID: 24627271.
212. Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA. Incidence and Time Course of Everolimus-Related Adverse Events in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer: Insights From BOLERO-2. Ann Oncol 25(4):808-15, 2014. e-Pub 2014. PMID: 24615500.
213. Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN, Barnett CM. Incidence, Risk Factors, and Management of Infusion Related Reactions in Breast Cancer Patients Receiving Trastuzumab. Oncologist 19(3):228-34, 2014. e-Pub 2014. PMID: 24536030.
214. Gagliato DD, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M. Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. J Clin Oncol 32(8):735-744, 2014. e-Pub 2014. PMID: 24470007.
215. Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 143(3):459-67, 2014. e-Pub 2014. PMID: 24362951.
216. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-Macgregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-91, 2014. e-Pub 2014. PMID: 24351399.
217. Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes. Cancer Epidemiol Biomarkers Prev 23(2):316-23, 2014. e-Pub 2014. PMID: 24296856.
218. Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H, Ueno NT. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Oncogene 33(4):1-9, 2014. e-Pub 2014. PMID: 23376849.
219. Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarøe J, Wärnberg F, Børresen-Dale AL, Mills GB, Thompson PA, Bondy ML. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 143(1):189-201, 2014. e-Pub 2014. PMID: 24305980.
220. Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143(2):351-8, 2014. e-Pub 2014. PMID: 24352574.
221. Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer 5(9):745-53, 2014. e-Pub 2014. PMID: 25368674.
222. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One 9(1):e83113, 2014. e-Pub 2014. PMID: 24416156.
223. Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2. Clin Breast Cancer 13(6):421-432.e8, 2013. e-Pub 2013. PMID: 24267730.
224. Niikura N, Odisio BC, Tokuda Y, Symmans FW, Hortobagyi GN, Ueno NT. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol 10(12):711-9, 2013. e-Pub 2013. PMID: 24145987.
225. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45(12):1439-45, 2013. e-Pub 2013. PMID: 24185512.
226. Chavez-Macgregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer. J Clin Oncol 31(33):4222-8, 2013. e-Pub 2013. PMID: 24127446.
227. Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Res 73(21):6516-25, 2013. e-Pub 2013. PMID: 24014597.
228. Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA. Health-Related Quality of Life and Disease Symptoms in Postmenopausal Women With HR(+), HER2(-) Advanced Breast Cancer Treated With Everolimus Plus Exemestane Versus Exemestane Monotherapy. Curr Med Res Opin 29(11):1463-73, 2013. e-Pub 2013. PMID: 23962028.
229. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans WF, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. Comparison of Molecular Subtype Distribution in Triple-Negative Inflammatory and Non-inflammatory Breast Cancers. Breast Cancer Res 15(6):R112. e-Pub 2013. PMID: 24274653.
230. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19(19):5533-5540, 2013. e-Pub 2013. PMID: 23948975.
231. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, Diabetes, and Survival Outcomes in a Large Cohort of Early-stage Breast Cancer Patients. Ann Oncol 24(10):2506-14, 2013. e-Pub 2013. PMID: 23793035.
232. Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther 30(10):870-84, 2013. e-Pub 2013. PMID: 24158787.
233. Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol 24(10):2515-21, 2013. e-Pub 2013. PMID: 23798614.
234. Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM. Functional Proteomics Characterization of Residual Triple-negative Breast Cancer After Standard Neoadjuvant Chemotherapy. Ann Oncol 24(10):2522-6, 2013. e-Pub 2013. PMID: 23925999.
235. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-42, 2013. e-Pub 2013. PMID: 23729783.
236. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. Effect of Visceral Metastases on the Efficacy and Safety of Everolimus in Postmenopausal Women With Advanced Breast Cancer: Subgroup Analysis From the BOLERO-2 Study. Eur J Cancer 49(12):2621-32, 2013. e-Pub 2013. PMID: 23735704.
237. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 2013. e-Pub 2013. PMID: 23562929.
238. Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. J Clin Oncol 31(20):2627-33, 2013. e-Pub 2013. PMID: 23733756.
239. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 109(2):318-24, 2013. e-Pub 2013. PMID: 23820253.
240. Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute-Sponsored Trials. J Natl Cancer Inst 105(13):947-953, 2013. e-Pub 2013. PMID: 23776198.
241. Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet 381(9883):2077-8, 2013. e-Pub 2013. PMID: 23769223.
242. Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN, Ueno NT. Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP. Mol Cancer Ther 12(6):1099-111, 2013. e-Pub 2013. PMID: 23543364.
243. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male Breast Cancer According to Tumor Subtype and Race: a Population Based Study. Cancer 119(9):1611-7, 2013. e-Pub 2013. PMID: 23341341.
244. Alvarez RH, Hortobagyi GN. Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer. Breast Cancer 20(2):103-10, 2013. e-Pub 2013. PMID: 23377763.
245. Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional Proteomics Characterization of Residual Breast Cancer After Neoadjuvant Systemic Chemotherapy. Ann Oncol 24(4):909-16, 2013. e-Pub 2013. PMID: 23139263.
246. Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. The Prognostic Impact of Age in Patients with Triple Negative Breast Cancer. Breast Cancer Res Treat 138(2):591-9, 2013. e-Pub 2013. PMID: 23460246.
247. Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, Pierga JY, Cristofanilli M, Bidard FC. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res 19(6):1596-602, 2013. e-Pub 2013. PMID: 23340302.
248. Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119(10):1908-1915. e-Pub 2013. PMID: 23504821.
249. Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas CH, Hortobagyi GN, Rouzier R, Esteva FJ, Pusztai L. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 108(2):285-291, 2013. e-Pub 2013. PMID: 23299541.
250. Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Thomas Budd G, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137(3):903-13, 2013. e-Pub 2013. PMID: 23306462.
251. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI. Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. J Natl Cancer Inst 105(9):654-663. e-Pub 2013. PMID: 23425564.
252. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast Conserving Therapy. Ann Surg 257(2):173-9, 2013. e-Pub 2013. PMID: 23291658.
253. Hayashi N, Costelloe CM, Hamaoka T, Wei C, Niikura N, Theriault RL, Hortobagyi GN, Madewell JE, Ueno NT. A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer. Clin Breast Cancer 13(1):24-30, 2013. e-Pub 2013. PMID: 23098575.
254. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-642. e-Pub 2013. PMID: 23370825.
255. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63-72, 2013. e-Pub 2013. PMID: 23053261.
256. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, Deverka P, Veenstra D, Hortobagyi GN. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials 34(1):1-9, 2013. e-Pub 2013. PMID: 23000081.
257. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. Cancer J 19(1):10-7, 2013. e-Pub 2013. PMID: 23337751.
258. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 2013. e-Pub 2013. PMID: 23242617.
259. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated Breast Cancers. Breast J 19(1):87-91, 2013. e-Pub 2013. PMID: 23231005.
260. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 137(1):319-27, 2013. e-Pub 2013. PMID: 23208590.
261. Lang JE, Tereffe W, Mitchell MP, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Hortobagyi GN, Babiera GV. Primary Tumor Extirpation in Breast Cancer Patients who Present with Stage IV Disease Is Associated with Improved Survival. Ann Surg Oncol 20(6):1893-1899. e-Pub 2013. PMID: 23306905.
262. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-Macgregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 2013. e-Pub 2013. PMID: 22736407.
263. Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Hortobágyi GN, Theriault RL. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist 18(4):369-76, 2013. e-Pub 2013. PMID: 23576478.
264. Hortobagyi G, Conte P. Interpreting cancer biology: refining our therapeutic algorithm in breast cancer. Oncologist 18(4):e8-e10, 2013. e-Pub 2013. PMID: 23633451.
265. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor M. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 4(7):549-56, 2013. e-Pub 2013. PMID: 23983819.
266. Lynch SP, Lei X, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang H, Hortobágyi GN, Gonzalez-Angulo AM, Valero V. Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence. Oncologist 18(11):1167-73, 2013. e-Pub 2013. PMID: 24136008.
267. Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M, André F, Turner NC, Symmans WF, Hortobágyi GN, Pusztai L, Bianchini G. DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. Oncologist 18(10):1063-73, 2013. e-Pub 2013. PMID: 24072219.
268. Torikoshi Y, Gohda K, Davis ML, Symmans WF, Pusztai L, Kazansky A, Nakayama S, Yoshida T, Matsushima T, Hortobagyi GN, Ishihara H, Kim SJ, Noguchi S, Ueno NT. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. J Cancer 4(9):697-702, 2013. e-Pub 2013. PMID: 24312139.
269. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of Brain Metastases as a First Site of Recurrence Among Women with Triple Receptor-negative Breast Cancer. Cancer doi: 10.1002/cncr.27434(19):4652-9, 2012. e-Pub 2012. PMID: 22359359.
270. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of Body Mass Index on Survival Outcome among Women with Early Stage Triple-negative Breast Cancer. Clin Breast Cancer 12(5):364-72, 2012. e-Pub 2012. PMID: 23040004.
271. Chen CT, Du Y, Yamaguchi H, Hsu JM, Kuo HP, Hortobagyi GN, Hung MC. Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-related Breast Cancer. Mol Cancer Ther 11(10):2212-21, 2012. e-Pub 2012. PMID: 22826466.
272. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):331-345. e-Pub 2012. PMID: 23073759.
273. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo AM. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 14(5):R138. e-Pub 2012. PMID: 23102376.
274. Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. Progress against Solid Tumors in Danger: The Metastatic Breast Cancer Example. J Clin Oncol 30(28):3444-7, 2012. e-Pub 2012. PMID: 22927522.
275. Wang Q, Li SH, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D. Concomitant Targeting of Tumor Cells and Induction of T Cell Response Synergizes to Effectively Inhibit Trastuzumab-resistant Breast Cancer. Cancer Res 72(17):4417-4428, 2012. e-Pub 2012. PMID: 22773664.
276. Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An Open-Label, Phase II Trial of RPI.4610 (Angiozyme) in the Treatment of Metastatic Breast Cancer. Cancer doi: 10.1002/cncr.26730(17):4098-104, 2012. e-Pub 2012. PMID: 22281842.
277. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 135(2):619-27, 2012. e-Pub 2012. PMID: 22890751.
278. Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and Multicentricity in Breast Cancer and Survival Outcomes. Ann Oncol 23(12):3063-3069. e-Pub 2012. PMID: 22776706.
279. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the User of Anthracyclines for Breast Cancer. J Clin Oncol 30(18):2232-9, 2012. e-Pub 2012. PMID: 22614988.
280. Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines?. J Clin Oncol 30(18):2179-82, 2012. e-Pub 2012. PMID: 22614986.
281. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. Ganglioside GD2 Identifies Breast Cancer Stem Cells and Promotes Tumorigenesis. J Clin Invest pii: 59735. doi: 10.1172/JCI59735. e-Pub 2012. PMID: 22585577.
282. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 2012. e-Pub 2012. PMID: 22006179.
283. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 23(5):1144-50, 2012. e-Pub 2012. PMID: 21965473.
284. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-93, 2012. e-Pub 2012. PMID: 21953213.
285. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clin Breast Cancer 12(4):264-269. e-Pub 2012. PMID: 22591634.
286. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobagyi GN, Ueno NT. Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist 17(7):891-899. e-Pub 2012. PMID: 22584436.
287. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 17(2):96-104, 2012. e-Pub 2012. PMID: 21671160.
288. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 134(1)(333-343). e-Pub 2012. PMID: 22538770.
289. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
290. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer 118(8):2039-47, 2012. e-Pub 2012. PMID: 22139648.
291. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23(4):870-5, 2012. e-Pub 2012. PMID: 21765048.
292. Hortobagyi GN. Towards Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside. Oncologist 17(4):577-584, 2012. e-Pub 2012. PMID: 22474069.
293. Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM. Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 118(5):1221-7, 2012. e-Pub 2012. PMID: 21823108.
294. Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN, Martín M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer 20(11):2661-2668. e-Pub 2012. PMID: 22382588.
295. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III Trial Evaluating Weekly Paclitaxel versus Docetaxel in Combination with Capecitabine in Operable Breast Cancer. J Clin Oncol 30(9):930-5, 2012. e-Pub 2012. PMID: 22331946.
296. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2012. PMID: 21837669.
297. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. e-Pub 2012. PMID: 22009639.
298. Dutta B, Pusztai L, Qi Y, André F, Lazar V, Bianchini G, Ueno N, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Balázsi G. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer 106(6):1107-16, 2012. e-Pub 2012. PMID: 22343619.
299. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729-34, 2012. e-Pub 2012. PMID: 22291085.
300. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202-11, 2012. e-Pub 2012. PMID: 21800293.
301. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res 72(5):1290-300, 2012. e-Pub 2012. PMID: 22253230.
302. Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int J Clin Oncol 17(1):55-62, 2012. e-Pub 2012. PMID: 21607830.
303. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Jr BG, Gonzalez-Angulo AM. cMET and Phospho cMET Protein Levels in Breast Cancers and Survival Outcomes. Clin Cancer Res 18(8):2269-2277. e-Pub 2012. PMID: 22374333.
304. Schott AF, Barlow WE, Albain KS, Chew HK, JLrd W, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430. Oncologist 17(2):179-187, 2012. e-Pub 2012. PMID: 22267853.
305. Corey-Lisle PK, Peck R, Mukhopadhyay P, Orsini L, Safikhani S, Bell JA, Hortobagyi G, Roche H, Conte P, Revicki DA. Q-TWiST Analysis of Ixabepilone in Combination with Capecitabine on Quality of Life in Patients with Metastatic Breast Cancer. Cancer 118(2):461-468, 2012. e-Pub 2012. PMID: 21598243.
306. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans F, Pusztai L. Gene Expression, Molecular Class Changes and Pathway Analysis After Neoadjuvant Systemic Therapy for Breast Cancer. Clin Cancer Res 18(4):1109-1119. e-Pub 2012. PMID: 22235097.
307. Chavez-MacGregor M, Gonzalez-Angulo AM, Hortobagyi GN. Breast Cancer Medical Therapy in High-resource Countries. World Breast Cancer Report 2012:435-447, 2012. e-Pub 2012.
308. Barcenas CH, Zhang N, Zhao H, Duan Z, Buchholz TA, Hortobagyi GN, Giordano SH. Anthracycline Regimen Adherence in Older Patients with Early Breast Cancer. Oncologist 17(3):303-311, 2012. e-Pub 2012. PMID: 22371383.
309. Lee J, Bartholomeusz C, Krishnamurthy S, Liu P, Saso H, Lafortune TA, Hortobagyi GN, Ueno NT. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin. Oncogenesis 1:e22, 2012. e-Pub 2012. PMID: 23552738.
310. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobágyi GN. High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients. Oncologist 17(6):766-74, 2012. e-Pub 2012. PMID: 22584435.
311. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer 3:369-80, 2012. e-Pub 2012. PMID: 23074378.
312. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. N Engl J Med 367(5):435-444. e-Pub 2012. PMID: 22853014.
313. Hortobagyi GN. Toward individualized breast cancer therapy: translating biological concepts to the bedside. Oncologist 17(4):577-84, 2012. e-Pub 2012. PMID: 22474069.
314. Gonzalez-Angulo AM, Hortobagyi GN. Is there an ideal way to combine trastuzumab with chemotherapy?. J Clin Oncol 29(34):4474-6, 2011. e-Pub 2011. PMID: 22042935.
315. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130(3):993-1002, 2011. e-Pub 2011. PMID: 21766209.
316. Baselga J, Campone M, Piccart M, Burris HA, III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med 366(6):520-529. e-Pub 2011. PMID: 22149876.
317. Arun BK, Valero V, Liu D, Brewster AM, Green M, Gutierrez-Barrera AM, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short–term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer. Cancer Prev Res (Phila) 5(2):276-282. e-Pub 2011. PMID: 22102688.
318. Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YC, Giordano SH. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 22(11):2394-402, 2011. e-Pub 2011. PMID: 21393379.
319. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and Thiazolidinediones Are Associated with Improved Cancer-specific Survival of Diabetic Women with HER2-positive Breast Cancer. Ann Oncol 23(7):1771-1780. e-Pub 2011. PMID: 22112968.
320. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. J Clin Oncol 30(6):593-599. e-Pub 2011. PMID: 22124109.
321. Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat 130(1):123-31, 2011. e-Pub 2011. PMID: 21826527.
322. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow J, Kuerer HM, Hunt KK. Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated with Surgery as The First Intervention: Time to Modify Current American Joint Committee on Cancer Staging System. J Clin Oncol 29(35):4654-4661. e-Pub 2011. PMID: 22084362.
323. Arun BK, Dinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy With or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results. Oncologist 16(11):1527-1534. e-Pub 2011. PMID: 22042783.
324. Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN. Bevacizumab Treatment for Advanced Breast Cancer. Oncologist 16(12):1684-1697. e-Pub 2011. PMID: 21976315.
325. Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. Int J Clin Oncol 16(5):596-600, 2011. e-Pub 2011. PMID: 21210173.
326. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Hortobagyi GN, Hung MC. BIKDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell 20(3):341-356, 2011. e-Pub 2011. PMID: 21907925.
327. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clin Breast Cancer 11(5):325-31, 2011. e-Pub 2011. PMID: 21764391.
328. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A Phase I Study of Weekly Everolimus (RAD001) in Combination with Docetaxel in Patients with Metastatic Breast Cancer. Cancer 118(9):2378-2384. e-Pub 2011. PMID: 22006179.
329. Collaborative Group EBCT, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of Radiotherapy after Breast-conserving Surgery on 10-year Recurrence and 15-year Breast Cancer Death: Meta-analysis of Individual Patient Data on 10,801 Women in 17 Randomised Trials. Lancet 378(9804):1707-1716. e-Pub 2011. PMID: 22019144.
330. Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Jr BR, Hortobagyi GN, and Hung MC. FOXO3a Dependent Mechanisms of E1A-induced Chemosensitization. Cancer Res 71(21):6878-6887. e-Pub 2011. PMID: 21911455.
331. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Non-carriers: A Single-Institution Experience. J Clin Oncol 29(28):3739-3746. e-Pub 2011. PMID: 21900106.
332. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier Age of Onset of BRCA Mutation-Related Cancers in Subsequent Generations. Cancer 118(2):321-325. e-Pub 2011. PMID: 21913181.
333. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline and Non-anthracycline-based Regimens for HER2-Positive Breast Cancer. Cancer 118(9):2385-2393. e-Pub 2011. PMID: 21953213.
334. Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA. Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer. Breast J 17(5):462-9, 2011. e-Pub 2011. PMID: 21726347.
335. Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat 129(2):451-8, 2011. e-Pub 2011. PMID: 21710134.
336. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900-7, 2011. e-Pub 2011. PMID: 21365619.
337. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
338. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. J Clin Oncol 29(24):3214-23, 2011. e-Pub 2011. PMID: 21768471.
339. Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin-Cytosine Deaminase-Uracil Phosphoribosyl Transferase. Mol Cancer Ther 10(8):1327-36, 2011. e-Pub 2011. PMID: 21610170.
340. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsachavidis S, Wand Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML. Selective Genomic Copy Number Imbalances and Probability of Recurrence in Early-Stage Breast Cancer. PLoS One 6(8):e23543. e-Pub 2011. PMID: 21858162.
341. Iwamoto T, Lee JS, Bianchini G, Hubbard RE, Young E, Matsuoka J, Kim SB, Symmans WF, Hortobagyi GN, Pusztai L. First Generation Prognostic Gene Signatures for Breast Cancer Predict both Survival and Chemotherapy Sensitivity and Identify Overlapping Patient Populations. Breast Cancer Res Treat 130(1):155-164. e-Pub 2011. PMID: 21833625.
342. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of Triple-Negative Breast Cancer in Patients with or without Deleterious BRCA Mutations. Breast Cancer Res Treat 130(1):145-153. e-Pub 2011. PMID: 21830012.
343. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. J Clin Oncol 29(23):3126-32, 2011. e-Pub 2011. PMID: 21730275.
344. Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer 117(16):3641-9, 2011. e-Pub 2011. PMID: 21656514.
345. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol 29(19):2645-52, 2011. e-Pub 2011. PMID: 21632501.
346. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. J Clin Oncol 29(19):2628-34, 2011. e-Pub 2011. PMID: 21606433.
347. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-913. e-Pub 2011. PMID: 21761402.
348. Collaborative Group EBCT. Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-level Meta-analysis of Randomised Trials. Lancet 378(9793):771-784. e-Pub 2011. PMID: 21802721.
349. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13(3):R67. e-Pub 2011. PMID: 21699723.
350. Gonzalez-Angulo AM, Hortobagyi GN, Ellis LM. Targeted therapies: Peaking beneath the surface of recent bevacizumab trials. Nat Rev Clin Oncol 8(6):319-20, 2011. e-Pub 2011. PMID: 21556024.
351. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Mol Cancer Ther 10(6):1093-101, 2011. e-Pub 2011. PMID: 21490305.
352. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic Value of HER2-positive Circulating Tumor Cells in Patients with Metastatic Breast Cancer. Int J Clin Oncol 17(2):96-104. e-Pub 2011. PMID: 21671160.
353. Corey-Lisle PK, Peck R, Mukhopadhyay P, Orsini L, Safikhani S, Bell JA, Hortobagyi G, Roche H, Conte P, Revicki DA. Q-TWiST Analysis of Ixabepilone in Combination with Capecitabine on Quality of Life in Patients with Metastatic Breast Cancer. Cancer 118(2):461-468. e-Pub 2011. PMID: 21598243.
354. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819-26, 2011. e-Pub 2011. PMID: 21509759.
355. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. J Clin Oncol 29(15):1956-62, 2011. e-Pub 2011. PMID: 21482989.
356. Chavez-MacGregor M, Brown E, Lei X, Litton J, Meric-Bernstam F, Mittendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and Pathologic Complete Response to Taxane and Anthracycline-based Neoadjuvant Chemotherapy in Patients with Breast Cancer. Cancer 118(2):326-332. e-Pub 2011. PMID: 21590688.
357. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-81, 2011. e-Pub 2011. PMID: 21558518.
358. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. Ann Surg Oncol 18(4):932-8, 2011. e-Pub 2011. PMID: 21061075.
359. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 17(8):2591-601, 2011. e-Pub 2011. PMID: 21248301.
360. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17(4):461-9, 2011. e-Pub 2011. PMID: 21399647.
361. Howatson G, Taylor MB, Rider P, Motawar BR, McNally MP, Solnik S, DeVita P, Hortobágyi T. Ipsilateral motor cortical responses to TMS during lengthening and shortening of the contralateral wrist flexors. Eur J Neurosci 33(5):978-90, 2011. e-Pub 2011. PMID: 21219480.
362. Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012. J Clin Oncol 29(8):1014-21, 2011. e-Pub 2011. PMID: 21220618.
363. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer. e-Pub 2011. PMID: 21387303.
364. Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 17(2):210-2, 2011. e-Pub 2011. PMID: 21294809.
365. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 2011. e-Pub 2011. PMID: 21233401.
366. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L. Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. J Natl Cancer Inst 103(3):264-72, 2011. e-Pub 2011. PMID: 21191116.
367. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype. Eur J Cancer. e-Pub 2011. PMID: 21334874.
368. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 125(3):785-95, 2011. e-Pub 2011. PMID: 21153052.
369. Roché H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat 125(3):755-65, 2011. e-Pub 2011. PMID: 21128114.
370. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-ß-Catenin Signaling. Cancer Cell 19(1):86-100, 2011. e-Pub 2011. PMID: 21215703.
371. Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NT. Gemcitabine overcomes erlotinib resistance in EGFR-overexpressing cancer cells through downregulation of Akt. J Cancer 2:435-42, 2011. e-Pub 2011. PMID: 21850211.
372. Woodward WA, Cohen E, Gao H, Li L, Xu W, Debeb BG, Jiminez CA, Bethancourt DL, Krishnamurthy S, Tucker SL, Hortobagyi GN, Cristofanilli M, Buchholz T, Reuben JM. Percentage of CD45-CD326+ CD44+CD24-/lo Cells in Pleural Effusion Fluid of Patients with Metastatic Breast Cancer Predicts for Overall Survival. J Interventional Oncol 1((1)):4-10, 2011. e-Pub 2011.
373. Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer. Oncologist 16(8):1111-9, 2011. e-Pub 2011. PMID: 21765193.
374. Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. Oncologist 16(7):956-65, 2011. e-Pub 2011. PMID: 21712485.
375. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist 16(2):155-64, 2011. e-Pub 2011. PMID: 21266401.
376. Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, Yu TK, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. Oncologist 16(6):772-82, 2011. e-Pub 2011. PMID: 21632453.
377. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist 16(6):726-9, 2011. e-Pub 2011. PMID: 21632448.
378. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8(1):11, 2011. e-Pub 2011. PMID: 21906370.
379. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res 16(24):6169-76, 2010. e-Pub 2010. PMID: 21169260.
380. Buzdar AU, Buchholz TA, Taylor SH, Hortobagyi GN, Hunt KK. (Reviewed for Sixty Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center on 12/18/2010). Breast Cancer, 2010. e-Pub 2010.
381. Hortobagyi GN. Why my neighbor's health is important to me. Oncology (Williston Park) 24(13):1238, 2010. e-Pub 2010. PMID: 21192567.
382. Jin Q, Yuan LX, Boulbes D, Baek JM, Wang YN, Gomez-Cabello D, Hawke DH, Yeung SC, Lee MH, Hortobagyi GN, Hung MC, Esteva FJ. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 12(6):R96. e-Pub 2010. PMID: 21080941.
383. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22):5161-7, 2010. e-Pub 2010. PMID: 20665886.
384. Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 116(21):4933-43, 2010. e-Pub 2010. PMID: 20665494.
385. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 70(21):8852-62, 2010. e-Pub 2010. PMID: 20959472.
386. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16(21):5351-61, 2010. e-Pub 2010. PMID: 20829329.
387. Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹° p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther 9(11):3090-9, 2010. e-Pub 2010. PMID: 21045138.
388. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7(11):641-51, 2010. e-Pub 2010. PMID: 20808302.
389. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. e-Pub 2010. PMID: 21117228.
390. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18(5):423-35, 2010. e-Pub 2010. PMID: 21075308.
391. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat 124(2):433-9, 2010. e-Pub 2010. PMID: 20309628.
392. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival Differences Among Women with de novo Stage IV and Relapsed Breast Cancer. Ann Oncol 21(11):2169-74, 2010. e-Pub 2010. PMID: 20427349.
393. Hennessy B, Lu Y, Gonzalez-Angulo AM, Carey M, Myhre S, Ju Z, Coombes K, Liu W, Meric-Bernstam F, Bedrosian I, Yu Q, Yu S, Siwak D, McGahren M, Agarwal R, Zhang F, Hortobagyi GN, Li J, Sahin A, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen Dale AL, Mills GB. A novel approach to the study of the functional proteome in human breast cancers. Accepted for Clin Proteomics, 2010. e-Pub 2010.
394. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 28(28):4316-23, 2010. e-Pub 2010. PMID: 20805453.
395. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177(4):1647-56, 2010. e-Pub 2010. PMID: 20813970.
396. Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M, Schmelter T, Wang Y, Hortobagyi GN, Vahdat LT. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Res Treat 123(3):837-42, 2010. e-Pub 2010. PMID: 20697802.
397. Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L. Amplification of Fibroblast Growth Factor Receptor-1 in Breast Cancer and the Effects of Brivanib Alaninate. Breast Cancer Res Treat 123(3):747-55, 2010. e-Pub 2010. PMID: 20024612.
398. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer. e-Pub 2010. PMID: 20877352.
399. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28(27):4111-9, 2010. e-Pub 2010. PMID: 20697068.
400. Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17):4168-77, 2010. e-Pub 2010. PMID: 20564153.
401. Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung MC. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. Oncogene. e-Pub 2010. PMID: 20676141.
402. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 51(8):1213-8, 2010. e-Pub 2010. PMID: 20660382.
403. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W, Woodward WA, Tucker SL, Hunt KK, Hortobagyi GN, Buchholz TA. Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients with T1ambB0 Breast Cancer. Int J Radiat Oncol Biol Phys 75(S7):1296-302, 2010. e-Pub 2010. PMID: 20472353.
404. Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, Woodward WA. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 116(13):3084-92, 2010. e-Pub 2010. PMID: 20564633.
405. Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, Valero V, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast J 2009. e-Pub 2010. PMID: 20626396.
406. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of Overall Survival from a Phase III Study of Ixabepilone plus Capecitabine versus Capecitabine in Patients with MBC Resistant to Anthracyclines and Taxanes. Breast Cancer Res Treat 122(2):409-418, 2010. e-Pub 2010. PMID: 20454927.
407. Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR, Pusztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat 121(2):301-309, 2010. e-Pub 2010. PMID: 19603265.
408. Morrow PK, Tarrand JJ, Taylor SH, Kau SW, Theriault RL, Hortobagyi GN, Broglio KR, Hahn KM. Effects of chronic hepatitis C infection on the treatment of breast cancer patients. Ann Oncol 21(6):1233-6, 2010. e-Pub 2010. PMID: 19875760.
409. Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC. Activation of FOXO3a is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer. Cancer Res 70(11):4709-4718, 2010. e-Pub 2010. PMID: 20484037.
410. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA. Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy. Cancer Invest 28(5):554-9, 2010. e-Pub 2010. PMID: 20210524.
411. Hortobagyi GN, Young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore I. A phase 2 study of a fixed combination of Uracil and Ftorafur and Leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer 116(10):2301-6, 2010. e-Pub 2010. PMID: 20225231.
412. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9(5):1120-7, 2010. e-Pub 2010. PMID: 20423993.
413. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and Survival Following Brain Metastases Among Women with Inflammatory Breast Cancer. Ann Oncol. e-Pub 2010. PMID: 20439340.
414. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer. Breast J 16(3):327-30, 2010. e-Pub 2010. PMID: 20408820.
415. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model. Mol Cancer Ther 9(5):1180-7, 2010. e-Pub 2010. PMID: 20423989.
416. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28(12):2114-22, 2010. e-Pub 2010. PMID: 20308661.
417. Le-Petross H, Kundra V, Szklaruk J, Wei W, Hortobagyi GN, Ma J. Fast three-dimensional dual echo dixon technique improves fat suppression in breast MRI. J Magn Reson Imaging 31(4):889-94, 2010. e-Pub 2010. PMID: 20373433.
418. Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28(12):2032-7, 2010. e-Pub 2010. PMID: 20308667.
419. Alvarez RH, Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 116(5):1210-7, 2010. e-Pub 2010. PMID: 20082452.
420. Hortobagyi GN, Heim W, Hutchins L, Rivera E, Mason B, Booser DJ, Kirshner J. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.[Abstracted by The Breast Cancer Network News March 8, 2010. Cancer 116(6):1440-5, 2010. e-Pub 2010. PMID: 20091835.
421. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. J Clin Oncol 28(11):1821-28, 2010. e-Pub 2010. PMID: 20231683.
422. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase. Clin Cancer Res 16(6):1802-11. e-Pub 2010. PMID: 20215547.
423. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 102(4):651-7, 2010. e-Pub 2010. PMID: 20104228.
424. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116(4):814-21, 2010. e-Pub 2010. PMID: 20052721.
425. Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows That Both High and Low Levels of HER2 Are Associated with Poor Outcome. Am J Pathol 176(4):1639-47. e-Pub 2010. PMID: 20150438.
426. Sparano JA, Hortobagyi GN, Gralow JR, Perez EA, Comis RL. Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Res Treat 119(3):511-27, 2010. e-Pub 2010. PMID: 19526354.
427. Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi G, Berinstein NL, Murray JL, Radvanyi L. Quantitative Immunohistochemical Analysis and Prognostic Significance of TRPS-1, a New GATA Transcription Factor Family Member, in Breast Cancer. Horm Cancer 1(1):21-33, 2010. e-Pub 2010. PMID: 21761348.
428. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12(1):R5. e-Pub 2010. PMID: 20064235.
429. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. J Clin Oncol 28(1):92-8, 2010. e-Pub 2010. PMID: 19933921.
430. Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat 119(2):391-8, 2010. e-Pub 2010. PMID: 19851858.
431. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women With Node-Positive, Oestrogen-Receptor-Positive Breast Cancer on Chemotherapy: A Retrospective Analysis of a Randomised Trial. Lancet Oncol 11(1):55-65, 2010. e-Pub 2010. PMID: 20005174.
432. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21(1):33-9, 2010. e-Pub 2010. PMID: 19602564.
433. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-14, 2010. e-Pub 2010. PMID: 19241157.
434. Andre F, Broglio K, Pusztai L, Berrada N, Mackey JR, Nabholtz JM, Chan S, Hortobagyi GN. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. Oncologist 15(5):476-83, 2010. e-Pub 2010. PMID: 20421265.
435. Gonzalez-Angulo AM, Hortobagyi GN. Brain metastases and breast cancer subtypes. Onkologie 33(4):143-4, 2010. e-Pub 2010. PMID: 20389139.
436. Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, Ramirez MM, Yang W, Hortobagyi GN, Theriault RL, Litton JK. Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis 31(1):1-5, 2010. e-Pub 2010. PMID: 20519803.
437. Esteva FJ, Yu D, Hung MC, Hortobagi GN. Molecular Predictors of Response to Trastuzumab and Lapatinib in Breast Cancer. Nature Rev Clin Oncol 7(2):98-107, 2010. e-Pub 2010. PMID: 20027191.
438. Hortobagyi GN. Why My Neighbor’s Health Is Important. Oncology 24(13):1238, 2010. e-Pub 2010. PMID: 21192567.
439. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381-8, 2009. e-Pub 2009. PMID: 19920100.
440. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700-6, 2009. e-Pub 2009. PMID: 19884543.
441. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S, Cristofanilli M. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 14(12):1182-8, 2009. e-Pub 2009. PMID: 19939894.
442. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Onc 20(12):1953-8, 2009. e-Pub 2009. PMID: 19596702.
443. Sparano JA, Pisano ED, White JR, Hunt KK, Mamounas EP, Perez EA, Hortobagyi GN, Gralow JR, Comis RL. Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. Breast Cancer Res Treat 120(2):273-84. e-Pub 2009. PMID: 20024613.
444. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 15(21):6639-48, 2009. e-Pub 2009. PMID: 19825949.
445. Smith GL, Xu Y, Shih YC, Giordano SH, Smith BD, Hunt KK, Strom EA, Perkins GH, Hortobagyi GN, Buchholz TA. Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg 209(4):425-433.e2, 2009. e-Pub 2009. PMID: 19801315.
446. Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol 27(26):4287-92, 2009. e-Pub 2009. PMID: 19667268.
447. Ueno NT, de Souza JA, Booser D, Nakayama K, Madewell J, Wendt RE, Hortobagyi GN, Podoloff D, Champlin RE. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer 9(3):173-7, 2009. e-Pub 2009. PMID: 19661041.
448. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27(20):3303-11, 2009. e-Pub 2009. PMID: 19451443.
449. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27(19):3185-91, 2009. e-Pub 2009. PMID: 19364972.
450. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (Accompanied by an editorial by Goodwin PJ, Ligibel JA, and Stambolic V: Metformin in Breast Cancer: Time for Action. J Clin Oncol 27(20):3297-302, 2009. e-Pub 2009. PMID: 19487376.
451. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 6(7):387-94, 2009. e-Pub 2009.
452. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D. Breast cancer metastasis: challenges and opportunities. Cancer Res 69(12):4951-3, 2009. e-Pub 2009. PMID: 19470768.
453. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine Receptors in Advanced Breast Cancer: Differential Expression in Metastatic Disease Sites With Diagnostic And Therapeutic Implications. Ann Oncol 20(6):1013-1019, 2009. e-Pub 2009. PMID: 19237480.
454. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. (Accompanied by an editorial by McCoy JM Samaras AT and Bennett CL: Providing Cancer Care to a Graying and Diverse Cancer Population in the 21st Century: Are We Prepared?). J Clin Oncol 27(17):2758-65, 2009. e-Pub 2009. PMID: 19403886.
455. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116-24, 2009. e-Pub 2009. PMID: 19435916.
456. Ma J, Costelloe CM, Madewell JE, Hortobagyi GN, Green MC, Cao G, Sun F, Kundra V. Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases. J Magn Reson Imaging 29(5):1154-62, 2009. e-Pub 2009. PMID: 19388121.
457. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. e-Pub 2009. PMID: 19280625.
458. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15(7):2472-8, 2009. e-Pub 2009. PMID: 19276248.
459. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 27(13):2170-6. e-Pub 2009. PMID: 19307509.
460. Ready K, Vogel K, Atchley D, Broglio K, Solomon K, Amos C, Lu K, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO Model Among Women with Bilateral Breast Cancer. Cancer 115(4):725-30, 2009. e-Pub 2009. PMID: 19127556.
461. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15(2):441-51, 2009. e-Pub 2009. PMID: 19147748.
462. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. J Clin Oncol 27(2):220-6, 2009. e-Pub 2009. PMID: 19047281.
463. Andre F, Job B, Dessen P, tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular Characterization of Breast Cancer with High-resolution Oligonucleotide Comparative Genomic Hybridization array. Clin Cancer Res 15(2):441-451, 2009. e-Pub 2009.
464. Arun B, Vogel KJ, Solomon TL, Lopez A, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, and Albarracin CT. High Prevalence of Pre-invasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prev Res 2(2):122-7. e-Pub 2009. PMID: 19174581.
465. Tabchy A, Hennessy BT, Hortobagyi G, Mills GB. Systems Biology of Breast Cancer. Current Breast Cancer Reports 1:238-245. e-Pub 2009.
466. Green MC, Esteva FJ, Hortobagyi GN. Neoadjuvant Chemotherapy. Breast Dis(21):23-31, 2009. e-Pub 2009. PMID: 19729775.
467. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20(4):621-627, 2009. e-Pub 2009. PMID: 19150943.
468. Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res 11(1):R12, 2009. e-Pub 2009. PMID: 19239702.
469. Hortobagyi GN, Balch CM. Accomplishments in Academic Leadership. Breast Diseases: A Year Book Quarterly 20(2):123, 2009. e-Pub 2009.
470. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14(23):7909-16, 2008. e-Pub 2008. PMID: 19047121.
471. Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow J, Hortobagyi GN, Livingston R. A Phase II Study of Imatinib Mesylate and Capecitabine in Metastatic Breast Cancer: Southwest Oncology Group Study 0338. Clin Breast Cancer 8(6):511-5, 2008. e-Pub 2008. PMID: 19073506.
472. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer 8(6):516-21, 2008. e-Pub 2008. PMID: 19073507.
473. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? (Abstracted in Breast Diseases: A Year Book Quarterly (20)(3):256-257, 2009. Cancer 113(9):2422-30, 2008. e-Pub 2008. PMID: 18785255.
474. Yang WT, Dryden M, Broglio K, Gilcrease M, Dawood S, Dempsey PJ, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111(3):405-10, 2008. e-Pub 2008. PMID: 18026834.
475. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072-7, 2008. e-Pub 2008. PMID: 18757321.
476. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47(9):701-6, 2008. e-Pub 2008. PMID: 18176935.
477. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.(Accompanied by an editorial: Lynch HT, Marcus JN, Rubinstein WS: Stemming the Tide of Cancer for Brca 1/2 Mutation Carriers)Abstracted in Breast Diseases: A Year Book Quarterly 20(2):145-146, 2009). J Clin Oncol 26(26):4239-4243, 2008. e-Pub 2008. PMID: 18779615.
478. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26(30):4891-8. e-Pub 2008. PMID: 18725649.
479. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179-83. e-Pub 2008. PMID: 18695137.
480. Andreopoulou E, Hortobagyi GN. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol 26(22):3660-2, 2008. e-Pub 2008. PMID: 18669447.
481. Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. J Clin Oncol 26(28):4679-83. e-Pub 2008. PMID: 18662965.
482. Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long TI, Ananthnarayan S, Liang G, Esteva FJ, Hortobagyi GN, McCormick F, Jones PA, Laird PW. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res 36(14):4689-98. e-Pub 2008. PMID: 18628296.
483. Buchholz TA, Woodward WA, Duan Z, Fang S, Oh JL, Tereffe W, Strom EA, Perkins GH, Yu TK, Hunt KK, Meric-Bernstam F, Hortobagyi GN, Giordano SH. Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 71(4):1022-7, 2008. e-Pub 2008. PMID: 18234447.
484. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242-8, 2008. e-Pub 2008. PMID: 18334512.
485. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 7(7):1846-50, 2008. e-Pub 2008. PMID: 18644997.
486. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone Receptor Status and Pathologic Response of HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Trastuzumab. Ann Oncol 2008 19(12):2020-2025. e-Pub 2008. PMID: 18667396.
487. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer, 2008. e-Pub 2008. PMID: 18560403.
488. Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 26(16):2636-43, 2008. e-Pub 2008. PMID: 18509176.
489. Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer 112(11):2456-66, 2008. e-Pub 2008. PMID: 18428196.
490. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826-36, 2008. e-Pub 2008. PMID: 18558816.
491. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 109(3):417-26, 2008. e-Pub 2008. PMID: 17653852.
492. Rao R, Feng L, Kuerer HM, Singletary SE, Bedrosian I, Hunt KK, Ross MI, Hortobagyi GN, Feig BW, Ames FC, Babiera GV. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 15(6):1696-702, 2008. e-Pub 2008. PMID: 18357493.
493. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68(9):3243-50, 2008. e-Pub 2008. PMID: 18451150.
494. Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 13(5):494-502, 2008. e-Pub 2008. PMID: 18515734.
495. Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol 26(15):2482-8, 2008. e-Pub 2008. PMID: 18427152.
496. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Gonzalez-Angulo AM. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112(9):1905-11, 2008. e-Pub 2008. PMID: 18300243.
497. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13(5):477-93, 2008. e-Pub 2008. PMID: 18515733.
498. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455-61, 2008. e-Pub 2008. PMID: 18300256.
499. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA. Locoregional Treatment Outcomes After Multimodality Management Of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys, 2008. e-Pub 2008. PMID: 18439768.
500. Srokowski TP, Fang S, Duan Z, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH. Completion of adjuvant radiation therapy among women with breast cancer. (Abstracted in Breast Diseases: A Year Book Quarterly 20(3):307-308, 2009. Cancer 113(1):22-29, 2008. e-Pub 2008. PMID: 18442124.
501. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, Cristofanilli M. Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res 14(6):1718-25, 2008. e-Pub 2008. PMID: 18347172.
502. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-81, 2008. e-Pub 2008. PMID: 18250347.
503. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10(2):138-48, 2008. e-Pub 2008. PMID: 18204439.
504. Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, Meslin F, Spielmann M, Tomasic G, Pusztai L, Hortobagyi GN, Michiels S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 19(2):315-20, 2008. e-Pub 2008. PMID: 17804473.
505. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13(1):6-15, 2008. e-Pub 2008. PMID: 18245008.
506. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 14(1):62-8, 2008. e-Pub 2008. PMID: 18303485.
507. El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi G. Guideline Implementation for Breast Healthcare in Low- and Middle-Income Countries: Diagnosis Resource Allocation. Cancer 113(S8):2257-2268, 2008. e-Pub 2008. PMID: 18837018.
508. El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi G: on behalf of the Breast Health Global Initiative Systemic Therapy Focus Group The Breast Health Global Initiative Systemic Therapy Focus Group Members Included Aziz Z, Bines J, Budrukkar A, Carlson R, Cazap E, El Saghir N, Elzawawy A, Eniu A, Hortobagyi G, Jakesz R, Love R, Reyes JM, Russell C, and Vorobiof D. Locally Advanced Breast Cancer: Treatment Guideline Implementation With Particular Attention to Low-and Middle Income Countries. Cancer 113((S8)):2315-2324, 2008. e-Pub 2008. PMID: 18837023.
509. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-148, 2008. e-Pub 2008. PMID: 18581139.
510. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations. Ann Oncol 2008 19(10):1713-1719, 2008. e-Pub 2008. PMID: 18515258.
511. Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10(2):R37, 2008. e-Pub 2008. PMID: 18445275.
512. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 10(2):R27, 2008. e-Pub 2008. PMID: 18371219.
513. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. The Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast cancer patients Treated with Neoadjuvant Therapy. (Abstracted in Breast Diseases: A Year Book Quarterly 19(4):358-9, 2009. J Clin Onc 26(2):246-252, 2008. e-Pub 2008. PMID: 18056680.
514. Beinart G, Gonzalez-Angulo AM, Broglio K, Mejia J, Ruggeri A, Mininberg E, Hortobagyi GN, Valero V. Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clin Breast Cancer 7(11):867-74, 2007. e-Pub 2007. PMID: 18269777.
515. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414-22, 2007. e-Pub 2007. PMID: 17785706.
516. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110(7):1436-44, 2007. e-Pub 2007. PMID: 17694554.
517. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 2007. e-Pub 2007. PMID: 17676585.
518. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 110(6):1195-200, 2007. e-Pub 2007. PMID: 17647266.
519. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25(25):3871-6, 2007. e-Pub 2007. PMID: 17664457.
520. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13(16):4943-8, 2007. e-Pub 2007. PMID: 17699874.
521. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130(3):440-55, 2007. e-Pub 2007. PMID: 17693255.
522. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, and Hortobagyi GN. Inflammatory Breast Cancer and Patterns of Recurrence: Understanding the Biology of a Unique Disease. Cancer. e-Pub 2007.
523. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6(8):2168-77, 2007. e-Pub 2007. PMID: 17671085.
524. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobagyi GN. Trends for inflammatory breast cancer: is survival improving?. Oncologist 12(8):904-12, 2007. e-Pub 2007. PMID: 17766649.
525. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-9, 2007. e-Pub 2007. PMID: 17418973.
526. Peintinger F, Anderson K, Mazouni C, Kuerer HM, Hatzis C, Lin F, Hortobagyi GN, Symmans WF, Pusztai L. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clin Cancer Res 13(14):4078-82, 2007. e-Pub 2007. PMID: 17634532.
527. Sher T, Hennessy BT, Valero V, Broglio K, Woodward WA, Trent J, Hunt KK, Hortobagyi GN, Gonzalez-Angulo AM. Primary angiosarcomas of the breast. Cancer 110(1):173-8, 2007. e-Pub 2007. PMID: 17541936.
528. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25(19):2650-5, 2007. e-Pub 2007. PMID: 17602071.
529. Yang WT, Le-Petross HT, Macapinlac H, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, M: C. Inflammatory Breast Cancer - PET/CT, MRI, Mammography, and Sonography Findings. Breast Cancer Res Treat. e-Pub 2007.
530. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67(12):5779-88, 2007. e-Pub 2007. PMID: 17575145.
531. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 18(6):1021-9, 2007. e-Pub 2007. PMID: 17351259.
532. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18(5):874-80, 2007. e-Pub 2007. PMID: 17293601.
533. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 Expression and Efficacy of Preoperative Paclitaxel/FAC Chemotherapy in Breast Cancer. Breast Cancer Res Treat 108(2):183-90. e-Pub 2007. PMID: 17468948.
534. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8(3):203-11, 2007. e-Pub 2007. PMID: 17329190.
535. Cabioglu, N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, and Cristofanilli M. Expression of Growth Factor and Chemokine Receptors: New insights in the Biology of Inflammatory Breast Cancer. Ann Oncol 18(6):1021-1029, 2007. e-Pub 2007.
536. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 7(6):471-9, 2007. e-Pub 2007. PMID: 17386124.
537. Huang EH, Strom EA, Valero V, Fornage B, Perkins GH, Oh JL, Yu TK, Tereffe W, Woodward WA, Hunt KK, Meric-Bernstam F, Sahin AA, Bedrosian I, Hortobagyi GN, Buchholz TA. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys 67:490-6, 2007. e-Pub 2007. PMID: 17236970.
538. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109:496-501, 2007. e-Pub 2007. PMID: 17149760.
539. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-33, 2007. e-Pub 2007. PMID: 17200359.
540. Brewster AM, Do KA, Thompson PA, Hahn KM, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML. Relationship between Epidemiological Risk Factors and Breast Cancer Recurrence. J Clin Onc 25(28):4438-4444, 2007. e-Pub 2007. PMID: 17785707.
541. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos C, Lu KH, Hortobagyi GN, Arun B. BRCA1 and BRCA2 Genetic Testing in Hispanic Patients: Mutation Prevalence and Evaluation of the BRCAPRO Risk Assessment Model. Clin Oncol 25(29):4635-4614, 2007. e-Pub 2007. PMID: 17925560.
542. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC. EGFR Cooperates with STAT3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression. Cancer Res 67(19):9066-9076, 2007. e-Pub 2007. PMID: 17909010.
543. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Broglio K, Hortobagyi GN, Valero V. Overall Survival and Cause-specific Mortality of Patients with Stage T1a,b N0 M0 Breast Carcinoma. J Clin Oncol 25(3):4952-4960, 2007. e-Pub 2007. PMID: 17971593.
544. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Hortobagyi GN, Yang W, Albarracin C, Meric F, R: T. Development of new cancers in patients with DCIS: The MD Anderson Experience. Ann Sug Oncol 15(1):244-249, 2007. e-Pub 2007. PMID: 18043978.
545. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E. Clinicopathologic Characteristics and Prognostic Factors in 420 Metastatic Breast Cancer Patients with Central Nervous System Metastases ((Abstracted in Breast Diseases: A Year Book Quarterly 19(3):245-6, 2008). Cancer 110(12):2640-7, 2007. e-Pub 2007. PMID: 17960791.
546. Peintinger F, Anderson K, Mazouni C, Kuerer HM, Hatzis C, Lin F, Hortobagyi GN, Symmans WF, Pusztai L. Thirty-gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preopertative chemotherapy for Breast Cancer. Clin Cancer Res 15(13):4078-4082, 2007. e-Pub 2007.
547. Yamasaki F, Hortobagyi GN, Kurisu K, NT: U. Sensitivity to Erlotinib Depends on Cyclin-Dependent Kinase 2 Activity. Molecular-Cancer Therapeutics 6(8):2168-2177, 2007. e-Pub 2007.
548. Patt DA, Duan Z, Fang S, Hortobagyi GN, SH: G. Acute Myeloid Leukemia after Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk. J Clin Oncol 25(25):3871-3876, 2007. e-Pub 2007.
549. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, B: A. Multifocal Breast Cancer in Women < 35 Years Old. Cancer, 2007. e-Pub 2007.
550. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, GN: H. Trends for Inflammatory Breast Cancer: Is Survival Improving?. The Oncologist 12(8):904-912, 2007. e-Pub 2007.
551. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU. Efficacy and Safety of Neoadjuvant Trastuzumab Combined with Paclitaxel and Epirubicin: A Retrospective Review of the M.D. Anderson Experience. Cancer 110(6):1195-1200, 2007. e-Pub 2007.
552. Beinart GA, Gonzalez-Angulo AM, Broglio K, Frye D, Walters R, Holmes FA, Gunale S, Booser D, Rosenthal J, Dhingra K, Young JA, Hortobagyi GN. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemotherapy Pharmacol 60(1):61-67, 2007. e-Pub 2007. PMID: 17009032.
553. Cristofanilli M, Broglio RK, Guarneri V, Jackson, S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno N, Hortobagyi GN Valero V. Circulating Tumor Celles in Metastatic Breast Cancer: Biological Staging Beyond Tumor Burden. Clin Breast Cancer 7(6):471-479, 2007. e-Pub 2007.
554. Andre F, Hatzis C, Anderson K, Sotiriu C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 13(7):2061-2067, 2007. e-Pub 2007.
555. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, and Buchholz TA. Postmastectomy Radiation Improves the Outcome of Patients with Locally Advanced Breast Cancer Who Achieve a Pathologic Complete Response to Neoadjuvant Chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-1009, 2007. e-Pub 2007.
556. Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, and Mavligit G. Pilot Study of Regional, Hepatic Intra-Arterial Paclitaxel in Patients with Breast Carcinoma Metastatic to the Liver. Cancer 109(11):2190-2196, 2007. e-Pub 2007.
557. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, and Sneige N. Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials. Clin Cancer Resh 13(16):4943-4948, 2007. e-Pub 2007.
558. Lu CH, Wyszomierski SL, Sun MH, Lan KH, Neal CL, Rodriguez-Cruz T, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Pre-clinical Testing of Clinically Applicable Strategies for Overcoming Herceptin Resistance Caused by PTEN Deficiency. Clin Cancer Res 13(9):5883-5888, 2007. e-Pub 2007. PMID: 17908983.
559. Mazouni C, Peintinger F, Kau SW, Andre F, Gonzalez-Angulo A, Symmans WF, Meric F, Valero V, Hortobagyi GN, Pusztai L. Residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25(19):2650-2655, 2007. e-Pub 2007.
560. Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, De La Garza JG. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. Int J Radiat Oncol Biol Phys 13(6):551-556, 2007. e-Pub 2007. PMID: 17983394.
561. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Mukhopadhyay P, Mullaney B, Peck R, Hortobagyi GN. Efficacy and Safety of Ixabepilone (BMS-247550), a Novel Epothilone Analog, in a Phase II Study of Patients with Advanced Breast Cancer Resistant to and Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 25(23):3407-3414, 2007. e-Pub 2007.
562. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808-3815, 2007. e-Pub 2007. PMID: 17664460.
563. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Downregulation of MMAC1/PTEN and Upregulation of Phosphorylated Akt. Cancer Res 67(12):5779-5788, 2007. e-Pub 2007.
564. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement Of Residual Cancer Burden To Predict Survival After Neoadjuvant Chemotherapy. J Clin Oncol 25(28):4414-4422, 2007. e-Pub 2007. PMID: 177857706.
565. Sher T, Hennessy BT, Valero V, Broglio K, Woodward WA, Trent J, Hunt KK, Hortobagyi GN, AM: G. Primary Angiosarcomas of the Breast. Cancer 110(1):173-178, 2007. e-Pub 2007.
566. Mazouni C, Kau SW, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of Taxanes, Particularly Weekly Paclitaxel, in Preoperative Chemotherapy Improves Pathologic Complete Response Rate in Estrogen Receptor-positive Breast Cancers. Ann Oncol 18(5):874-880, 2007. e-Pub 2007.
567. D-F L, H-P K, C-T C, J-M H, C-K C, Wei Y, L-Y L, Ping B, W-C H, He X, J-Y H, C-C L, Ding Q, J-L S, J-Y Y, Sahin AA, Hortobagyi GN, F-J T, C-H T, M-C H. Suppression of TSC1 by IKKβ Confers tumor Angiogenesis Through the mTOR Pathway. Cell 130(3):440-455, 2007. e-Pub 2007.
568. Woodward WA, Huang EH, McNeese MD, Perkins GH, Tucker SL, Strom EA, Middleton L, Hahn K, Hortobagyi GN, Buchholz TA. African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer 107:2662-8, 2006. e-Pub 2006. PMID: 17061247.
569. Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer 7:396-400, 2006. e-Pub 2006. PMID: 17239264.
570. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Personalized medicine for breast cancer: moving forward and going back. Per Med 3(4):363-370, 2006. e-Pub 2006. PMID: 29788594.
571. Gonzalez-Angulo AM, Guarneri V, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, Hortobagyi GN, Esteva FJ. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin Breast Cancer 7:326-30, 2006. e-Pub 2006. PMID: 17092400.
572. Yu Z, Xia W, Wang HY, Wang SC, Pan Y, Kwong KY, Hortobagyi GN, Hung MC. Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol Carcinog 45(9):667-75, 2006. e-Pub 2006. PMID: 16652376.
573. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. (Accompanied by an editorial: Hayes DF and Picard MH Heart of Darkness: The Downside of Trastuzumab. J Clin Oncol 24(25): 4056-4058 (Abstracted in Breast Diseases: A Year Book Quarterly 18(2):205, 2007. J Clin Oncol 24(25):4107-15, 2006. e-Pub 2006. PMID: 16908934.
574. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107(5):935-44, 2006. e-Pub 2006. PMID: 16874816.
575. Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys, 2006. e-Pub 2006. PMID: 16887286.
576. Xia WY, Lien HC, Wang SC, Pan Y, Sahin A, Kuo YH, Chang KJ, Zhou X, Wang H, Yu Z, Hortobagyi G, Shi DR, Hung MC. Expression of PEA3 and Lack of Correlation Between PEA3 and HER-2/neu Expression in Breast Cancer. Breast Cancer Res Treat 98(3):295-301, 2006. e-Pub 2006. PMID: 16752078.
577. Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer. e-Pub 2006. PMID: 16948128.
578. Hess KR, Anderson K, Fraser Symmans W, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. J Clin Oncol, 2006. e-Pub 2006. PMID: 16896004.
579. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107(6):1348-1354, 2006. e-Pub 2006. PMID: 16909414.
580. Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, Yang W, Perkins G, Hortobagyi GN, Theriault RL. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107(6):1219-1226, 2006. e-Pub 2006. PMID: 16894524.
581. Buchholz TA, Strom EA, Oswald MJ, Perkins GH, Oh J, Domain D, Yu TK, Woodward WA, Tereffe W, Singletary SE, Thomas E, Buzdar AU, Hortobagyi GN, McNeese MD. Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys 65(4):1155-60, 2006. e-Pub 2006. PMID: 16750325.
582. Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 13(7):706-19, 2006. e-Pub 2006. PMID: 16514421.
583. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer.(Accompanied by an Editorial: Silliman RA, Ganz PA: Adjuvant Chemotherapy Use and Outcomes in Older Women with Breast Cancer: What Have We Learned?. J Clin Oncol 24(18):2750-6, 2006. e-Pub 2006. PMID: 16782915.
584. Woodward WA, Giordano SH, Duan Z, Hortobagyi GN, Buchholz TA. Supraclavicular radiation for breast cancer does not increase the 10-year risk of stroke. Cancer 106(12):2556-62, 2006. e-Pub 2006. PMID: 16691617.
585. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106(11):2327-36, 2006. e-Pub 2006. PMID: 16639731.
586. Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK, Ross MI, Gwyn KM, Feig BW, Ames FC, Hortobagyi GN. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 13(6):776-82, 2006. e-Pub 2006. PMID: 16614878.
587. Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17(5):813-7, 2006. e-Pub 2006. PMID: 16403809.
588. Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, Babiera G, Hortobagyi GN, Valero V. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 17(4):605-13, 2006. e-Pub 2006. PMID: 16469754.
589. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24(12):1940-9, 2006. e-Pub 2006. PMID: 16622270.
590. Avis NE, Smith KW, Link CL, Hortobagyi GN, Rivera E. Factors associated with participation in breast cancer treatment clinical trials. J Clin Oncol 24(12):1860-7, 2006. e-Pub 2006. PMID: 16622260.
591. Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi G, Mettinger KL, Cristofanilli M. Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol 57:540-4, 2006. e-Pub 2006. PMID: 16193332.
592. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106(5):1000-6, 2006. e-Pub 2006. PMID: 16444747.
593. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7):1037-44, 2006. e-Pub 2006. PMID: 16505422.
594. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Freeman J, Goodwin JS. Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst 98(6):382-8, 2006. e-Pub 2006. PMID: 16537830.
595. Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res 12(6):1721-7, 2006. e-Pub 2006. PMID: 16551855.
596. Chen IF, Ou-Yang F, Hung JY, Liu JC, Wang H, Wang SC, Hou MF, Hortobagyi GN, Hung MC. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Mol Cancer Ther 5(1):1-7, 2006. e-Pub 2006. PMID: 16432157.
597. Ou-Yang F, Lan KL, Chen CT, Liu JC, Weng CL, Chou CK, Xie X, Hung JY, Wei Y, Hortobagyi GN, Hung MC. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 66(1):378-84, 2006. e-Pub 2006. PMID: 16397252.
598. Groot MT, Baltussen R, Uyl-de Groot CA, Anderson BO, Hortobagyi GN. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J 12 Suppl 1:S81-90, 2006. e-Pub 2006. PMID: 16430401.
599. Eniu A, Carlson RW, Aziz Z, Bines J, Hortobagyi GN, Bese NS, Love RR, Vikram B, Kurkure A, Anderson BO. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J 12 Suppl 1:S38-53, 2006. e-Pub 2006. PMID: 16430398.
600. Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN. Adjuvant systemic therapy for male breast carcinoma. Cancer 104(11):2359-64, 2005. e-Pub 2005. PMID: 16270318.
601. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23(36):9304-11, 2005. e-Pub 2005. PMID: 16361629.
602. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer 12(4):1059-69, 2005. e-Pub 2005. PMID: 16322343.
603. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 11(23):8398-402, 2005. e-Pub 2005. PMID: 16322301.
604. Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V, Hortobagyi GN. Squamous cell carcinoma of the breast. J Clin Oncol 23(31):7827-35, 2005. e-Pub 2005. PMID: 16258085.
605. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23(33):8331-9, 2005. e-Pub 2005. PMID: 16293864.
606. Schechter NR, Strom EA, Perkins GH, Arzu I, McNeese MD, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Babiera G, Hunt KK, Hortobagyi GN, Buchholz TA. Immediate breast reconstruction can impact postmastectomy irradiation. Am J Clin Oncol 28(5):485-94, 2005. e-Pub 2005. PMID: 16199989.
607. Patt DA, Goodwin JS, Kuo YF, Freeman JL, Zhang DD, Buchholz TA, Hortobagyi GN, Giordano SH. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 23(30):7475-82, 2005. e-Pub 2005. PMID: 16157933.
608. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23(29):7265-77, 2005. e-Pub 2005. PMID: 16145055.
609. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23(28):7098-104, 2005. e-Pub 2005. PMID: 16192593.
610. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-92, 2005. e-Pub 2005. PMID: 16087943.
611. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019-26, 2005. e-Pub 2005. PMID: 16135470.
612. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 104(6):1158-71, 2005. e-Pub 2005. PMID: 16047352.
613. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 104(4):676-81, 2005. e-Pub 2005. PMID: 15981280.
614. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11(16):5686-93, 2005. e-Pub 2005. PMID: 16115904.
615. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Different Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-85, 2005. e-Pub 2005. PMID: 16115903.
616. Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn 7(3):357-67, 2005. e-Pub 2005. PMID: 16049308.
617. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104(4):682-91, 2005. e-Pub 2005. PMID: 15986399.
618. Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer 104(2):229-35, 2005. e-Pub 2005. PMID: 15937910.
619. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 62(2):351-7, 2005. e-Pub 2005. PMID: 15890574.
620. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-85, 2005. e-Pub 2005. PMID: 15738535.
621. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 103(12):2466-72, 2005. e-Pub 2005. PMID: 15852360.
622. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 102(23):8315-20, 2005. e-Pub 2005. PMID: 15914550.
623. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11:3315-9, 2005. e-Pub 2005. PMID: 15867229.
624. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7):1420-30, 2005. e-Pub 2005. PMID: 15735118.
625. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103(6):1122-8, 2005. e-Pub 2005. PMID: 15712375.
626. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97(6):419-24, 2005. e-Pub 2005. PMID: 15770005.
627. Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML. Breast cancer treatment guidelines in older women. J Clin Oncol 23(4):783-91, 2005. e-Pub 2005. PMID: 15681522.
628. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Babiera G, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy. Cancer 103(4):689-95, 2005. e-Pub 2005. PMID: 15641036.
629. Bartholomeusz G, Wu Y, Ali Seyed M, Xia W, Kwong KY, Hortobagyi G, Hung MC. Nuclear translocation of the pro-apoptotic Bcl-2 family member Bok induces apoptosis. Mol Carcinogen 45:73-83, 2005. e-Pub 2005. PMID: 16302269.
630. Esteva FJ, Hortobagyi GN. Targeting the Tumor: Translating Genetic and Molecular Profiling into Clinical Reality. Business Briefing: US Oncology Review:2-4, 2005. e-Pub 2005.
631. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. A Study of Gene Expression Profiles and the Prediction of Long-Term Survival in Patients with Node Negative Breast Cancer. Clin Cancer Res 11(9):3315-3319, 2005. e-Pub 2005.
632. Montero A, Booser D, Esparza-Guerra L, Murray J, Rosales M, Hortobagyi G, Valero V. Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer. Drugs R D 6(5):299-305, 2005. e-Pub 2005. PMID: 16128600.
633. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23(1):41-8, 2005. e-Pub 2005. PMID: 15625359.
634. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 22(23):4691-9, 2004. e-Pub 2004. PMID: 15570071.
635. Cheng YC, Rondon G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 10(11):794-804, 2004. e-Pub 2004. PMID: 15505610.
636. Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 96(22):1676-81, 2004. e-Pub 2004. PMID: 15547180.
637. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6(5):459-69, 2004. e-Pub 2004. PMID: 15542430.
638. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101(7):1508-13, 2004. e-Pub 2004. PMID: 15378497.
639. Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo Aldaz C, Hortobagyi GN, Pusztai L. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat 87(3):205-14, 2004. e-Pub 2004. PMID: 15528963.
640. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101(8):1760-6, 2004. e-Pub 2004. PMID: 15386311.
641. Resetkova E, Gonzalez-Angulo AM, Sneige N, McDonnell TJ, Buzdar AU, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN, Cristofanilli M. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer 101(5):913-7, 2004. e-Pub 2004. PMID: 15329897.
642. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 10(18 Pt 1):6215-21, 2004. e-Pub 2004. PMID: 15448010.
643. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS. The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 91(6):1190-4, 2004. e-Pub 2004. PMID: 15305194.
644. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 59(5):1337-42, 2004. e-Pub 2004. PMID: 15275718.
645. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117-27, 2004. e-Pub 2004. PMID: 15324695.
646. Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101(2):258-63, 2004. e-Pub 2004. PMID: 15241821.
647. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 101(1):51-7, 2004. e-Pub 2004. PMID: 15221988.
648. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22(12):2303-12, 2004. e-Pub 2004. PMID: 15197191.
649. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 22(12):2294-302, 2004. e-Pub 2004. PMID: 15197190.
650. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 2004. e-Pub 2004. PMID: 15136595.
651. Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Jr, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100(9):1814-22, 2004. e-Pub 2004. PMID: 15112261.
652. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 59(1):138-45, 2004. e-Pub 2004. PMID: 15093909.
653. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100(7):1365-73, 2004. e-Pub 2004. PMID: 15042669.
654. Yan DH, Wen Y, Su LK, Xia W, Wang SC, Zhang S, Gan L, Lee DF, Spohn B, Frey JA, Hortobagyi GN, Hung MC. A delayed chemically induced tumorigenesis in Brca2 mutant mice. Oncogene 23(10):1896-901, 2004. e-Pub 2004. PMID: 14981540.
655. Rivera E, Valero V, Francis D, Asnis AG, Schaaf LJ, Duncan B, Hortobagyi GN. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 10(6):1943-8, 2004. e-Pub 2004. PMID: 15041710.
656. Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, Hortobagyi GN. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 100:465-9, 2004. e-Pub 2004. PMID: 14745861.
657. Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, Bodurka DC, Basen-Engquist K, Hortobagyi GN, Kavanagh JJ, Smith JA. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22(4):671-7, 2004. e-Pub 2004. PMID: 14966090.
658. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100(3):499-506, 2004. e-Pub 2004. PMID: 14745865.
659. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer 4(6):415-9, 2004. e-Pub 2004. PMID: 15023242.
660. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102, 2004. e-Pub 2004. PMID: 14698135.
661. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving?. Cancer 100(1):44-52, 2004. e-Pub 2004. PMID: 14692023.
662. Schwartz GF Hortobagyi GN, Conference Committee TC. Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast, April 26-28, 2003, Philadelphia, PA. The Breast J 10(4):273-294, 2004. e-Pub 2004.
663. Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Jr, Hortobagyi GN. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest 22(2):248-56, 2004. e-Pub 2004. PMID: 15199607.
664. Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S, Hung MC. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 100(1):12-9, 2004. e-Pub 2004. PMID: 14692019.
665. Cristofanilli M Hortobagyi GN. Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective. Oncologist 9(4):471-8, 2004. e-Pub 2004. PMID: 15266101.
666. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 2003. e-Pub 2003. PMID: 12881308.
667. Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, Buzdar AU, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 57(2):336-44, 2003. e-Pub 2003. PMID: 12957243.
668. Woodward WA, Strom EA, McNeese MD, Perkins GH, Outlaw EL, Hortobagyi GN, Buzdar AU, Buchholz TA. Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. Int J Radiat Oncol Biol Phys 57(2):327-35, 2003. e-Pub 2003. PMID: 12957242.
669. Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, Singletary SE, Theriault RL, Hortobagyi GN, Hunt KK, Buchholz TA. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21(17):3244-8, 2003. e-Pub 2003. PMID: 12947058.
670. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21(18):3454-61, 2003. e-Pub 2003. PMID: 12972520.
671. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, rd, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21(17):3249-54, 2003. e-Pub 2003. PMID: 12947059.
672. Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, Colucci P, DeJager R, Hortobagyi GN. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer 98(5):900-7, 2003. e-Pub 2003. PMID: 12942555.
673. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ, Kumar R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 9(8):3198-203, 2003. e-Pub 2003. PMID: 12912973.
674. Chagpar A, Meric-Bernstam F, Hunt KK, Ross MI, Cristofanilli M, Singletary SE, Buchholz TA, Ames FC, Marcy S, Babiera GV, Feig BW, Hortobagyi GN, Kuerer HM. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol 10(6):628-34, 2003. e-Pub 2003. PMID: 12839847.
675. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9(7):2406-15, 2003. e-Pub 2003. PMID: 12855612.
676. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9(7):2426-34, 2003. e-Pub 2003. PMID: 12855614.
677. Rivera E, Erder MH, Moore TD, Shiftan TL, Knight CA, Fridman M, Brannan C, Danel-Moore L, Hortobagyi GN. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model. Cancer 98(2):222-8, 2003. e-Pub 2003. PMID: 12872339.
678. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer 97(11):2716-23, 2003. e-Pub 2003. PMID: 12767083.
679. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12):2960-71, 2003. e-Pub 2003. PMID: 12784330.
680. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97(7):1758-65, 2003. e-Pub 2003. PMID: 12655533.
681. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78(1):105-18, 2003. e-Pub 2003. PMID: 12611463.
682. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 21(6):999-1006, 2003. e-Pub 2003. PMID: 12637463.
683. Rivera E, Haim Erder M, Fridman M, Frye D, Hortobagyi GN. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Res 5(5):R114-20, 2003. e-Pub 2003. PMID: 12927041.
684. Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagyi GN. Molecular Profiles of Invasive Mucinous and Invasive Ductal Carcinomas of the Breast, a Molecular Case Study. . Cancer Genetics and Cytogenetics 141(2):148-153, 2003. e-Pub 2003. PMID: 12606133.
685. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9(1):33-41, 2003. e-Pub 2003. PMID: 12602766.
686. Offit K, Bertagnolli MM, Bombard AT, Come S, Eng C, Garber JE, Joffe S, Greene MH, Tucker MA, Gruber SB, Guillem JG, Robson M, Halberg FE, Hampel H, Olopade OI, Rieger PT, Rodriguez-Bigas MA, Tomlinson G, Watson MS, Weber BL, Weitzel J, Wiesner GL, Niederhuber JE, Forastiere AA, Baggstrom MQ, Balducci L, Bosserman LD, Bosworth LL, Brose M, Schnipper LE, Cripe LD, Fisch M, Hortobagyi GN, Zwelling LA, Gesme D, Goldstein M, Gordon BG, Gralow J, Grunberg SM, Klimberg VS, Kuzel T, Lessin LS, Pazdur R, Pfister DG, Runowicz CD, Schuchter LM, Sigal EV, Stovall E, Ward JH. American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility. . J Clin Oncol 21(12):2397-2406, 2003. e-Pub 2003. PMID: 12692171.
687. Niederhuber JE, Forastiere AA, Baggstrom MQ, Balducci L, Bosserman LD, Bosworth JL, Brose M, Goldstein M, Cripe LD, Fisch M, Hortobagyi GN, Zwelling L, Gesme D, Gordon BG, Gralow J, Grunberg SM, Klimberg VS, Kuzel T, Lessin S, Pazdur R, Pfister DG, Runowicz CD, Come SE, Schnipper LE, Schuchter LM, Sigal EV, Stovall E, Ward JH. American Society of Clinical Oncology policy statement update: Tobacco control-reducing cancer incidence and saving. . J Clin Oncol 21(14):2777-2786, 2003. e-Pub 2003. PMID: 12777442.
688. Schnipper LE, Atkins M, Beveridge RA, Brenner D, Bunn P, Coleman E, Comis RL, Einhorn L, Emanuel E, Fields S, Forastiere A, Gordon BG, Halberg F, Haluska F, Hortobagyi G, Kolker A, Miller LL, Norton L, Sallan S, Scherr S, Niederhuber JE, Baggstrom MQ, Balducci L, Bosserman LD, Bosworth LL, Brose M, Come SE, Cripe LD, Fisch M, Gesme D, Goldstein M, Gordon BG, Gostout B, Gralow J, Grunberg SM, Klimberg VS, Kuzel T, Lessin LS, Pazdur R, Pfister DG, Raghavan D, Runowicz CD, Schuchter LM, Schwartz BS, Sigal EV, Stovall E, Ward JH, Zwelling LA. American Society of Clinical Oncology Policy Statement: Oversight of Clinical Research. J Clin Oncol 21(12):2377-2386, 2003. e-Pub 2003. PMID: 12721281.
689. Pusztai L, Ayers M, Simmans FW, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi GN, Stec J. Emerging Science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. (Oral presentation at the plenary session). J Clin Oncol 21(23SI):237S, 2003. e-Pub 2003.
690. Vlastos G, Mirza NQ, Meric F, Hunt KK, Mirza AN, Newman LA, Ames FC, Kuerer HM, Ross MI, Feig B, Babiera G, Buchholz TA, Hortobagyi GN, Singletary SE. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol 9(9):912-9, 2002. e-Pub 2002. PMID: 12417515.
691. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Smith TL, Theriault RL. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 95(9):1817-26, 2002. e-Pub 2002. PMID: 12404273.
692. Silva EG, Mistry D, Li D, Kuerer HM, Atkinson EN, Lopez AN, Shannon R, Hortobagyi GN. Elevated luteinizing hormone in serum, breast cancer tissue, and normal breast tissue from breast cancer patients. Breast Cancer Res Treat 76(2):125-30, 2002. e-Pub 2002. PMID: 12452449.
693. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8(11):3407-18, 2002. e-Pub 2002. PMID: 12429628.
694. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8(6):461-8, 2002. e-Pub 2002. PMID: 12500855.
695. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 347(20):1566-75, 2002. e-Pub 2002. PMID: 12432043.
696. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 8(11):3360-8, 2002. e-Pub 2002. PMID: 12429622.
697. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62(20):5703-10, 2002. e-Pub 2002. PMID: 12384528.
698. Ding Y, Wen Y, Spohn B, Wang L, Xia W, Kwong KY, Shao R, Li Z, Hortobagyi GN, Hung MC, Yan DH. Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer. Clin Cancer Res 8(10):3290-7, 2002. e-Pub 2002. PMID: 12374701.
699. Huang E, McNeese MD, Strom EA, Perkins GH, Katz A, Hortobagyi GN, Valero V, Kuerer HM, Singletary SE, Hunt KK, Buzdar AU, Buchholz TA. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys 53(5):1225-33, 2002. e-Pub 2002. PMID: 12128124.
700. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ, Vadlamudi RK. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418(6898):654-7, 2002. e-Pub 2002. PMID: 12167865.
701. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53(4):880-8, 2002. e-Pub 2002. PMID: 12095553.
702. Meric F, Buchholz TA, Mirza NQ, Vlastos G, Ames FC, Ross MI, Pollock RE, Singletary SE, Feig BW, Kuerer HM, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 9(6):543-9, 2002. e-Pub 2002. PMID: 12095969.
703. Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 50(1):6-8, 2002. e-Pub 2002. PMID: 12111105.
704. Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, Esteva FJ, Hortobagyi GN, Sahin AA. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94(12):3107-14, 2002. e-Pub 2002. PMID: 12115341.
705. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 11(6):587-90, 2002. e-Pub 2002. PMID: 12050101.
706. Rivera E, Valero V, Cristofanilli M, Frye DK, Booser DJ, Rosales MM, Hortobagyi GN. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. Cancer 94(9):2321-6, 2002. e-Pub 2002. PMID: 12015755.
707. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8(5):1073-9, 2002. e-Pub 2002. PMID: 12006521.
708. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038-44, 2002. e-Pub 2002. PMID: 12006516.
709. Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 49(4):299-302, 2002. e-Pub 2002. PMID: 11914909.
710. Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 13(2):218-21, 2002. e-Pub 2002. PMID: 11885997.
711. Cristofanilli M, De Gasperis G, Zhang L, Hung MC, Gascoyne PR, Hortobagyi GN. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. Clin Cancer Res 8(2):615-9, 2002. e-Pub 2002. PMID: 11839684.
712. Rivera E, Sutton L, Colwell B, Graham M, Frye D, Somerville M, Conklin HS, McGuirt C, Levin J, Hortobagyi GN. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. J Clin Oncol 20(4):987-93, 2002. e-Pub 2002. PMID: 11844821.
713. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 8(1):2-9, 2002. e-Pub 2002. PMID: 11856154.
714. Ibrahim NK, Rahman Z, Valero V, Murray JL, rd, Frye D, Hortobagyi GN. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest 20(1):29-37, 2002. e-Pub 2002. PMID: 11852999.
715. Buchholz TA, Tucker SL, Katz A, McNeese MD, Strom EA, Perkins GH, Buzdar AU, Kuerer HM, Hunt KK, Singletary SE, Sahin AA, Thames HD, Meric F, Masullo L, Hortobagyi GN. Factors Predictive for Local-Regional Recurrence After Neoadjuvant Chemotherapy and Mastectomy: Implications for Radiation Treatments. (Accompanied by two invited commentaries: (1) Sabel MS, Cimmino VM: Neoadjuvant chemotherapy: what’s up front that counts and (2) Shulman LN: Neoadjuvant chemotherapy followed by mastectomy: who needs radiation? Am J Oncol Rev 1(1):17-21, 2002.). Am J Oncol Rev 1(1):13-16, 2002. e-Pub 2002.
716. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20(1):17-23, 2002. e-Pub 2002. PMID: 11773149.
717. Sneige N, Kemp B, Pusztai L, Asmar L, Hortobagyi GN. Chemotherapy-induced histologic changes in mastectomy specimens and their potential significance. Breast 10(6):492-500, 2001. e-Pub 2001. PMID: 14965629.
718. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 182(6):601-8, 2001. e-Pub 2001. PMID: 11839324.
719. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 92(10):2523-8, 2001. e-Pub 2001. PMID: 11745185.
720. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92(7):1775-82, 2001. e-Pub 2001. PMID: 11745249.
721. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 7(5):413-20, 2001. e-Pub 2001. PMID: 11693900.
722. Vlastos G, Mirza NQ, Meric F, Hunt KK, Kuerer HM, Ames FC, Ross MI, Buchholz TA, Hortobagyi GN, Singletary SE. Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer 92(5):1092-100, 2001. e-Pub 2001. PMID: 11571720.
723. Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, Lipton A. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19(14):3434-7, 2001. e-Pub 2001. PMID: 11454892.
724. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 2001. e-Pub 2001. PMID: 11454891.
725. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19(10):2587-95, 2001. e-Pub 2001. PMID: 11352950.
726. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, Buzdar AU, Hunt KK. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol 19(8):2240-6, 2001. e-Pub 2001. PMID: 11304777.
727. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Jr, Hortobagyi GN. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19(6):1716-22, 2001. e-Pub 2001. PMID: 11251001.
728. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19(3):628-33, 2001. e-Pub 2001. PMID: 11157012.
729. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 91(4):664-71, 2001. e-Pub 2001. PMID: 11241232.
730. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7):1800-1808, 2001. e-Pub 2001. PMID: 11919237.
731. Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 109(6):1188-91, 2001. e-Pub 2001. PMID: 12045065.
732. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, rd, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19(5):459-66, 2001. e-Pub 2001. PMID: 11458813.
733. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PL, Hortobagyi G. Anastrozole, a Potent and Selective Aromatase Inhibitor, Versus Megestrol Acetate in Postmenopausal Women With Advanced Breast Cancer: Results of Overview Analysis of Two Phase III Trials. Classic Papers and Current Comments 5(4):829-840, 2001. e-Pub 2001.
734. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-Term Follow-Up of Patients With Complete Remission Following Combination Chemotherapy for Metastatic Breast Cancer. . Classic Papers and Current Comments 5(4):872-881, 2001. e-Pub 2001.
735. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II Trial of Docetaxel: A New, Highly Effective Antineoplastic Agent in the Management of Patients With Anthracycline-Resistant Metastatic Breast Cancer. Classic Papers and Current Comments 5(4):759-768, 2001. e-Pub 2001.
736. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7(3):171-7, 2001. e-Pub 2001. PMID: 11692142.
737. Cristofanilli M, Hortobagyi GN. Prevention Strategies for breast cancer. Ref Gynecol Obstet 8:453-69, 2001. e-Pub 2001.
738. . Recent Developments and Future Directions with HER-2 in Breast Cancer and Other Tumor Types. Proceedings of a roundtable. August 11-14, 1999. Olympic Valley, California, USA. Semin Oncol 27(6 Suppl 11):1-100, quiz 101-10, 2000. e-Pub 2000. PMID: 11245159.
739. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 89(11):2195-201, 2000. e-Pub 2000. PMID: 11147589.
740. Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol 11(12):1597-601, 2000. e-Pub 2000. PMID: 11205469.
741. Freedman LM, Buchholz TA, Thames HD, Strom EA, McNeese MD, Hortobagyi GN, Singletary SE, Heaton KM, Hunt KK. Local-regional control in breast cancer patients with a possible genetic predisposition. Int J Radiat Oncol Biol Phys 48(4):951-7, 2000. e-Pub 2000. PMID: 11072150.
742. Mirza NQ, Vlastos G, Meric F, Sahin AA, Singletary SE, Newman LA, Kuerer HM, Ames FC, Ross MI, Feig BW, Pollock RE, Buchholz TA, McNeese MD, Strom EA, Hortobagyi GN, Hunt KK. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol 7(9):656-64, 2000. e-Pub 2000. PMID: 11034242.
743. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18(20):3480-6, 2000. e-Pub 2000. PMID: 11032588.
744. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, Hortobagyi G, Buzdar AU, Theriault R, Singletary SE, McNeese MD. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 18(15):2817-27, 2000. e-Pub 2000. PMID: 10920129.
745. Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, Pollock RE, Newman LA, Feig BW, Strom EA, Buchholz TA, McNeese MD, Hortobagyi GN, Singletary SE. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol 7(6):435-40, 2000. e-Pub 2000. PMID: 10894139.
746. Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Buzdar AU, Singletary SE. Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer. Breast 6(4):242-246, 2000. e-Pub 2000. PMID: 11348372.
747. Hoff PM, Valero V, Buzdar AU, Singletary SE, Theriault RL, Booser D, Asmar L, Frye D, McNeese MD, Hortobagyi GN. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 88(9):2054-60, 2000. e-Pub 2000. PMID: 10813717.
748. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology 58(3):185-90, 2000. e-Pub 2000. PMID: 10765118.
749. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol 23(2):117-21, 2000. e-Pub 2000. PMID: 10776969.
750. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082-90, 2000. e-Pub 2000. PMID: 10699899.
751. Booser DJ, Walters RS, Holmes FA, Hortobagyi GN. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol 23(1):40-1, 2000. e-Pub 2000. PMID: 10683074.
752. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82(3):529-34, 2000. e-Pub 2000. PMID: 10682660.
753. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92(3):225-33, 2000. e-Pub 2000. PMID: 10655439.
754. Gale RP, Park RE, Dubois R, Bitran JD, Buzdar A, Hortobagyi G, Jones SE, Lazar GS, Spitzer G, Swain SM, Vaughn CB, Vogel CE, Martino S. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant 14(1):32-41, 2000. e-Pub 2000. PMID: 10693633.
755. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355(9200):281-3, 2000. e-Pub 2000. PMID: 10675076.
756. Buchholz TA, Tucker SL, Moore RA, McNeese MD, Strom EA, Jhingrin A, Hortobagyi GN, Singletary SE, Champlin RE. Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiat Oncol Biol Phys 46(2):337-43, 2000. e-Pub 2000. PMID: 10661340.
757. Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, Hortobagyi GN. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 46(5):382-6, 2000. e-Pub 2000. PMID: 11127942.
758. Booser DJ, Perez-Soler R, Cossum P, Esparza-Guerra L, Wu QP, Zou Y, Priebe W, Hortobagyi GN. Phase I study of liposomal annamycin. Cancer Chemother Pharmacol 46(5):427-32, 2000. e-Pub 2000. PMID: 11127949.
759. Esteva FJ, Pusztai L, Symmans WF, Sneige N, Hortobagyi GN. Clinical Relevance of HER-2 Amplification and Overexpression in Human Cancers. Ref Gynecol Obstet 7(4/5):267-276, 2000. e-Pub 2000.
760. Lenert JT, Vlastos G, Mirza NQ, Winchester DJ, Binkley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Strom E, Buzdar AU, Hortobagyi GN, Singletary SE. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 6(8):762-7, 1999. e-Pub 1999. PMID: 10622504.
761. Antman KH, Heitjan DF, Hortobagyi GN. High-dose chemotherapy for breast cancer. Jama 282(18):1701-3, 1999. e-Pub 1999. PMID: 10568629.
762. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17(11):3412-7, 1999. e-Pub 1999. PMID: 10550135.
763. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, rd, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86(7):1251-7, 1999. e-Pub 1999. PMID: 10506711.
764. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230(1):72-8, 1999. e-Pub 1999. PMID: 10400039.
765. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Theriault RL. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 17(5):1482-7, 1999. e-Pub 1999. PMID: 10334534.
766. Buchholz TA, Hunt KK, Amosson CM, Tucker SL, Strom EA, McNeese MD, Buzdar AU, Singletary SE, Hortobagyi GN. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am 5(3):159-64, 1999. e-Pub 1999. PMID: 10367172.
767. Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 55(1):1-8, 1999. e-Pub 1999. PMID: 10472774.
768. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17(5):1425-34, 1999. e-Pub 1999. PMID: 10334527.
769. Cristofanilli M, Holmes FA, Esparza L, Valero V, Buzdar AU, Neidhart JA, Hortobagyi GN. Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Res Treat 54(3):225-33, 1999. e-Pub 1999. PMID: 10445421.
770. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol 10(4):403-11, 1999. e-Pub 1999. PMID: 10370782.
771. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17(3):846-54, 1999. e-Pub 1999. PMID: 10071275.
772. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 17(3):855-61, 1999. e-Pub 1999. PMID: 10071276.
773. Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5(2):343-53, 1999. e-Pub 1999. PMID: 10037184.
774. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460-9, 1999. e-Pub 1999. PMID: 10080586.
775. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 85(1):104-11, 1999. e-Pub 1999. PMID: 9921981.
776. Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol 43(6):471-8, 1999. e-Pub 1999. PMID: 10321507.
777. Pusztai L, Holmes FA, Fraschini G, Hortobagyi GN. Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. Cancer Chemother Pharmacol 43(1):86-91, 1999. e-Pub 1999. PMID: 9923546.
778. Rivera E Hortobagyi GN. Hepatic Arterial Infusion in Patients With Metastatic Breast Cancer. References en Gynecologie Obstetrique 6(1):41-46, 1999. e-Pub 1999.
779. Rivera E, Fraschini G, Esparza-Guerra L, Asmar L, Booser DJ, Buzdar AU, Theriault RL, Carrasco CH, Hortobagyi GN. Frontline Arterial Infusion Chemotherapy for Hepatic Metastases in Breast Cancer Patients. Cancer Therapeutics 2:44-49, 1999. e-Pub 1999.
780. Kuerer HM, Newman LA, Fornage BD, Dhingra K, Hunt KK, Buzdar AU, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol 5(8):673-80, 1998. e-Pub 1998. PMID: 9869512.
781. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34(13):2021-6, 1998. e-Pub 1998. PMID: 10070304.
782. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176(6):502-9, 1998. e-Pub 1998. PMID: 9926779.
783. Cristofanilli M, Bryan WJ, Miller LL, Chang AY, Gradishar WJ, Kufe DW, Hortobagyi GN. Phase II study of adozelesin in untreated metastatic breast cancer. Anticancer Drugs 9(9):779-82, 1998. e-Pub 1998. PMID: 9840723.
784. Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 21(5):442-6, 1998. e-Pub 1998. PMID: 9781596.
785. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA, rd. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16(10):3362-8, 1998. e-Pub 1998. PMID: 9779713.
786. Walters RS, Holmes FA, Valero V, Esparza-Guerra L, Hortobagyi GN. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol 21(4):413-5, 1998. e-Pub 1998. PMID: 9708645.
787. Hortobagyi GN, Hung MC, Lopez-Berestein G. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther 9(12):1775-98, 1998. e-Pub 1998. PMID: 9721088.
788. Ibrahim NK, Hortobagyi GN. New antiestrogens in breast cancer: a review. Breast J 4(4):213-29, 1998. e-Pub 1998. PMID: 21223440.
789. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 4(4):230-6, 1998. e-Pub 1998. PMID: 9689981.
790. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16(6):2038-44, 1998. e-Pub 1998. PMID: 9626201.
791. Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16(22):2855-63, 1998. e-Pub 1998. PMID: 9671406.
792. Diaz-Canton EA, Valero V, Rahman Z, Rodriguez-Monge E, Frye D, Smith T, Buzdar AU, Hortobagyi GN. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol 9(4):413-8, 1998. e-Pub 1998. PMID: 9636832.
793. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16(16):2087-94, 1998. e-Pub 1998. PMID: 9572489.
794. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16(3):986-93, 1998. e-Pub 1998. PMID: 9508181.
795. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 82(5):965-9, 1998. e-Pub 1998. PMID: 9486588.
796. Pusztai L, Hortobagyi GN. High-dose chemotherapy: how resistant is breast cancer?. Drug Resist Updat 1(1):62-72, 1998. e-Pub 1998. PMID: 17092798.
797. Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat 48(2):165-74, 1998. e-Pub 1998. PMID: 9596488.
798. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu SQ, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Przepiorka D, Burtness B, Cote R, Bast R, Hortobagyi G, Deisseroth A. Chemotherapy Immediately Following Autologous Stem-Cell Transplantation in Patients With Advanced Breast Cancer. Clin Cancer Res 4(11):2717-2721, 1998. e-Pub 1998. PMID: 9829734.
799. Headley JA, Theriault RL, LeBlanc AD, Vassilopoulou-Sellin R, Hortobagyi GN. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 16(1):6-11, 1998. e-Pub 1998. PMID: 9474245.
800. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D, Hortobagyi G. Anastrozole versus Megestrol Acetate in the Treatment of Postmenopausal Women with Advanced Breast Carcinoma. For the Arimidex Study Group. Cancer 83(6):1142-1152, 1998. e-Pub 1998. PMID: 9740079.
801. Ioannidou-Mouzaka L, Hortobagyi GN, Gros D, Prats-Esteve M, Colin C, Pusterla E, Lamarque JL. Senology - The Urgent Need for a Specialty. The Breast J 4(4):280-284, 1998. e-Pub 1998.
802. Ibrahim NK Hortobagyi GN. New Antiestrogens in Breast Cancer: A Review. The Breast J 4(4):213-229, 1998. e-Pub 1998.
803. Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, Buzdar AU, Frye DK, Dhingra K. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 80(12):2240-9, 1997. e-Pub 1997. PMID: 9404700.
804. Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F, Hortobagyi G, Lippman SM, Dhingra K, Lotan R. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res 57(22):4992-6, 1997. e-Pub 1997. PMID: 9371489.
805. Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L. Phase II study of semisynthetic paclitaxel in metastatic breast cancer. Eur J Cancer 33(13):2198-202, 1997. e-Pub 1997. PMID: 9470806.
806. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15(10):3171-7, 1997. e-Pub 1997. PMID: 9336352.
807. Holmes FA, Lopez A, Mavligit G, Fraschini G, Frye D, Hortobagyi GN. Secondary drug resistance in breast cancer: failure to reverse with oral nifedipine. Int J Cancer 73(2):184-6, 1997. e-Pub 1997. PMID: 9335439.
808. Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 3(9):1565-9, 1997. e-Pub 1997. PMID: 9815844.
809. Buzdar AU, Asmar L, Hortobagyi GN. Impact of patient characteristics on treatment outcome: anthracycline resistance. Eur J Cancer 33 Suppl 7:S3-6, 1997. e-Pub 1997. PMID: 9486095.
810. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, Kiang D, Kennedy BJ, Evelegh M. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15(6):2322-8, 1997. e-Pub 1997. PMID: 9196146.
811. Rahman Z, Esparza-Guerra L, Yap HY, Fraschini G, Bodey G, Hortobagyi G. Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy. Cancer 79(6):1150-7, 1997. e-Pub 1997. PMID: 9070492.
812. Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14(5):561-8, 1997. e-Pub 1997. PMID: 9053854.
813. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40(4):321-9, 1997. e-Pub 1997. PMID: 9225950.
814. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A, Hortobagyi GN. A Phase III Trial Comparing Anastrozole (1 and 10 Milligrams), a Potent and Selective Aromatase Inhibitor, with Megestrol Acetate in Postmenopausal Women with Advanced Breast Carcinoma. For the Arimidex Study Group. Cancer 79(4):730-739, 1997. e-Pub 1997. PMID: 9024711.
815. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335(24):1785-91, 1996. e-Pub 1996. PMID: 8965890.
816. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A 93(26):15346-51, 1996. e-Pub 1996. PMID: 8986814.
817. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14(10):2713-21, 1996. e-Pub 1996. PMID: 8874332.
818. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 14(10):2722-30, 1996. e-Pub 1996. PMID: 8874333.
819. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14(8):2197-205, 1996. e-Pub 1996. PMID: 8708708.
820. Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, Trancik RJ, Bandstra BA, Compton LD. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35(1):74-8, 1996. e-Pub 1996. PMID: 8682968.
821. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 156(8):882-8, 1996. e-Pub 1996. PMID: 8774207.
822. Deisseroth AB, Holmes F, Hortobagyi G, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Hum Gene Ther 7(3):401-16, 1996. e-Pub 1996. PMID: 8835224.
823. Chen T, Dhingra K, Sahin A, Sneige N, Hortobagyi G, Aldaz CM. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Breast Cancer Res Treat 39(2):177-85, 1996. e-Pub 1996. PMID: 8872326.
824. Sara AS, Katz RL, Sahin AA, Holmes F, Frye DK, Hortobagyi GN. P-Glycoprotein Expression and Response to Chemotherapy in Advanced Breast Cancer: An Immunocytochemical Comparative Analysis of Pretreatment Cytology and Posttreatment Histology Materials. Breast Disease 9(6):317-326, 1996. e-Pub 1996.
825. Rivera E, Valero V, Hortobagyi GN. Breast Cancer in Identical Twins with Different Clinical Course. The Breast 2(4):400-402, 1996. e-Pub 1996.
826. Sanford DB, Yeomans-Kinney A, McLaughlin PW, Hortobagyi GN, Dhingra K. Ninety-one Cases of Breast Cancer and Chronic Lymphoproliferative Neoplasm: A Retrospective Review of a Population at High Risk for Multiple Malignancies. The Breast Journal 2(5):312-319, 1996. e-Pub 1996.
827. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper, Hortobagyi GN. Fadrozole HCL (CGS-16949A) versus Megestrol Acetate Treatment of Postmenopausal Patients with Metastatic Breast Carcinoma - Results of Two Randomized Double Blind Controlled Multiinstitutional Trials. Cancer 77(12):2503-2513, 1996. e-Pub 1996. PMID: 8640699.
828. Theriault RL, Walters RS, Holmes FA, Esparza-Guerra L, Kowal C, Hortobagyi GN. A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer. Cancer Chemother Pharmacol 38(3):289-91, 1996. e-Pub 1996. PMID: 8646805.
829. Hoffman K, Holmes FA, Fraschini G, Esparza L, Frye D, Raber MN, Newman RA, Hortobagyi GN. Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol 37(3):254-8, 1996. e-Pub 1996. PMID: 8529286.
830. Dhingra K, Hittelman WN, Hortobagyi GN. Evolución Genética por Etapas del Cáncer de Mama (Multistep Genetic Evolution of Human Breast Cancer). Focus 9:16-22, 1996. e-Pub 1996.
831. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PL, Hortobagyi G. Anastrozole, a Potent and Selective Aromatase Inhibitor, Versus Megestrol Acetate in Postmenopausal Women With Advanced Breast Cancer: Results of Overview Analysis of Two Phase III Trials. (Reprinted in Classic Papers and Current Comments 5(4):829-840, 2001). J Clin Oncol 14(7):2000-2011, 1996. e-Pub 1996. PMID: 8683230.
832. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13(12):2886-94, 1995. e-Pub 1995. PMID: 8523051.
833. Walters RS, Theriault RL, Booser DJ, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J Immunother Emphasis Tumor Immunol 18(3):185-7, 1995. e-Pub 1995. PMID: 8770774.
834. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res 1(7):691-7, 1995. e-Pub 1995. PMID: 9816034.
835. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V, Booser D, Whealin H, Collins TJ, Pursley JM, Hortobagyi G. Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L6 by Deoxyspergualin. Cancer Res 55(14):3060-3067, 1995. e-Pub 1995. PMID: 7606728.
836. Càrdenas J, Aceves A, Ayala JR, de la Garza J, Díaz R, Erazo A, Espinosa M, Flores AM, García H, Gerson R, Gómez E, González JF, Hernández R, Hortobagyi GN, Lara F, Mainero F, Ramírez T, Rodriguez S, Romero R, Sánchez C, Sandoval F, Serrano JA, Silva A, Tenorio F, Torres R, Vázquez A. Consenso Nacional Sobre Tratamiento del Cáncer Mamario. Revista del Instituto Nacional de Cancerología 41(3):136-145, 1995. e-Pub 1995.
837. Resnick JM, Sneige N, Kemp BL, Sahin A, Ordoñez NG, Frye DK, Hortobagyi GN. p53 and c-erbB-2 Expression and Response to Preoperative Chemotherapy in Locally Advanced Breast Carcinoma. Breast Disease 8(2):149-158, 1995. e-Pub 1995.
838. Abu-Farsakh H, Sneige N, Atkinson EN, Hortobagyi G. Pathologic Predictors of Tumor Response to Preoperative Chemotherapy in Locally Advanced Breast Carcinoma. The Breast Journal 1(2):96-101, 1995. e-Pub 1995.
839. Cho SH, Sahin A, Hortobagyi GN, Hittelman WN, Dhingra K. Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res 54(24):6302-5, 1994. e-Pub 1994. PMID: 7987817.
840. Walters RS, Theriault RL, Holmes FA, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer. J Immunother Emphasis Tumor Immunol 16(4):303-5, 1994. e-Pub 1994. PMID: 7881639.
841. Beitsch P, Lotzova E, Hortobagyi G, Pollock R. Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surg Oncol 3(4):211-9, 1994. e-Pub 1994. PMID: 7834112.
842. Dhingra K, Sneige N, Pandita TK, Johnston DA, Lee JS, Emami K, Hortobagyi GN, Hittelman WN. Quantitative analysis of chromosome in situ hybridization signal in paraffin-embedded tissue sections. Cytometry 16(2):100-12, 1994. e-Pub 1994. PMID: 7924678.
843. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 73(8):2157-67, 1994. e-Pub 1994. PMID: 8156520.
844. Holmes FA, Buzdar AU, S-W K, Fraschini G, Ames FC, McNeese MD, Hortobagyi GN. Combined-Modality Approach for Patients with Isolated Recurrences of Breast Cancer (IV-NED): The M.D. Anderson Experience. Breast Disease 7:7-20, 1994. e-Pub 1994.
845. Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 33(4):313-6, 1994. e-Pub 1994. PMID: 8281625.
846. Dhingra K, Valero V, Gutierrez L, Theriault R, Booser D, Holmes F, Buzdar A, Fraschini G, Hortobagyi G. Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs 12(3):235-41, 1994. e-Pub 1994. PMID: 7896543.
847. Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol 12(1):50-4, 1994. e-Pub 1994. PMID: 8270984.
848. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 120(1):18-25, 1994. e-Pub 1994. PMID: 8250452.
849. Hortobagyi GN. El Reto del Cancer Mamario Metastatico: Nuevas Estrategias y Oportunidades. Boletin de la Academia Nacional de Medicina de Buenos Aires 72:125-141, 1994. e-Pub 1994.
850. Buzdar AU, Kau SW, Smith TL, Ames F, Singletary E, Strom E, McNeese M, Hortobagyi GN. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer 71(11):3680-4, 1993. e-Pub 1993. PMID: 8490917.
851. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71(12):3920-5, 1993. e-Pub 1993. PMID: 8389655.
852. Theriault RL, Fraschini G, Holmes FA, Frye D, Gutterman JU, Hortobagyi GN. The myeloprotective effect of recombinant human granulocyte-macrophage colony-stimulating factor given sequentially with continuous infusion vinblastine in metastatic breast cancer patients. Am J Clin Oncol 16(2):132-6, 1993. e-Pub 1993. PMID: 8452104.
853. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al. Genetic therapy of human neoplastic disease. J Hematother 2(3):373-5, 1993. e-Pub 1993. PMID: 7921999.
854. Hortobagyi GN. Diagnostic breast imaging. JAMA 268:1926, 1992. e-Pub 1992. PMID: 1404721.
855. Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol 10(10):1540-6, 1992. e-Pub 1992. PMID: 1403033.
856. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 69(11):2849-52, 1992. e-Pub 1992. PMID: 1571916.
857. Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L. Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer. Invest New Drugs 10(1):43-4, 1992. e-Pub 1992. PMID: 1376723.
858. Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer 69(2):476-81, 1992. e-Pub 1992. PMID: 1728377.
859. Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 69(2):448-52, 1992. e-Pub 1992. PMID: 1728373.
860. Dhingra K, Sahin A, Supak J, Kim SY, Hortobagyi G, Hittelman WN. Chromosome in situ hybridization on formalin-fixed mammary tissue using non-isotopic, non-fluorescent probes: technical considerations and biological implications. Breast Cancer Res Treat 23(3):201-10, 1992. e-Pub 1992. PMID: 1463859.
861. Voravud N, Sneige N, Theriault R, Hortobagyi G. Sarcoidosis and Breast Cancer. Breast Disease 5:191-197, 1992. e-Pub 1992.
862. Simmons JR, Buzdar AU, Ota DM, Marts K, Hortobagyi GN. Complications associated with indwelling catheters. Med Pediatr Oncol 20(1):22-5, 1992. e-Pub 1992. PMID: 1727207.
863. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83(24):1797-805, 1991. e-Pub 1991. PMID: 1683908.
864. Fraschini G, Holmes FA, Esparza L, Theriault RL, Buzdar AU, Hortobagyi GN. Phase I-II study of high-dose etoposide in patients with refractory breast cancer. Invest New Drugs 9(4):365-7, 1991. e-Pub 1991. PMID: 1804815.
865. Huan SD, Yau JC, Dunphy FR, Wallerstein RO, Dicke K, Spencer V, LeMaistre CF, Deisseroth AB, Hortobagyi GN, Holmes FA, et al. Impact of autologous bone marrow infusion on hematopoietic recovery after high-dose cyclophosphamide, etoposide, and cisplatin. J Clin Oncol 9(9):1609-17, 1991. e-Pub 1991. PMID: 1875221.
866. Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat 18(3):165-70, 1991. e-Pub 1991. PMID: 1756259.
867. Ziegler LD, Connelly JH, Frye D, Smith TL, Hortobagyi GN. Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer. Cancer 68(3):628-33, 1991. e-Pub 1991. PMID: 1648436.
868. Sahin AA, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68(3):549-57, 1991. e-Pub 1991. PMID: 1648433.
869. Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS, Hortobagyi GN. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 9(7):1268-74, 1991. e-Pub 1991. PMID: 1828499.
870. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 Monoclonal Antibody in the Detection and Staging of Breast Cancer: a phase I study. J Nucl Med (Abstracted in Yearbook of Nucear Medicine, 1993) 32(7):1326-32, 1991. e-Pub 1991. PMID: 2066785.
871. Pathak S, Hopwood VL, Hortobagyi GN, Jackson GL, Hughes JI, Melillo D. Chromosome anomalies in human breast cancer: evidence for specific involvement of 1q region in lymphocyte cultures. Anticancer Res 11(3):1055-60, 1991. e-Pub 1991. PMID: 1888138.
872. Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM. Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg 213(2):126-9, 1991. e-Pub 1991. PMID: 1992938.
873. Theriault RL, Mansell PW, Hortobagyi GN. Copovithane therapy for multiple myeloma, acquired immune deficiency syndrome (AIDS), and AIDS-related complex. Int J Exp Clin Chemother 3:143-145, 1991. e-Pub 1991.
874. Wallerstein R, Jr, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, Buzdar A, Holmes F, Theriault R, Ewer M, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 8(11):1782-8, 1990. e-Pub 1990. PMID: 2121909.
875. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21(8):787-91, 1990. e-Pub 1990. PMID: 1974874.
876. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8(7):1207-16, 1990. e-Pub 1990. PMID: 2358837.
877. Holmes FA, Fritsche HA, Loewy JW, Geitner AM, Sutton RC, Buzdar AU, Hortobagyi GN. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. J Clin Oncol 8(6):1025-35, 1990. e-Pub 1990. PMID: 2189952.
878. Katz RL, Patel S, Sneige N, Fritsche HA, Jr, Hortobagyi GN, Ames FC, Brooks T, Ordonez NG. Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat 15(3):191-203, 1990. e-Pub 1990. PMID: 1695528.
879. Buzdar AU, McNeese MD, Hortobagyi GN, Smith TL, Kau S, Fraschini G, Hug V, Ellerbroek N, Holmes FA, Ames F, et al. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?. Cancer 65(3):394-9, 1990. e-Pub 1990. PMID: 2297630.
880. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 65(4):847-50, 1990. e-Pub 1990. PMID: 2297653.
881. Koh EH, Buzdar AU, Ames FC, Singletary SE, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Theriault RL, Balch CM, Hortobagyi GN. Inflammatory carcinoma of the breast: results of a combined-modality approach - MD Anderson Cancer Center experience. Cancer Chemother Pharmacol 27:94-100, 1990. e-Pub 1990. PMID: 2249339.
882. Buzdar AU, Hortobagyi GN, Esparza LT, Holmes FA, Ro JS, Fraschini G, Lichtiger B. Elliptinium acetate in metastatic breast cancer--a phase II study. Oncology 47(2):101-4, 1990. e-Pub 1990. PMID: 2314820.
883. Ro JS, Ro JY, El-Naggar A, Holmes FA, Close D, Hortobagyi GN. Brain metastasis. Initial presentation of breast cancer: DNA flow cytometric comparison of two sites. Breast Dis 3:35-38, 1990. e-Pub 1990.
884. Ro JS, el-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49(24 Pt 1):6941-4, 1989. e-Pub 1989. PMID: 2573424.
885. Ang PT, Buzdar AU, Smith TL, Kau S, Hortobagyi GN. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol 7(11):1677-84, 1989. e-Pub 1989. PMID: 2809682.
886. Koh EH, Ro J, Wildrick DM, Hortobagyi GN, Blick M. Analysis of the estrogen receptor gene structure in human breast cancer. Anticancer Res 9(6):1841-5, 1989. e-Pub 1989. PMID: 2576351.
887. Patel HZ, nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 64(8):1583-5, 1989. e-Pub 1989. PMID: 2676137.
888. Hortobagyi GN, Hug V, Buzdar AU, Kau SW, Holmes FA, Fritsche HA. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer 64(5):1002-6, 1989. e-Pub 1989. PMID: 2527085.
889. Jabboury K, Holmes FA, Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64(4):793-7, 1989. e-Pub 1989. PMID: 2743272.
890. Jabboury K, Frye D, Holmes FA, Fraschini G, Hortobagyi G. Phase II evaluation of gallium nitrate by continuous infusion in breast cancer. Invest New Drugs 7(2-3):225-9, 1989. e-Pub 1989. PMID: 2793377.
891. Taha M, Ordonez NG, Kulkarni S, Owen M, Ro JS, Hortobagyi G, Reading CL, Dicke KA, Spitzer G. A monoclonal antibody cocktail for detection of micrometastatic tumor cells in the bone marrow of breast cancer patients. Bone Marrow Transplant 4(3):297-303, 1989. e-Pub 1989. PMID: 2471564.
892. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12(2):123-8, 1989. e-Pub 1989. PMID: 2705401.
893. Ro J, Bresser J, Ro JY, Brasfield F, Hortobagyi G, Blick M. SIS/PDGF-B expression in benign and malignant human breast lesions. Oncogene 4(3):351-4, 1989. e-Pub 1989. PMID: 2649848.
894. Theriault RL, Hortobagyi GN, Fritsche HA, Frye D, Martinez R, Buzdar AU. The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. Cancer 63(5):828-35, 1989. e-Pub 1989. PMID: 2914290.
895. Chu PS, Buzdar AU, Hortobagyi GN. Trilostane with hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Res Treat 13(2):117-21, 1989. e-Pub 1989. PMID: 2659103.
896. Hortobagyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, Chawla SP, Benjamin RS. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12(1):57-62, 1989. e-Pub 1989. PMID: 2643296.
897. Sneige N, White VA, Katz RL, Troncoso P, Libshitz HI, Hortobagyi GN. Ductal carcinoma-in-situ of the breast: fine-needle aspiration cytology of 12 cases. Diagn Cytopathol 5(4):371-7, 1989. e-Pub 1989. PMID: 2558863.
898. Holmes FA, Esparza L, Yap HY, Fraschini G, Blumenschein GR, Jabboury K, Hortobagyi, GN. A randomized phase II study of etoposide versus tenoposide in refractory metastatic brast cancer. Intl J Experimental & Clin Chemotherapy 2(2):95-98, 1989. e-Pub 1989.
899. Ro J, Fraschini G, Frye D, Buzdar A, Hortobagyi G. Reutilization of doxorubicin in patients with progressive metastatic breast cancer. Int J Exp Clin Chemother 2:234-238, 1989. e-Pub 1989.
900. Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63(1):37-45, 1989. e-Pub 1989. PMID: 2910423.
901. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124(1):21-5, 1989. e-Pub 1989. PMID: 2910244.
902. Buzdar AU, Hortobagyi GN, Smith TL, Kau S, Marcus C, Holmes FA, Hug V, Fraschini G, Ames FC, Martin RG. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer 62(10):2098-104, 1988. e-Pub 1988. PMID: 3179922.
903. Theriault RL, Hortobagyi GN, Kau SW, Holmes FA, Hug V, Fraschini G, Jabboury K, Buzdar AU. Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer 62(10):2105-10, 1988. e-Pub 1988. PMID: 3179923.
904. Segel MC, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 169(1):49-54, 1988. e-Pub 1988. PMID: 3420282.
905. Fraschini G, Holmes FA, Buzdar AU, Hug V, Hortobagyi GN. Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer. Am J Clin Oncol 11(4):448-50, 1988. e-Pub 1988. PMID: 3407623.
906. Berte E, Buzdar AU, Smith TL, Hortobagyi GN. Bilateral primary breast cancer in patients treated with adjuvant therapy. Am J Clin Oncol 11(2):114-8, 1988. e-Pub 1988. PMID: 3128945.
907. Fraschini G, Charnsangavej C, Carrasco CH, Buzdar AU, Jabboury KW, Hortobagyi GN. Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol 11(1):34-8, 1988. e-Pub 1988. PMID: 3277374.
908. Buzdar AU, Yap HY, Esparza L, Holmes F, Fraschini G, Hug V, Hortobagyi GN. A comparative randomized trial of doxorubicin and cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer. Intl J Exp & Clin Chemother 1:48-55, 1988. e-Pub 1988.
909. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45(5):344-5, 1988. e-Pub 1988. PMID: 3412740.
910. Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 48(1):161-4, 1988. e-Pub 1988. PMID: 3334990.
911. Bastarrachea Ortiz J, Gongora Biachi R, Hortobagyi G, Buzdar A. Carcinomatosis linfangitica unilateral en cancer de mama. Reporte de un caso. Cancerologia 34(2):582-584, 1988. e-Pub 1988.
912. Hortobagyi GN, Buzdar AU, Frye D, Hug V, Fraschini G, Ames FC, Montague E, Gutterman JU, Martin RG. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. Cancer 60(11):2596-604, 1987. e-Pub 1987. PMID: 3315173.
913. Hortobagyi GN, Frye D, Holmes FA, Hug V, Fraschini G, Buzdar AU. Phase II study of iproplatin in metastatic breast carcinoma. Cancer Treat Rep 71(12):1193-6, 1987. e-Pub 1987. PMID: 3690529.
914. Fraschini G, Fleishman G, Charnsangavej C, Carrasco CH, Hortobagyi GN. Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer. Cancer Treat Rep 71(11):1001-5, 1987. e-Pub 1987. PMID: 3677109.
915. Hug V, Rashid R, Johnston D, Hortobagyi G. Clonogenic growth and hormone sensitivity of benign and malignant breast tissues. Br J Cancer 56(5):619-21, 1987. e-Pub 1987. PMID: 3322354.
916. Fraschini G, Yap HY, Mann G, Buzdar AU, Blumenschein GR, Hortobagyi GN. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer 60(8):1724-8, 1987. e-Pub 1987. PMID: 3652000.
917. Ro J, Buzdar AU, Esparza L, Hortobagyi GN. Phase II study of peplomycin in advanced breast carcinoma. Cancer Treat Rep 71(7-8):777-8, 1987. e-Pub 1987. PMID: 2440571.
918. Holmes FA, Yap HY, Esparza L, Buzdar AU, Blumenschein GR, Hug V, Hortobagyi GN. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer 59(12):1992-9, 1987. e-Pub 1987. PMID: 3567861.
919. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5(5):773-82, 1987. e-Pub 1987. PMID: 3106583.
920. Ventura GJ, Buzdar AU, Kau S, Lichtiger B, Hortobagyi GN. Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer. Cancer Treat Rep 71(4):411-3, 1987. e-Pub 1987. PMID: 3548958.
921. Ajani JA, Hortobagyi GN, Frye D, Levin B, Boman BM, Faintuch JS. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. Am J Clin Oncol 10(2):139-40, 1987. e-Pub 1987. PMID: 3551577.
922. Fraschini G, Fleishman G, Yap HY, Carrasco CH, Charnsangavej C, Patt YZ, Hortobagyi GN. Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. Cancer Treat Rep 71(3):313-5, 1987. e-Pub 1987. PMID: 3815396.
923. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 5(3):354-64, 1987. e-Pub 1987. PMID: 3819804.
924. Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol 5(2):178-84, 1987. e-Pub 1987. PMID: 3543241.
925. Larroquette CA, Hortobagyi GN, Buzdar AU, Holmes FA. Subclinical hepatic toxicity during combination chemotherapy for breast cancer. Jama 256(21):2988-90, 1986. e-Pub 1986. PMID: 3773217.
926. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 58(12):2589-93, 1986. e-Pub 1986. PMID: 3779609.
927. Theriault RL, Hortobagyi GN, Buzdar AU, Levy HB, Hersh EM. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. Cancer Treat Rep 70(11):1341-2, 1986. e-Pub 1986. PMID: 3768878.
928. Hug V, Thames H, Hortobagyi G, Finders M. Chemosensitivities of human clonogenic breast tumor cells. Eur J Cancer Clin Oncol 22(8):971-81, 1986. e-Pub 1986. PMID: 3770053.
929. Hortobagyi GN, Hersh EM, Papadopoulos NE, Frye D, Rios A, Reuben JM, Plager C, Rosenblum M, Quesada J. Initial clinical studies with copovithane. J Biol Response Mod 5(4):319-29, 1986. e-Pub 1986. PMID: 2942646.
930. Herring MK, Buzdar AU, Smith TL, Hortobagyi GN, Blumenschein GR. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol 9(3):269-75, 1986. e-Pub 1986. PMID: 3755282.
931. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46(5):2578-81, 1986. e-Pub 1986. PMID: 3697997.
932. Hug V, Johnston D, Finders M, Hortobagyi G. Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res 46(1):147-52, 1986. e-Pub 1986. PMID: 3509991.
933. Holmes FA, Esparza L, Yap HY, Buzdar AU, Blumenschein GR, Hortobagyi GN. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol 18(2):157-61, 1986. e-Pub 1986. PMID: 3791560.
934. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 57(1):40-3, 1986. e-Pub 1986. PMID: 3940620.
935. Hortobagyi GN, Papadoupoulos NE, Frye D, Ajani J, Reuben JM. Phase I clinical study of nafazatrom. Invest New Drugs 4(3):251-5, 1986. e-Pub 1986. PMID: 3818230.
936. Rosenblum MG, Hortobagyi GN. Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer. Cancer Chemother Pharmacol 18(3):247-51, 1986. e-Pub 1986. PMID: 3802380.
937. Casimir MT, Buzdar AU, Blumenschein GR, Hortobagyi GN, Bodey GP. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology 43(4):205-7, 1986. e-Pub 1986. PMID: 3755230.
938. Hug V, Hortobagyi GN, Drewinko B, Finders M. Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 3(12):1672-7, 1985. e-Pub 1985. PMID: 4067614.
939. Fainstein V, Elting L, Pitlik S, Hortobagyi G, Keating M, Bodey GP. Ticarcillin plus clavulanic acid in the treatment of patients with cancer. Am J Med 79(5B):62-6, 1985. e-Pub 1985. PMID: 4073096.
940. Pasterz RB, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer 56(10):2381-4, 1985. e-Pub 1985. PMID: 4042070.
941. McBride CM, Hortobagyi GN. Primary inflammatory carcinoma of the female breast: staging and treatment possibilities. Surgery 98(4):792-8, 1985. e-Pub 1985. PMID: 4049251.
942. Mann GB, Hortobagyi GN, Buzdar AU, Yap HY, Valdivieso M. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. Cancer 56(6):1320-4, 1985. e-Pub 1985. PMID: 4027872.
943. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M. Doxorubicin-induced congestive heart failure in adults. Cancer 56(6):1361-5, 1985. e-Pub 1985. PMID: 4027874.
944. Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer 56(2):225-9, 1985. e-Pub 1985. PMID: 4005794.
945. Fastenberg NA, Martin RG, Buzdar AU, Hortobagyi GN, Montague ED, Blumenschein GR, Jessup JM. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol 8(2):134-41, 1985. e-Pub 1985. PMID: 3841746.
946. Yau JC, Yap YY, Buzdar AU, Hortobagyi GN, Bodey GP, Blumenschein GR. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer 55(2):337-40, 1985. e-Pub 1985. PMID: 3880657.
947. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, Freireich EJ, Gehan EA. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 55(2):341-6, 1985. e-Pub 1985. PMID: 3965092.
948. Hug V, Drewinko B, Hortobagyi GN, Blumenschein G. Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors. Breast Cancer Res Treat 6(3):237-40, 1985. e-Pub 1985. PMID: 4092099.
949. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, Blumenschein GR. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 5(3):321-6, 1985. e-Pub 1985. PMID: 3161565.
950. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, Martin RG. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol 20(11):1353-61, 1984. e-Pub 1984. PMID: 6548710.
951. Hug V, Haynes M, Rashid R, Spitzer G, Blumenschen G, Hortobagyi G. Improved culture conditions for clonogenic growth of primary human breast tumours. Br J Cancer 50(2):207-13, 1984. e-Pub 1984. PMID: 6466537.
952. Tannir N, Yap HY, Hortobagyi GN, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep 68(7-8):1039-41, 1984. e-Pub 1984. PMID: 6547638.
953. Aboud A, Buzdar AU, Yap HY, Hortobagyi GN, Blumenschein GR. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. J Surg Oncol 26(3):205-7, 1984. e-Pub 1984. PMID: 6610802.
954. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer 53(9):1836-40, 1984. e-Pub 1984. PMID: 6231092.
955. Chawla SP, Buzdar AU, Hortobagyi GN, Blumenschein GR. Tumor-associated fever in breast cancer. Cancer 53(7):1596-9, 1984. e-Pub 1984. PMID: 6697296.
956. Buzdar AU, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Ames FC, Martin RG, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer 53(3):384-9, 1984. e-Pub 1984. PMID: 6362814.
957. Buzdar AU, Blumenschein GR, Montague ED, Hortobagyi GN, Yap HY, Pinnamaneni K, Marcus CE, Smith TL. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol 7(1):45-50, 1984. e-Pub 1984. PMID: 6364779.
958. Hortobagyi GN, Libshitz HI, Seabold JE. Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy. Cancer 53(3):577-82, 1984. e-Pub 1984. PMID: 6692261.
959. Aboud A, Yap HY, Esparza L, Blumenschein GR, Hortobagyi G, Issell B, Bodey GP. Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer. Cancer 53(1):9-12, 1984. e-Pub 1984. PMID: 6546298.
960. Rosenblum MG, Hortobagyi GN, Wingender W, Hersh EM. Analysis of the antitumor agent BAY i 7433 (copovithane) in plasma and urine by high performance liquid chromatography. J Liquid Chromatography 7:159-166, 1984. e-Pub 1984.
961. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, Buzdar AU, Blumenschein GR. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1(12):776-86, 1983. e-Pub 1983. PMID: 6668494.
962. Hortobagyi GN, Spanos W, Montague ED, Buzdar AU, Yap HY, Blumenschein GR. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys 9(5):643-50, 1983. e-Pub 1983. PMID: 6343312.
963. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. Jama 249(14):1881-6, 1983. e-Pub 1983. PMID: 6834584.
964. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F. Multimodal treatment of locoregionally advanced breast cancer. Cancer 51(5):763-8, 1983. e-Pub 1983. PMID: 6687377.
965. Hortobagyi GN, Yap HY, Blumenschein GR, Buzdar AU, Barnes BC, Legha SS, Wiseman CL. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer 51(5):769-72, 1983. e-Pub 1983. PMID: 6600415.
966. Yap HY, Valdivieso M, Blumenschein G, Hortobagyi G, Bedikian A. A phase I-II study of continuous 5-day infusion mitomycin-C. Am J Clin Oncol 6(1):109-12, 1983. e-Pub 1983. PMID: 6404154.
967. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143(2):237-40, 1983. e-Pub 1983. PMID: 6824391.
968. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer (in Japanese). JAMA (Japanese ed.) 12:63-70, 1983. e-Pub 1983.
969. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Mesures répétées de l'antigène carcinoembryonnaire plasmatique dans le traitement des cancers du sein metastases. JAMA (Française ed.) 7:619-620, 1983. e-Pub 1983.
970. Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU, Schell FC, Bodey GP. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol 5(5):511-4, 1982. e-Pub 1982. PMID: 7180829.
971. Buzdar AU, Legha SS, Hortobagyi GN, Powell KC, Blumenschein GR, Bodey GP. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol 5(4):383-7, 1982. e-Pub 1982. PMID: 6896794.
972. Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR. Treatment for meningeal carcinomatosis in breast cancer. Cancer 50(2):219-22, 1982. e-Pub 1982. PMID: 6177395.
973. Buzdar AU, Legha SS, Blumenschein GR, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Fraschini G, Bodey GP. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer 49(9):1767-70, 1982. e-Pub 1982. PMID: 7042074.
974. Schell FC, Yap HY, Hortobagyi GN, Issell B, Esparza L. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol 7(2-3):223-5, 1982. e-Pub 1982. PMID: 7083463.
975. Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU, DiStefano A. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep 65(9-10):775-9, 1981. e-Pub 1981. PMID: 7273012.
976. Rodriguez-Kraul R, Hortobagyi GN, Buzdar AU, Blumenschein GR. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer 48(2):227-32, 1981. e-Pub 1981. PMID: 7237395.
977. Buzdar AU, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47(12):2798-802, 1981. e-Pub 1981. PMID: 7260870.
978. Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR. Management of inflammatory carcinoma of breast with combined modality approach - an update. Cancer 47(11):2537-42, 1981. e-Pub 1981. PMID: 6790155.
979. Richman SP, Hersh EM, Gutterman JU, Hortobagyi GN, Blumenschein GR, Rios A, Ribi E. Administration of BCG cell wall skeleton into malignant effusions: toxic and therapeutic effects. Cancer Treat Rep 65(5-6):383-7, 1981. e-Pub 1981. PMID: 7237463.
980. Hortobagyi GN, Smith TL, Swenerton KD, Legha SS, Buzdar AU, Blumenschein GR, Gutterman JU, Hersh EM. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer 47(6):1369-76, 1981. e-Pub 1981. PMID: 7226061.
981. Laughter DC, Kean TJ, Dream KD, Esparza D, Hortobagyi G, Judkins A, Levitt DZ, Marcus C, Silverberg Y. The breast self-examination practices of high risk women: implications for patient education. Patient Couns Health Educ 3(3):103-7, 1981. e-Pub 1981. PMID: 10254297.
982. Libshitz HI, Hortobagyi GN. Radiographic evaluation of therapeutic response in bony metastases of breast cancer. Skeletal Radiol 7(3):159-65, 1981. e-Pub 1981. PMID: 7330671.
983. Snyder RD, Hortobagyi GN, Bodey GP, Gutterman JU, Hersh EM. Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin. J Surg Oncol 16(1):87-92, 1981. e-Pub 1981. PMID: 7464150.
984. Hortobagyi GN, Blumenschein GR, Buzdar AU, Yap HY, Schell FC, Barnes BC, Burgess MA. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol 18(2):163-72, 1981. e-Pub 1981. PMID: 7300363.
985. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93(3):399-406, 1980. e-Pub 1980. PMID: 6159812.
986. Legha SS, Buzdar AU, Smith TL, Swenerton KD, Hortobagyi GN, Blumenschein GR. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 46(3):438-45, 1980. e-Pub 1980. PMID: 7397619.
987. Hug V, Hortobagyi GN, Buzdar AU, Blumenschein GR, Grose W, Burgess MA, Bodey GP. A phase II study of peptichemio in advanced breast cancer. Cancer 45(10):2524-8, 1980. e-Pub 1980. PMID: 7378988.
988. Yap HY, Tashima CK, Blumenschein GR, Hortobagyi GN, Eckles N. Chemotherapy for advanced male breast cancer. Jama 243(17):1739-41, 1980. e-Pub 1980. PMID: 7365938.
989. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64(2-3):279-83, 1980. e-Pub 1980. PMID: 7407762.
990. Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Hersh EM. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer 45(4):742-9, 1980. e-Pub 1980. PMID: 6986970.
991. Buzdar AU, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Blumenschein GR. Pulmonary toxicity of mitomycin. Cancer 45(2):236-44, 1980. e-Pub 1980. PMID: 7351010.
992. Hortobagyi GN, Yap HY, Wiseman CL, Blumenschein GR, Buzdar AU, Legha SS, Gutterman JU, Hersh EM, Bodey GP. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treat Rep 64(1):157-9, 1980. e-Pub 1980. PMID: 6991103.
993. Benjamin RS, Hortobagyi GN, Swenerton KD, Blumenschein GR, Bodey GP. Strategy for evaluation of a new antitumor agent in the treatment of breast cancer. Recent Results Cancer Res 70:153-7, 1980. e-Pub 1980. PMID: 7355246.
994. Yap HY, Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Krutchik AN, Benjamin RS, Gutterman JU, Bodey GP, Sr. Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. J Surg Oncol 12(4):333-41, 1979. e-Pub 1979. PMID: 392197.
995. Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 91(6):847-52, 1979. e-Pub 1979. PMID: 517883.
996. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer 44(5):1955-62, 1979. e-Pub 1979. PMID: 387212.
997. Legha SS, Buzdar AU, Hortobagyi GN, DiStefano A, Wiseman CL, Yap HY, Blumenschein GR, Bodey GP. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. Cancer Treat Rep 63(11-12):2053-6, 1979. e-Pub 1979. PMID: 118805.
998. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 44(5):1913-8, 1979. e-Pub 1979. PMID: 498057.
999. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN, Bodey GP. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep 63(11-12):1961-4, 1979. e-Pub 1979. PMID: 526929.
1000. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. Jama 242(14):1509-13, 1979. e-Pub 1979. PMID: 470088.
1001. Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer 44(2):398-405, 1979. e-Pub 1979. PMID: 383255.
1002. Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. Jama 242(1):49-52, 1979. e-Pub 1979. PMID: 448865.
1003. Yap HY, Blumenschein GR, Tashima CK, Hortobagyi GN, Buzdar AU, Wiseman CL. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer 44(1):32-4, 1979. e-Pub 1979. PMID: 222433.
1004. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39(5):1552-62, 1979. e-Pub 1979. PMID: 427797.
1005. Yap HY, Blumenschein GR, Yap BS, Hortobagyi GN, Tashima CK, Wang AY, Benjamin RS, Bodey GP. High-dose methotrexate for advanced breast cancer. Cancer Treat Rep 63(5):757-61, 1979. e-Pub 1979. PMID: 313246.
1006. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer 43(4):1225-33, 1979. e-Pub 1979. PMID: 445325.
1007. Hortobagyi GN, Gutterman JU, Blumenschein GR, Yap HY, Buzdar AU, Tashima CK, Burgess MA, Hersh EM. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. Cancer 43(3):1112-22, 1979. e-Pub 1979. PMID: 427716.
1008. Ali MK, Soto A, Maroongroge D, Bekheit-Saad S, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Wiseman CL, Shullenberger CC. Electrocardiographic changes after adriamycin chemotherapy. Cancer 43(2):465-71, 1979. e-Pub 1979. PMID: 421174.
1009. Yap HY, Benjamin RS, Blumenschein GR, Hortobagyi GN, Tashima CK, Buzdar AU, Bodey GP. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep 63(1):77-83, 1979. e-Pub 1979. PMID: 369695.
1010. Legha SS, Benjamin RS, Buzdar AU, Hortobagyi GN, Blumenschein GR. Rubidazone in metastatic breast cancer. Cancer Treat Rep 63(1):135-6, 1979. e-Pub 1979. PMID: 369685.
1011. Buzdar AU, Blumenschein GR, Smith TL, Tashima CK, Hortobagyi GN, Yap HY, Gutterman JU, Hersh EM, Gehan EA. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol 12(1):27-40, 1979. e-Pub 1979. PMID: 480951.
1012. Krutchik AN, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Gutterman JU, Yap HY, Hersh EM. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol 11(4):325-32, 1979. e-Pub 1979. PMID: 109703.
1013. Buzdar AU, Blumenschein GR, Krutchik AN, Tashima CK, Hortobagyi GN, Gutterman JU, Hersh EM. Combined modality approach for inflammatory breast cancer: Prolongation of disease-free interval and survival. Cancer Bulletin 31:95-96, 1979. e-Pub 1979.
1014. Ali MK, Bekheit-Saad S, Ewer MS, Soto A, Buzdar AU, Blumenschein GR, Tashima CK, Wiseman CL, Hortobagyi GN, Maroongroge DP. Noninvasive evaluation of myocardial function in patients receiving Adriamycin chemotherapy. Cancer Bulletin 31:93-94, 1979. e-Pub 1979.
1015. Legha SS, Swenerton KD, Buzdar AU, Hortobagyi GN, Smith TL, Bodey GP, Blumenschein GR. Patterns of relapse after complete remission in metastatic breast cancer treatment with chemoimmunotherapy. Cancer Bulletin 31:108, 1979. e-Pub 1979.
1016. Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep 63(1):115-20, 1979. e-Pub 1979. PMID: 369682.
1017. Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, Buzdar AU, Tashima CK, Hersh EM. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guerin. Cancer Treat Rep 62(11):1685-92, 1978. e-Pub 1978. PMID: 728894.
1018. Buzdar AU, Legha SS, Tashima CK, Hortobagyi GN, Yap HY, Krutchik AN, Luna MA, Blumenschein GR. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep 62(7):1005-8, 1978. e-Pub 1978. PMID: 688243.
1019. Waterfield WC, Tashima CK, Hortobagyi GN, Blumenschein GR, Buzdar AU, Burgess MA. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer 41(4):1235-9, 1978. e-Pub 1978. PMID: 638989.
1020. Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 41(3):1064-75, 1978. e-Pub 1978. PMID: 638948.
1021. Yap HY, Salem P, Hortobagyi GN, Bodey GP, Sr, Buzdar AU, Tashima CK, Blumenschein GR. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep 62(3):405-8, 1978. e-Pub 1978. PMID: 348308.
1022. Buzdar AU, Tashima CK, Blumenschein GR, Hortobagyi GN, Yap HY, Krutchik AN, Bodey GP, Livingston RB. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer 41(2):392-5, 1978. e-Pub 1978. PMID: 630529.
1023. Hortobagyi GN, Gutterman JU, Snyder RD, Richman SP, Hersh EM. Pseudomonas vaccine: A phase I evaluation for cancer research. Cancer Immunol Immunother 4:201-207, 1978. e-Pub 1978.
1024. Hortobagyi GN, Gutterman JU, Blumenschein GR, Buzdar A, Burgess MA, Richman SP, Tashima CK, Schwarz M, Hersh EM. Chemo immunotherapy of advanced breast cancer with BCG. Recent Results Cancer Res(62):143-50, 1977. e-Pub 1977. PMID: 601328.
1025. Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB, Mavligit GM, Freireich EJ, Gottlieb JA, Hersh EM. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Br Med J 2(6046):1222-5, 1976. e-Pub 1976. PMID: 791447.
1026. Gutterman JU, Blumenschein GR, Hortobagyi GN, Mavligit GM, Hersh E. Immunotherapy of breast cancer. Breast 2:29-34, 1976. e-Pub 1976.
1027. Blumenschein GR, Montague ED, Eckles NE, Hortobagyi GN, Barker JL. Sequential combined modality therapy for inflammatory breast cancer. Breast 2:16-20, 1976. e-Pub 1976.
1028. Fujii T, Le Du F, Xiao L, Kogawa T, Hortobagyi GN, Valero V, Shen Y, Ueno NT. Optimal Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: a Systematic Review and Bayesian Network Meta-analysis. JAMA Oncol.
1029. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, BlackwellKL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Ekmeliegy M, Germa C, O'Shaughnessy J. Prognostic factors in metastatic breast cancer patients with bone only metastases. The Oncologist.
1030. Hortobagyi GN. Breakthroughs in Breast Cancer: Management Approaches, Treatment Recommendations and Future Outlook. Foundations of Clinical Cancer Research:.
1031. Murthy RK, Chavez-MacGregor M, Hortobagyi GN. Adjuvant HER2-Targeted therapy update in breast cancer - Escalation and de-escalation of therapy in 2018. Current Breast Cancer Reports.
1032. Sharma P, Barlow WE, Ak G, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gokmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN. Valiadiation of the DNA Damage Immune Response (DDIR) Signature in Triple-Negative Breast Canct (TNBC) Patients from the SWOG 9313c Trial. J Clin Oncol.
1033. Chen CS, Zirpoli G, Budd GT, Barlow WE, Pusztai L, Hortobagyi GN, Albain KS, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, Hertz DL. Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221. Cancer Chemother Pharmacol 94(2):311-321. PMID: 38814343.

Invited Articles

1. Hortobagyi GN, Edge SB, Giuliano A. New and Important Changes in the TNM System. Am Soc Clin Oncol Educ Book 23(38):457-467, 2018. e-Pub 2018. PMID: 30231399.
2. Gonzalez-Angulo AM, Hortobagyi GN, Ellis L. Bevacizumab in Breast Cancer: Peaking Beneath the Surface of the Recent Clinical Trials. Nature Rev Clin Oncol, 2011. e-Pub 2011. PMID: 21556024.
3. Alvarez RH, Valero V, Hortobagyi GN. Ixabepilone for the treatment of breast cancer. Ann Med 43(6):477-86, 2011. e-Pub 2011. PMID: 21585248.
4. Alvarez RH, Hortobagyi GN. Primary Systemic Therapy for Operable Breast Cancer Patients: The Need for the New Generation of Trial Design. (Invited Commentary). Breast Cancer Res Treat 124(3):701-705, 2010. e-Pub 2010. PMID: 20953832.
5. Hortobagyi, GN. Systemic Therapy for Bone Metastasis: Past, Present and Future. ASCO Annual '10 Meeting. Educational Book. American Society of Clinical Oncology, Alexandria, VA:1-7, 2010. e-Pub 2010.
6. Gonzalez-Angulo AM, Hortobagyi GN. Brain Metastases and Breast Cancer Subtypes. (Editorial). Onkologie 33(4):143-144. e-Pub 2010. PMID: 20389139.
7. Hortobagyi GN, Brown PH. Two Good Choices to Prevent Breast Cancer: Great Taste, Less Filling. Cancer Prevention Res 3(6):681-685, 2010. e-Pub 2010. PMID: 20522797.
8. Hortobagyi, GN. Why My Neighbor's Health Is Important To Me. Oncology (Williston Park) 24(13):1238, 2010. e-Pub 2010. PMID: 21192567.
9. Andreopoulou E, Hortobagyi GN. Treatment of Hormone Receptor-Negative Breast Cancer. IN: Molecular and clinical heterogeneity in breast cancer. Hot Topics in Oncology 4(7):7-22. e-Pub 2010.
10. Kelly KM, Hortobagyi GN. Adjuvant Chemotherapy in Early-Stage Breast Cancer: What When and for Whom?. Surg Oncol Clin North America 19(3):649-668, 2010. e-Pub 2010. PMID: 20620933.
11. Melhem-Bertrand A, Hortobagyi GN. Primary Invasive Breast Cancer. BMJ Point-of-Care, 2010. e-Pub 2010.
12. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular Predictors of Response to Trastuzumab and Lapatinib in Breast Cancer. Nature Rev Clin Oncol 7(2):98-107. e-Pub 2009. PMID: 20027191.
13. Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, Promish D, Ueno NT, Tai P, Nieto Y, Joseph S, Janni W, Vicini F, Royce M, Storme G, Wallace AM, Vlastos G, Bouchardy C, Hortobagyi GN. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol 5(10):1585-603, 2009. e-Pub 2009. PMID: 20001797.
14. Carlson RW, Anderson BO, Bleiweiss IJ, Edge S, Hortobagyi GN, Ibarra JA. Identifying and Addressing Interdisciplinary Gaps in Systemic Treatment of Breast Cancer. IN: Ensuring Optimal Interdisciplinary Breast Care in the United States - Proceedings of a Colloquium. Published online on the ASBD website in December 2009, 2009. e-Pub 2009.
15. Hortobagyi, GN. A Physician's Perspective - Protein Markers of Risk and Prognosis: A Role for Proteomics. eProtein 2(1-3), 2009. e-Pub 2009.
16. Morrow, PK, Hortobagyi GN. Management of Breast Cancer in the Genome Era. Annu Rev Med 60(22):1-13, 2008. e-Pub 2008. PMID: 19630569.
17. Symmans WF, Hortobagyi GN. Fingerprinting lymph node metastases. Ann Surg Oncol 15(5):1275-6, 2008. e-Pub 2008. PMID: 18340490.
18. Esteva FJ, Hortobagyi GN. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?. J Natl Cancer Inst 100(8):521-3, 2008. e-Pub 2008. PMID: 18398093.
19. Giordano SH, Hortobagyi GN. Time to remove the subspecialty blinders: breast cancer does not exist in isolation. J Natl Cancer Inst 100(4):230-1, 2008. e-Pub 2008. PMID: 18270334.
20. Hortobagyi, GN. A Time for Creative Collaboration. Cancer 113(S8):2217-2220, 2008. e-Pub 2008. PMID: 18837030.
21. Esteva FJ, Hortobagyi GN. Gaining Ground on Breast Cancer. Sci Am 298(6):58-65, 2008. e-Pub 2008. PMID: 18642543.
22. Moulder SL, Craft BS, Hortobagyi GN. Inhibition of Receptor Tyrosine Kinases in Combination with Chemotherapy for the Treatment of Breast Cancer. Current Medicinal Chemistry-Anticancer Agents 8(5):481-7, 2008. e-Pub 2008. PMID: 18537531.
23. Craft BS, Hortobagyi GN, Moulder SL. Adjuvant Biologic Therapy for Breast Cancer. Cancer J 13(3)156-161, 2007. e-Pub 2007. PMID: 17620764.
24. Hortobagyi GN. From The ASCO President: Bridging the Gap Between Basic Research and Patient Care. J Oncol Practice 3(3):112, 2007. e-Pub 2007.
25. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2 and Sentinel Lymph Nodes. Clin Cancer Res 12(10):2831-2835, 2007. e-Pub 2007.
26. Giordano SH, Hortobagyi GN. Local Recurrence or Cardiovascular Disease: Pay Now or Later. J Natl Cancer Inst 99(5):340-341, 2007. e-Pub 2007. PMID: 17341720.
27. Hortobagyi GN. A Shortage of Oncologists? The American Society of Clinical Oncology Workforce Study. [Editorial Material]. J Clin Oncol 25(12):1468-1469, 2007. e-Pub 2007. PMID: 17360965.
28. Gonzalez-Angulo, AM, Morales-Vasquez F, Hortobagyi, GN. Overview of Resistance to Systemic therapy in Patients with Breast Cancer. Adv Exp Med & Biol 608:1-22, 2007. e-Pub 2007. PMID: 17993229.
29. Hortobagyi GN. The Future of Breast Cancer Management: Team Work and Team Science. Breast Diseases: A Year Book Quarterly 18(4):331-332, 2007. e-Pub 2007.
30. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11(8):857-67, 2006. e-Pub 2006. PMID: 16951389.
31. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-80, 2006. e-Pub 2006. PMID: 16683005.
32. Ocana A, Hortobagyi GN, Esteva FJ. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer 6(6):495-504, 2006. e-Pub 2006. PMID: 16595032.
33. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 367(9510):595-604, 2006. e-Pub 2006. PMID: 16488803.
34. Green MC, Hortobagyi GN. The Jordan Article Reviewed. Oncology 20(6):567-568, 2006. e-Pub 2006.
35. Ross JS, Symmans WF, Hortobagyi GN, Pusztai L. Emerging Molecular Prognostic and Predictive Factors in Early-Stage Breast Cancer. Biological Therapy of Breast Cancer 6(4):9-14 (Reviewed 8/23/05 for Pysician's Education Resource, 2006. e-Pub 2006.
36. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Personalized Medicine for Breast Cancer: Moving Forward and Going Back. Personalized Medicine 3(4):363-370, 2006. e-Pub 2006.
37. Hortobagyi GN. From the ASCO President: Supporting Patient Access to High-Quality Cancer Care. J Oncol Practice 2(6):264, 2006. e-Pub 2006.
38. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN. Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics. Nat Clin Pract Oncol 2(12):598-599, 2005. e-Pub 2005. PMID: 16341096.
39. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and clinical biomarkers in drug discovery and development. Am J Clin Pathol 124 Suppl:S29-41, 2005. e-Pub 2005. PMID: 16468416.
40. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 353(16):1734-6, 2005. e-Pub 2005. PMID: 16236745.
41. Hunt KK, Buchholz TA, Hortobagyi GN. Now and later? The sticky question of lymph node management in patients receiving preoperative chemotherapy. Ann Surg Oncol 12(9):683-5, 2005. e-Pub 2005. PMID: 16041472.
42. Thomas E, Hortobagyi GN. La Chimiothérapie Néo-adjuvante du Cancer du Sein. References en Gynecologie Obsterique 11:S185-191, 2005. e-Pub 2005.
43. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6(4):229-39, 2005. e-Pub 2005. PMID: 15811618.
44. Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years?. J Clin Oncol 23(8):1760-75, 2005. e-Pub 2005. PMID: 15755984.
45. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Breast cancer biomarkers. Adv Clin Chem 40:99-125, 2005. e-Pub 2005. PMID: 16355921.
46. Hortobagyi GN. Moving into the future: treatment of bone metastases and beyond. Cancer Treat Rev 31 Suppl 3:9-18, 2005. e-Pub 2005. PMID: 16249057.
47. Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 12(2):73-85, 2005. e-Pub 2005. PMID: 15858436.
48. Hortobagyi GN. Improving Outcomes of Breast Cancer Treatment: A 30-Year Journey. 29th Annual Jeffrey A. Gottlieb Memorial Award Lecture. Foundations in Clinical Cancer Research 3(1):3-10, 2005. e-Pub 2005.
49. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapies for cancer 2004. Am J Clin Pathol 122(4):598-609, 2004. e-Pub 2004. PMID: 15487459.
50. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 3(4):379-98, 2004. e-Pub 2004. PMID: 14762215.
51. Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn 4(2):169-88, 2004. e-Pub 2004. PMID: 14995904.
52. Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin Oncol 31(1 Suppl 3):21-7, 2004. e-Pub 2004. PMID: 15052540.
53. Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB. Molecular therapeutics: promise and challenges. Semin Oncol 31(1 Suppl 3):39-53, 2004. e-Pub 2004. PMID: 15052542.
54. Hortobagyi GN. Rational development of targeted therapy for breast cancer - Introduction. Semin Oncol 31(1 Suppl 3):1-2, 2004. e-Pub 2004.
55. Montero A Hortobagyi GN. The Emerging Role of Taxanes in the Management of Early Stage And Locally Advanced Breast Cancer. Oncology Exchange 3:5S-19S, 2004. e-Pub 2004.
56. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Multidisciplinary Considerations Involved In Using Neoadjuvant Chemotherapy For Breast Cancer. Am J Oncol Rev 3(3):156-164, 2004. e-Pub 2004.
57. Hortobagyi GN, Schwartz GF. Future Prospects. Semin Breast Disease 7(3):135-137, 2004. e-Pub 2004.
58. Buzdar AU, Hortobagyi GN. U.S. Experience in Neoadjuvant Therapy of Operable Breast Cancer. Semin Breast Disease 7(3):108-112, 2004. e-Pub 2004.
59. Garg AK, Hortobagyi GN, Aggarwal BB, Sahin AA, Buchholz TA. Nuclear factor-kappa B as a predictor of treatment response in breast cancer. Curr Opin Oncol 15(6):405-11, 2003. e-Pub 2003. PMID: 14624221.
60. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30(5 Suppl 16):93-104, 2003. e-Pub 2003. PMID: 14613030.
61. Hortobagyi GN. Novel approaches to the management of bone metastases. Semin Oncol 30(5 Suppl 16):161-6, 2003. e-Pub 2003. PMID: 14613037.
62. Buzdar AU Hortobagyi GN. Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. Cancer Treat Rev 29(5):449-52, 2003. e-Pub 2003. PMID: 12972364.
63. Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine: part I. Expert Rev Mol Diagn 3(5):573-85, 2003. e-Pub 2003. PMID: 14510178.
64. Hortobagyi GN, Sauter G. Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?. Semin Oncol 30(3 Suppl 7):47-53, 2003. e-Pub 2003. PMID: 12840800.
65. Nahta R, Hortobagyi GN, Esteva FJ. Novel pharmacological approaches in the treatment of breast cancer. Expert Opin Investig Drugs 12(6):909-21, 2003. e-Pub 2003. PMID: 12783596.
66. Nahta R, Hortobagyi GN, Esteva FJ. Signal transduction inhibitors in the treatment of breast cancer. Current Medicinal Chemistry - Anticancer Agents 3(3):201-16, 2003. e-Pub 2003. PMID: 12769778.
67. Thomas E, Hortobagyi GN. New paradigms in adjuvant systemic therapy of breast cancer. Endocrine-Related Cancer 10(1):75-89, 2003. e-Pub 2003. PMID: 12653671.
68. Hortobagyi GN. Future directions in the endocrine therapy of breast cancer. Breast Cancer Res Treat 80 Suppl 1:S37-9, 2003. e-Pub 2003. PMID: 14535533.
69. Hortobagyi GN. New approaches to breast cancer therapy. Breast Cancer Res Treat 80 Suppl 1:S1-2; discussion S13-8, 2003. e-Pub 2003. PMID: 14535529.
70. Ibrahim NK Hortobagyi GN. Taxane-Induced Colitis in Patients with Breast Cancer. (Editorial) . Breast Disease: A Year Book Quarterly 14(2):118-120, 2003. e-Pub 2003.
71. Ibrahim NK Hortobagyi GN. Taxane-Induced Colitis in Patients with Breast Cancer. (Editorial) . Breast Disease: A Year Book Quarterly, 2003. e-Pub 2003.
72. Giordano SH Hortobagyi GN. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res 5(6):284-8, 2003. e-Pub 2003. PMID: 14580242.
73. Hortobagyi GN. Multidrug Chemotherapy for Metastatic Breast Cancer: Simultaneous or Sequential?. American Society of Clinical Oncology 2003 Educational Book, 2003, MC Perry (Ed.), American Society of Clinical Oncology, Alexandria, VA:112-118, 2003. e-Pub 2003.
74. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. The Oncologist 8(1):5-17, 2003. e-Pub 2003. PMID: 12604728.
75. Hortobagyi GN. The Curability of Breast Cancer: Present and Future. Eur J Cancer Suppl 1(1):24-34, 2003. e-Pub 2003.
76. Pusztai L, Ayers M, Stec J, Hortobagyi GN. Clinical application of cDNA microarrays in oncology. Oncologist 8(3):252-8, 2003. e-Pub 2003. PMID: 12773747.
77. Singletary SE, Walsh G, Vauthey JN, Curley S, Sawaya R, Weber KL, Meric F, Hortobagyi GN. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8(3):241-51, 2003. e-Pub 2003. PMID: 12773746.
78. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 8(2):141-8, 2003. e-Pub 2003. PMID: 12697939.
79. Hortobagyi GN. Progress and Controversies in Targeted Therapies of Breast Cancer - Introduction. Semin Oncol 30(5 Suppl 16):1-3, 2003. e-Pub 2003.
80. Cristofanilli M Hortobagyi GN. Molecular targets in breast cancer: current status and future directions. Endocr Relat Cancer 9(4):249-66, 2002. e-Pub 2002. PMID: 12542402.
81. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer 3 Suppl 2:S63-S68, 2002. e-Pub 2002. PMID: 12435294.
82. Hortobagyi GN. The status of breast cancer management: challenges and opportunities. Breast Cancer Res Treat 75 Suppl 1:S61-5; discussion S57-9, 2002. e-Pub 2002. PMID: 12353825.
83. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12(4):319-28, 2002. e-Pub 2002. PMID: 12382190.
84. Green MC, Hortobagyi GN. Adjuvant chemotherapy for breast cancer. Langenbecks Arch Surg 387(3-4):109-116, 2002. e-Pub 2002. PMID: 12269263.
85. Hortobagyi GN. Integration of docetaxel into adjuvant breast cancer treatment regimens. Oncology (Williston Park) 16(6 Suppl 6):27-33, 2002. e-Pub 2002. PMID: 12108895.
86. Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 29(3 Suppl 11):134-44, 2002. e-Pub 2002. PMID: 12138408.
87. Hortobagyi GN, Kris MG. Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers. Semin Oncol 29(3 Suppl 12):1-3, 2002. e-Pub 2002. PMID: 12170444.
88. Hortobagyi GN. Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer. Clin Breast Cancer 3 Suppl 1:34-8, 2002. e-Pub 2002. PMID: 12057044.
89. Arun B Hortobagyi GN. Progress in breast cancer chemoprevention. Endocr Relat Cancer 9(1):15-32, 2002. e-Pub 2002. PMID: 11914180.
90. Green M, Hortobagyi GN. Neoadjuvant chemotherapy for operable breast cancer. Oncology (Williston Park) 16(7):871-84, 889; discussion 889-90, 892-4, 897-8, 2002. e-Pub 2002. PMID: 12164555.
91. Buchholz TA Hortobagyi GN. Sequencing of Surgery, Systemic Treatment, and Radiation in the Mangemetn of Breast Cancer. Wom Oncol Rev 1(4):349-354, 2002. e-Pub 2002.
92. Theriault, RL, Hortobagyi, GN. El Creciente Papel de los Bisfosfonatos. Semin Oncol (Edicion Espanola) 1(1):55-60, 2002. e-Pub 2002.
93. Nahta R, Hortobagyi, GN, Esteva, FJ. Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention. . The Oncologist 8(1):5-17, 2002. e-Pub 2002.
94. Hortobagyi, Hayes GN, DF, Pusztai L. Integrating Newer Science into Breast Cancer Prognosis and Treatment: A Review of Current Molecular Predictors and Profiles. ASCO 2002 Annual Meeting Summaries, DH Johnson (Ed.) Americal Society of Clinical Oncology, Alexandria, VA:192-266, 2002. e-Pub 2002.
95. Hortobagyi GN. Gemcitabine in Combination with Vinorelbine for Treatment of Advanced Breast Cancer. Clinical Breast Cancer 3(Suppl 1):S34-S38, 2002. e-Pub 2002.
96. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 28(6 Suppl 18):43-7, 2001. e-Pub 2001. PMID: 11774205.
97. Wang SC, Zhang L, Hortobagyi GN, Hung MC. Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol 28(6 Suppl 18):21-9, 2001. e-Pub 2001. PMID: 11774202.
98. Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol 28(5 Suppl 16):41-6, 2001. e-Pub 2001. PMID: 11706395.
99. Hortobagyi GN. Optimal duration of therapy with trastuzumab. Semin Oncol 28(5 Suppl 16):33-40, 2001. e-Pub 2001. PMID: 11706394.
100. Hortobagyi GN. Adjuvant systemic therapy for early breast cancer: progress and controversies. Clin Cancer Res 7(7):1839-42, 2001. e-Pub 2001. PMID: 11448893.
101. Theriault RL Hortobagyi GN. The evolving role of bisphosphonates. Semin Oncol 28(3):284-90, 2001. e-Pub 2001. PMID: 11402438.
102. Hortobagyi GN. Unmet needs in metastatic bone disease and its complications: is progress possible?. Semin Oncol 28(2 Suppl 6):1-3, 2001. e-Pub 2001. PMID: 11346858.
103. Hortobagyi GN. Treatment of advanced breast cancer with gemcitabine and vinorelbine. Oncology (Williston Park) 15(2 Suppl 3):15-7, 2001. e-Pub 2001. PMID: 11252883.
104. Esteva FJ, Krishnamurthy S, Hortobagyi, GN. A Case Study of Weekly Docetaxel and Trastuzumab in Advanced Breast Cancer. Case Studies in Oncology:1-5, 2001. e-Pub 2001.
105. Cristofanilli M Hortobagyi GN. New Horizons in Treating Metastatic Disease. Clinical Breast Cancer 1(4):20-31, 2001. e-Pub 2001.
106. Hortobagyi GN. Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr(30):72-9, 2001. e-Pub 2001. PMID: 11773296.
107. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6(2):133-46, 2001. e-Pub 2001. PMID: 11306725.
108. Hortobagyi GN. Management of Locally Advanced Breast Cancer. Oncology Forum 4(3):14-15, 2001. e-Pub 2001.
109. Hortobagyi GN. Progress and Controversies in Adjuvant Systemic Therapies for Early Breast Cancer. Oncology Forum 4(3):12-13, 2001. e-Pub 2001.
110. Cristofanilli M, Hortobagyi GN. Prevention Strategies for Breast Cancer. Ref En Gynecol Obste 8:453-69, 2001. e-Pub 2001.
111. Hortobagyi GN. Targeted therapies in the treatment of breast cancer – Introduction. Semin Oncol 28(5, Suppl 16):1-3, 2001. e-Pub 2001.
112. Hortobagyi GN. Targeting HER2: Recent Developments and Future Directions for Breast Cancer Patients. Introduction. Semin Oncol 28(6, Suppl 18):1-2, 2001. e-Pub 2001.
113. Hortobagyi GN. High-Dose Mitoxantrone Adjuvant Chemotherapy does not Prolong Survival for Women with Breast Cancer and Ten or more Involved Axillary Nodes. Evidence-Based Oncology 2:146-147, 2001. e-Pub 2001.
114. Cristofanilli M Hortobagyi GN. New horizons in treating metastatic disease. Clin Breast Cancer 1(4):276-87, 2001. e-Pub 2001. PMID: 11899350.
115. Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol 27(6 Suppl 11):26-32; discussion 92-100, 2000. e-Pub 2000. PMID: 11236024.
116. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23(5):401-28, 2000. e-Pub 2000. PMID: 11085347.
117. Hortobagyi GN Khayat D. Targeting progress: the development of growth factor receptor-directed therapy. Semin Oncol 27(5 Suppl 9):1-2, 2000. e-Pub 2000. PMID: 11049050.
118. Hortobagyi GN. Combined Modality Therapy for Primary Breast Cancer. Proc. 4th Annual Symposium of the Chinese Society of Clinical Oncology. Beijing, P.R.C:109-128, 2000. e-Pub 2000.
119. Hortobagyi GN. Developments in chemotherapy of breast cancer. Cancer 88(12 Suppl):3073-9, 2000. e-Pub 2000. PMID: 10898354.
120. Swain S, Chien K, Perez E, Sartor C, Hortobagyi G, Kumar R, Sliwkowski M, Arteaga C, Mass B. Recent Developments and Future Directions with HER-2 in Breast Cancer and Other Tumor Types - Panel Discussion II. Semin Oncol 27(6, Suppl 11):97-100, 2000. e-Pub 2000.
121. Dixon JM, Hortobagyi G. Treating young patients with breast cancer. (Editorial) . BMJ 320:457-458, 2000. e-Pub 2000.
122. Hortobagyi G. Adjuvant therapy for breast cancer. Annu Rev Med 51:377-92, 2000. e-Pub 2000. PMID: 10774471.
123. Hortobagyi G, Swain S, Sliwkowski M, Arteaga C, Mass B, Sledge G, Pegram M, Ozols R, Kumar R. Recent Developments and Future Directions with HER-2 in Breast Cancer and Other Tumor Types - Panel Discussion I. Semin Oncol 27(6, Suppl 11):92-96, 2000. e-Pub 2000.
124. Hortobagyi GN. Recent Developments and Future Directions with HER-2 in Breast Cancer and Other Tumor Types - Introduction. Semin Oncol 27(6, Suppl 11):1-2, 2000. e-Pub 2000.
125. Cristofanilli M Hortobagyi GN. Gene Therapy for Advanced Breast and Ovarian Cancer. Journal of Women’s Cancer 2(2):101-110, 2000. e-Pub 2000.
126. Pusztai L, Tanyi J, Hortobagyi GN. Current status of the cytotoxic treatment of breast cancer. CME Journal of Gynecologic Oncology 5:373-381, 2000. e-Pub 2000.
127. Hortobagyi GN Antman KH. High-Dose Chemotherapy in the Management of Breast Cancer - Introduction. Seminars in Breast Disease 3(3):131, 2000. e-Pub 2000.
128. Hortobagyi GN. The Saga of High-Dose Chemotherapy for Breast Cancer: Is There Finally More Light than Heat?. Breast Diseases: A Year Book Quarterly 10(4):380-384, 2000. e-Pub 2000.
129. Hortobagyi GN. High-dose chemotherapy for primary breast cancer: facts versus anecdotes. J Clin Oncol 17(11 Suppl):25-9, 1999. e-Pub 1999. PMID: 10630258.
130. Hortobagyi GN. Evolving Concepts in High-Dose Chemotherapy for Breast Cancer. American Society of Clinical Oncology 1999 Fall Educational Book, Perry MC, (Ed.) Fall Education Conference. San Francisco, CA:128-134, 1999. e-Pub 1999.
131. Esteva FJ Hortobagyi GN. Adjuvant systemic therapy for primary breast cancer. Surg Clin North Am 79(5):1075-90, 1999. e-Pub 1999. PMID: 10572552.
132. Buzdar AU Hortobagyi GN. Recent advances in adjuvant therapy of breast cancer. Semin Oncol 26(4 Suppl 12):21-7, 1999. e-Pub 1999. PMID: 10482191.
133. Hortobagyi GN, Hung MC, Buzdar AU. Recent developments in breast cancer therapy. Semin Oncol 26(4 Suppl 12):11-20, 1999. e-Pub 1999. PMID: 10482190.
134. Ibrahim NK Hortobagyi GN. The evolving role of specific estrogen receptor modulators (SERMs). Surg Oncol 8(2):103-23, 1999. e-Pub 1999. PMID: 10732962.
135. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 26(3 Suppl 9):32-6, 1999. e-Pub 1999. PMID: 10426457.
136. Cristofanilli M Hortobagyi GN. Bisphosphonates in the Management of Breast Cancer. Cancer Control 6(3):241-246, 1999. e-Pub 1999. PMID: 10758553.
137. Esteva FJ Hortobagyi GN. Locally advanced breast cancer. Hematol Oncol Clin North Am 13(2):457-72, vii, 1999. e-Pub 1999. PMID: 10363140.
138. Hortobagyi GN. Introduction to Sequencing of Therapeutic Interventions. Seminars in Breast Disease 2(2):107-109, 1999. e-Pub 1999.
139. Pusztai L, Hortobagyi GN, M-C H, Buzdar AU. Advances and Future Directions in Breast Cancer Therapy. Proc 22nd Congress of the International Association for Breast Cancer Research, September 25-28, 1998, Athens, Greece, Ioannidou-Mouzaka L, Agnantis NJ, Lopez DM (Eds.) Monduzzi Editore, International Proceedings Division, Bologna, Italy:79-83, 1999. e-Pub 1999.
140. Pusztai L Hortobagyi GN. Treatment of Early-Stage Breast Cancer. Home Health Care Consultant - Oncology 6(6):2-7, 1999. e-Pub 1999.
141. Hortobagyi GN. Options for Treatment of Metastatic Breast Cancer. American Society of Clinical Oncology 1999 Educational Book. MC Perry, (Ed.), Lippincott Williams & Wilkins, Baltimore:515-521, 1999. e-Pub 1999.
142. Buzdar AU Hortobagyi GN. Breast cancer. Cancer Chemother Biol Response Modif 18:435-69, 1999. e-Pub 1999. PMID: 10800497.
143. Hortobagyi G. An expanding role for docetaxel. Semin Oncol 25(6 Suppl 13):1-3, 1998. e-Pub 1998. PMID: 9865684.
144. Cristofanilli M Hortobagyi GN. Current methods to prevent the development of breast cancer. In Vivo 12(6):659-65, 1998. e-Pub 1998. PMID: 9891229.
145. Valero V, Hortobagyi GN. Primary chemotherapy: a better overall therapeutic option for patients with breast cancer. Ann Oncol 9(11):1151-4, 1998. e-Pub 1998. PMID: 9862043.
146. Pusztai L Hortobagyi GN. Discouraging news for high-dose chemotherapy in high-risk breast cancer. Lancet 352(9127):501-2, 1998. e-Pub 1998. PMID: 9716049.
147. Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin R. High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat Rev 24(4):249-63, 1998. e-Pub 1998. PMID: 9805506.
148. Hortobagyi GN. Progress in endocrine therapy for breast carcinoma. Cancer 83(1):1-6, 1998. e-Pub 1998. PMID: 9655286.
149. Hortobagyi GN. Early Breast Cancer: Introduction. American Society of Clinical Oncology Educational Book, Thirty-Fourth Annual Meeting, Los Angeles, CA. MC Perry (Ed.):129-131, 1998. e-Pub 1998.
150. Hortobagyi GN Hung MC. The Role of the HER-2 Gene and Its Product in the Management of Primary and Metastatic Breast Cancer. 1998 Fall Educational Book, American Society of Clinical Oncology, Perry MC (Ed.), American Society of Clinical Oncology, Alexandria, VA:146-154, 1998. e-Pub 1998.
151. Pusztai L Hortobagyi GN. High-Dose Chemotherapy: How Resistant is Breast Cancer?. Drug Resistance Updates 1(1):62-72, 1998. e-Pub 1998.
152. Hortobagyi GN. Gianni Bonadonna, M.D.: A Leader in Breast Cancer Research. Breast Diseases: A Year Book7 Quarterly 8(4):302-305, 1998. e-Pub 1998.
153. Esteva FJ Hortobagyi GN. Neoadjuvant Therapy for Breast Cancer. Biomedicina 1(5):161-165, 1998. e-Pub 1998.
154. Rahman ZU, Buzdar AU, Singletary E, Hortobagyi GN. Selection of Systemic Therapy: Is Axillary Lymph Node Status Important?. Semin Breast Dis 1(3):157-166, 1998. e-Pub 1998.
155. Esteva FJ Hortobagyi GN. Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. Oncologist 3(5):300-313, 1998. e-Pub 1998. PMID: 10388120.
156. Hortobagyi GN, Pivot X, Asmar L. Anthracycline-Resistant Breast Cancer. Journal of Japanese Breast Cancer Society 4(4):221-227, 1997. e-Pub 1997. PMID: 11091603.
157. Hortobagyi GN. Chemotherapy of breast cancer: a historical perspective. Semin Oncol 24(5 Suppl 17):S17-1-S17-4, 1997. e-Pub 1997. PMID: 9374083.
158. Rahman Z, Champlin R, Rondon G, Frye D, Valero V, Mehra R, Hortobagyi G. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 24(5 Suppl 17):S17-77-S17-80, 1997. e-Pub 1997. PMID: 9374100.
159. Buzdar AU, Hortobagyi GN, Asmar L, Theriault RL, Rahman Z, McNeese M, Singletary S, Ames F. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol 24(5, Suppl 17):S17-31-S17-34, 1997. e-Pub 1997. PMID: 9374089.
160. Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 24(5 Suppl 17):S17-65-S17-68, 1997. e-Pub 1997. PMID: 9374097.
161. Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z, Buzdar AU. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol 24(4 Suppl 11):S11-13-S11-19, 1997. e-Pub 1997. PMID: 9314293.
162. Hortobagyi GN. Introduction: taxoids and the management of breast cancer. Semin Oncol 24(4 Suppl 13):S13-1-S13-2, 1997. e-Pub 1997. PMID: 9335510.
163. Hortobagyi GN. Docetaxel: today's results and tomorrow's promises. Oncology (Williston Park) 11(8 Suppl 8):11-4, 1997. e-Pub 1997. PMID: 9364535.
164. Hortobagyi G. Docetaxel in breast cancer and a rationale for combination therapy. Oncology (Williston Park) 11(6 Suppl 6):11-5, 1997. e-Pub 1997. PMID: 9213321.
165. Hortobagyi GN, Sledge GW, Jr, Rowinsky EK. What New Drugs, Biologics, and Treatment Approaches Show Promise in Breast Cancer?. Cancer Control 4(3 Suppl 1):34-36, 1997. e-Pub 1997. PMID: 10763033.
166. Sledge GW, Jr, Rowinsky EK, Hortobagyi GN, Vaughan W, Horton J. What are the Roles of the Taxanes in Breast Cancer. Cancer Control 4(3 Suppl 1):23-33, 1997. e-Pub 1997. PMID: 10763032.
167. Hortobagyi GN. Can Metastatic Breast Cancer Be Cured or Controlled by hemotherapy?. Cancer Control 4(3 Suppl 1):19-22, 1997. e-Pub 1997. PMID: 10763031.
168. Hortobagyi GN. Paclitaxel-based combination chemotherapy for breast cancer. Oncology (Williston Park) 11(3 Suppl 2):29-37, 1997. e-Pub 1997. PMID: 9110340.
169. Piccart MJ, Hortobagyi GN. Conclusions: future strategies in the treatment of breast cancer. Semin Oncol 24(1 Suppl 3):S34-40, 1997. e-Pub 1997. PMID: 9071339.
170. Hortobagyi GN, Holmes FA. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol 24(1 Suppl 3):S4-7, 1997. e-Pub 1997. PMID: 9071332.
171. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol 24(1 Suppl 3):S30-3, 1997. e-Pub 1997. PMID: 9071338.
172. Hortobagyi GN. Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastasis. Topics on Supportive Care in Oncology 2/97(n123):8-9, 1997. e-Pub 1997.
173. Valero V Hortobagyi GN. Cáncer de Mama Localmente Avanzado. Revista de la Federación Latinoamericana de Mastología 1(1):23-30, 1997. e-Pub 1997.
174. Hortobagyi GN. Introduction. Docetaxel in Combined Modality Therapy for Breast Cancer. Oncology 11(6 (Suppl No. 6)):9-10, 1997. e-Pub 1997.
175. Hortobagyi GN. Nuevas Modalidades Terapéuticas para el Cáncer de Mama. Médico Interamericano 16(11):621-624, 1997. e-Pub 1997.
176. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 54 Suppl 4:1-7, 1997. e-Pub 1997. PMID: 9361955.
177. Theriault RL Hortobagyi GN. Medical Treatment of Bone Metastases. Diseases of the Breast Updates, Harris JR, Lippman ME (Eds.) Lippincott/Raven 1(3):1-11, 1997. e-Pub 1997.
178. Hortobagyi GN, Pivot X, Asmar L. Anthracycline-Resistant Breast Cancer. Breast Cancer - The Journal of the Japanese Breast Cancer Society 4(4):221-227, 1997. e-Pub 1997.
179. Rivera E Hortobagyi GN. Paclitaxel in the Treatment of Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. Advances In Oncology 13(3):10-16, 1997. e-Pub 1997.
180. Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Semin Oncol 23(5 Suppl 11):1-5, 1996. e-Pub 1996. PMID: 8893891.
181. Dhingra K, Hortobagyi GN. Critical evaluation of prognostic factors. Semin Oncol 23(4):436-45, 1996. e-Pub 1996. PMID: 8757270.
182. Buzdar AU, Plourde PV, Hortobagyi GN. Aromatase inhibitors in metastatic breast cancer. Semin Oncol 23(4 Suppl 9):28-32, 1996. e-Pub 1996. PMID: 8824462.
183. Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammatory breast cancer. Surg Clin North Am 76(2):393-410, 1996. e-Pub 1996. PMID: 8610271.
184. Hortobagyi GN Ibrahim N. Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Semin Oncol 23(1 Suppl 1):53-7, 1996. e-Pub 1996. PMID: 8629039.
185. Hortobagyi GN, Holmes FA. Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 23(1 Suppl 1):4-9, 1996. e-Pub 1996. PMID: 8629036.
186. Buzdar AU, Hortobagyi GN, Singletary SE, Holmes FA, Theriault RL, Walters R, Dhingra K, Booser D, Morris A, Asmar L, Wright-Browne V, Diamandidou E, Witjaksono MA, Strom E, McNeese M, Ames F. Impact of FAC-Adjuvant Therapy on Mortality of Early Breast Cancer: Long Term Results of the M.D. Anderson Cancer Center Studies. Adjuvant Therapy of Cancer VIII, Salmon SE (Ed.), Lippincott-Raven, Philadelphia:93-100, 1996. e-Pub 1996.
187. Buzdar AU, Hortobagyi GN, Frye D, Valero V. Second-Line Chemotherapy for Metastatic Breast Cancer Including Quality of Life Issues. The Breast 5(4):312-317, 1996. e-Pub 1996.
188. Hortobagyi GN. Summary of Clinical Results of Vinorelbine (Navelbine7) in the Treatment of Breast Cancer. Breast Cancer. Advances in Biology and Therapeutics. F Calvo, M Crepin, H Magdalenat (Eds.), John Libbey Eurotext, Montrouge, France:251-256, 1996. e-Pub 1996.
189. Valero V, Buzdar AU, Hortobagyi GN. Inflammatory Breast Cancer: Clinical Features and the Role of Multimodal Therapy. The Breast Journal 2(5):345-352, 1996. e-Pub 1996.
190. Hortobagyi GN. A New Partnership (Editorial). . The Breast J 2(5):287-288, 1996. e-Pub 1996.
191. Browne V, Buzdar AU, Hortobagyi GN. Current Status of Adjuvant Therapy of Breast Cancer. (Editorial). The Cancer J 9(4):174-176, 1996. e-Pub 1996.
192. Valero VV, Buzdar AU, Hortobagyi GN. Locally Advanced Breast Cancer. Oncologist 1(1 & 2):8-17, 1996. e-Pub 1996. PMID: 10387963.
193. Hortobagyi GN Ibrahim N. Combinations of New and Old Agents for Breast Cancer Treatment: Future Directions. Oncology 10(Suppl):30-36, 1996. e-Pub 1996.
194. Hortobagyi GN. New Cytotoxic Agents for the Treatment of Breast Cancer. Oncology 10(Suppl):21-29, 1996. e-Pub 1996.
195. Hortobagyi GN. Management of breast cancer: status and future trends. Semin Oncol 22(5 Suppl 12):101-7, 1995. e-Pub 1995. PMID: 7481851.
196. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 4(4):715-34, 1995. e-Pub 1995. PMID: 8535907.
197. Peters GN, Kardinal CG, Robidoux A, Hortobagyi GN. Consultation: Inflammatory breast cancer: what is the appropriate therapy for patients who have a clinical response to induction chemotherapy?. Semin Oncol 22(5):xiv, xxi, xxvi, xxxii, 1995. e-Pub 1995. PMID: 7570054.
198. Singletary SE, Hortobagyi GN, Kroll SS. Surgical and medical management of local-regional treatment failures in advanced primary breast cancer. Surg Oncol Clin N Am 4(4):671-84, 1995. e-Pub 1995. PMID: 8535904.
199. Hortobagyi GN. Innovative approaches to breast cancer treatment: the role of paclitaxel. Introduction. Semin Oncol 22(4 Suppl 8):1-2, 1995. e-Pub 1995. PMID: 7638638.
200. Hortobagyi GN Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 45(4):199-226, 1995. e-Pub 1995. PMID: 7600278.
201. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol 22(3 Suppl 6):101-4, 1995. e-Pub 1995. PMID: 7541151.
202. Hortobagyi GN. High-Dose Chemotherapy is Not An Established Treatment for Breast Cancer. Educational Book of the 31st Annual Meeting of the American Society of Clinical Oncology. Los Angeles, CA:341-346, 1995. e-Pub 1995.
203. Hortobagyi GN. Future directions for vinorelbine (Navelbine). Semin Oncol 22(2 Suppl 5):80-6; discussion 86-7, 1995. e-Pub 1995. PMID: 7740338.
204. Hortobagyi GN, Buzdar AU, Strom EA, Ames FC, Singletary SE. Primary chemotherapy for early and advanced breast cancer. Cancer Lett 90(1):103-9, 1995. e-Pub 1995. PMID: 7720036.
205. Hortobagyi GN. Are the Results of High-Dose Chemotherapy in Breast Cancer Really Better Than Standard Treatment?. Bone Marrow Transplantation 15(Suppl 1):S260-S264, 1995. e-Pub 1995.
206. Holmes FA Hortobagyi GN. Paclitaxel in Breast Cancer: The Next Generation. Breast Diseases: A Year Book Quarterly (Editorial) 6(1):20-23, 1995. e-Pub 1995.
207. Valero V Hortobagyi GN. Radiotherapy and Adjuvant Chemotherapy After Breast-Conserving Surgery in Patients With Stage I or II Breast Cancer: Does the Sequence Really Matter?. Breast Diseases; A Year Book Quarterly 6(3):251-253, 1995. e-Pub 1995.
208. Ibrahim NK, Buzdar AU, Hortobagyi GN. Breast Cancer in the Elderly. The Cancer Bulletin 47(3):212-217, 1995. e-Pub 1995.
209. Hortobagyi GN. Cancer du Sein - Nouvelles Modalités Thérapeutiques. La Gazette Médicale 102(25):38-40, 1995. e-Pub 1995.
210. Valero V, Rivera E, Hortobagyi G. Tratamiento Sistémico Adyuvante del Cáncer de Mama. Médico Interamericano 7:287-304, 1995. e-Pub 1995.
211. Hortobagyi GN. The American Society of Clinical Oncology (ASCO) - 21e Session (Los Angeles - USA - May 20th-23rd 1995). References en Gynecologie Obstetrique 3(4):396-398, 1995. e-Pub 1995.
212. Vázquez Albadalejo C, Prats Esteve M, Hortobagyi GN, Zornoza Celaya G, Biete Solá A, Rivera Fillat F, Verger Fransoy E. Cáncer de Mama: Estadio IV (1.0 Parte). Rev. Senologia y Patol. Mam 8(3):120-132, 1995. e-Pub 1995.
213. Hortobagyi GN, Holmes FA, Theriault RL, Buzdar AU. Use of Taxol (paclitaxel) in breast cancer. Oncology 51 Suppl 1:29-32, 1994. e-Pub 1994. PMID: 7970507.
214. Buzdar, AU, Hortobagyi GN, Holmes FA, McNeese M, Theriault RL, Singletary SE. M.D. Anderson Cancer Center Adjuvant Therapy Trials in Stage II or III Breast Cancer. Autologous Marrow and Blood Transplantation. Proc of the Seventh International Symposium, Arlington, Texas. KA Dicke, A Keating (Eds.):169-174, 1994. e-Pub 1994.
215. Hortobagyi GN. Management of Stage III Breast Cancer. Scientific Program/Syllabus of the Seventh Annual Meeting of the Southern Association for Oncology. Jekyll Island, GA, 1994. e-Pub 1994.
216. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 74(1 Suppl):416-23, 1994. e-Pub 1994. PMID: 8004615.
217. Booser DJ Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 47(2):223-58, 1994. e-Pub 1994. PMID: 7512899.
218. Hortobagyi G. Metastatic Breast Cancer: Current Management Options and Future Directions. Cancer Treatment - An Update. P Banzet, JF Holland, D Khayat, M Weil (Eds.) Springer-Verlag, Paris, France:62-65, 1994. e-Pub 1994.
219. Buzdar A, Hortobagyi G, Kau S, Holmes F, Fraschini G, Theriault R, McNeese M, Singletary S. Long-Term Efficacy and Late Sequelae of Doxorubicin-Containing Adjuvant Therapy for Breast Cancer: MD Anderson Cancer Center Studies. Cancer Treatment - An Update. P Banzet, JF Holland, D Khayat, M Weil (Eds.), Springer-Verlag, Paris, France:163-166, 1994. e-Pub 1994.
220. Fraschini G, Esparza L, Booser DJ, Theriault RL, Holmes FA, Hortobagyi GN. Frontline Arterial Infusion Chemotherapy for Hepatic Metastases in Patients with Breast Cancer. Recent Advances in Chemotherapy: Proc 18th International Congress of Chemotherapy. American Society for Microbiology. Einhorn J, Nord CE, Norrby SR (Eds.):980-981, 1994. e-Pub 1994.
221. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper M, Greene D, Booser D, Buzdar A, Raber M, Gutierrez L, Hortobagyi G. Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergualin: A Phase I Study. Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment, R.L. Ceriani (Ed.), Plenum Press, New York:193-202, 1994. e-Pub 1994.
222. Hortobagyi GN. Tratamiento del Cáncer de Mama Localmente Avanzado. Revisiones en Cáncer 8:125-129, 1994. e-Pub 1994.
223. Valero V, Theriault R, Esparza L, Fraschini G, Holmes F, Walters R, Buzdar A, Raber M, Pazdur R, Bellet R, Bayssas M, Hortobagyi GN. Phase II Study of Taxotere in Patients With Anthracycline-Resistant Metastatic Breast Cancer. Recent Advances in Chemotherapy: Proc 18th International Congress of Chemotherapy. American Society for Microbiology. Einhorn J, Nord CE, Norrby SR (Eds.):844-845, 1994. e-Pub 1994.
224. Hortobagyi GN. Locally Advanced Breast Cancer. Proc Controversies in the Management of Breast Cancer Patients, Columbia University College of Physicians and Surgeons and the European School of Oncology, May 19-20, 1994, New York, N.Y., KH Antman, D Kinne, U Veronesi (Eds.):145-171, 1994. e-Pub 1994.
225. Dhingra K Hortobagyi GN. To Delay or Not To Delay - That's the Question! Is it?. Breast Disease (Editorial) 7:335-337, 1994. e-Pub 1994.
226. Ueno NT, Buzdar AU, Hortobagyi GN. Inflammatory Breast Cancer. Breast Surgery Index & Reviews (Editorial) II:1-15, 1994. e-Pub 1994.
227. Hortobagyi GN, Buzdar AU, Frye D, Singletary SE, Holmes FA, Ames F, McNeese MD, Theriault RL. Primary Chemotherapy for Breast Cancer: Response to Preoperative Chemotherapy as Prognostic Factor. Cancer Treatment - An Update. P Banzet, JF Holland, D Khayat, M Weil (Eds.), Springer-Verlag, Paris, France:105-109, 1994. e-Pub 1994.
228. Hortobagyi GN. Terapia de Dose Intensiva para Câncer de Mama Metastático e Câncer Primário de Mama de Alto Risco. VITRÔ (J of the Brasilian Cancer Society) 1:16-18, 1994. e-Pub 1994.
229. Holmes FA, Valero V, Walters R, Theriault R, Booser D, Buzdar A, Gibbs H, Frye D, Young K, Hortobagyi G. Taxol in Metastatic Breast Cancer: the MD Anderson Cancer Center Experience. Cancer Treatment - An Update. P Banzet, JF Holland, D Khayat, M Weil (Eds.), Springer-Verlag, Paris, France:167-171, 1994. e-Pub 1994.
230. Nieweg OE, Wong WH, Singletary SE, Hortobagyi GN, Kim EE. Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging, and evaluation of chemotherapy. Ann N Y Acad Sci 698:423-8, 1993. e-Pub 1993. PMID: 8279782.
231. Hortobagyi GN. Mitomycin: its evolving role in the treatment of breast cancer. Oncology 50 Suppl 1:1-8, 1993. e-Pub 1993. PMID: 8483556.
232. Valero V, Buzdar A, Hortobágyi G. Quimioterapia y Hormonoterapia en el Cancer de Mama Metastásico. Proc Seminario Internacional Ultrasonido de la Mama y Mastografía. Aug 25-27, 1993, Mexico City, J Jellins, M Rickard, H Madjar, (Eds.), International Breast Ultrasound School, Baden, Switzerland:119-123, 1993. e-Pub 1993.
233. Buzdar A, Frye D, Ho D, Booser D, Valero V, Holmes F, Plourde P, Hortobagyi G. Bioavailability of Nolvadex (Tamoxifen Citrate) as Once-Daily and Twice-Daily Dosage Regimens in Patients With Breast Cancer. Adjuvant Therapy of Cancer VII, SE Salmon, (Ed.), Lippincott, Philadelphia:237-239, 1993. e-Pub 1993.
234. Buzdar AU, Hortobagyi GN, S-W K, Holmes FA, Fraschini G, Theriault RL, McNeese M, Ross M, Singletary E. Breast Cancer Adjuvant Therapy at the M.D. Anderson Cancer Center - Results of Four Prospective Studies. Adjuvant Therapy of Cancer VII, SE Salmon, (Ed.), Lippincott, Philadelphia:220-225, 1993. e-Pub 1993.
235. Dunphy F, Spitzer G, Yau J, Huan S, Spinolo J, Jagganath S, Wallerstein R, Dicke K, Buzdar A, Hortobagyi G. Long Term Follow Up of Poor Prognosis Stage IV Breast Cancer Patients Treated With Two Courses of High-Dose Chemotherapy and Bone Marrow Support. Autologous Bone Marrow Transplantation. Proc Sixth International Symposium. KA Dicke, A Keating (Eds.) Cancer Treatment Research Education Fund, Arlington, TX:118-123, 1993. e-Pub 1993.
236. Hortobagyi G. Results With Conventional Dose Chemotherapy in High-Risk Primary and Metastatic Breast Cancer. Autologous Bone Marrow Transplantation. Proc Sixth International Symposium. KA Dicke, A Keating (Eds.) Cancer Treatment Research Education Fund, Arlington, TX:111-117, 1993. e-Pub 1993.
237. Booser DJ Hortobagyi GN. Breast Preservation After Downstaging by Induction Chemotherapy for Locally Advanced Breast Cancer. The Cancer Bulletin 45:517-522, 1993. e-Pub 1993.
238. Kim EE, Podoloff DA, Moulopoulos LA, Hortobagyi GN, Yeatman T, Singletary SE. Magnetic Resonance Imaging, Positron Emission Tomography, and Radioimmunoscintigraphy of Breast Cancer. The Cancer Bulletin 45:500-505, 1993. e-Pub 1993.
239. Buzdar AU Hortobagyi GN. Recent Developments and New Directions in Adjuvant Therapy for Breast Cancer. . The Cancer Bulletin 45:523-527, 1993. e-Pub 1993.
240. Hortobagyi GN Singletary SE. Spectrum of Breast Cancer. (Editorial). The Cancer Bulletin 45:471-472, 1993. e-Pub 1993.
241. Deisseroth AB, Fu SQ, Hanania E, Randhawa G, Claxton D, Reading C, Champlin R, Andreeff M, Logothetis C, Hong WK, Holmes F, Hortobagyi G, Benedict W. Evolution of Gene Therapy: The M.D. Anderson Experience. Contemporary Oncology 3(7):10-25, 1993. e-Pub 1993.
242. Hortobagyi GN Buzdar AU. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs 45 Suppl 2:10-9; discussion 18-9, 1993. e-Pub 1993. PMID: 7693417.
243. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr(15):161-9, 1993. e-Pub 1993. PMID: 7912522.
244. Hortobagyi GN. Chemotherapy Dose Intensification for Breast Cancer. Libro Ponencias del IV Congreso Nacional de Oncologia Medica. Editorial Libro del Año, Aran, Madrid:65-72, 1993. e-Pub 1993.
245. Hortobagyi GN. Primary (Neoadjuvant) Chemotherapy of Breast Cancer. Libro Ponencias del IV Congreso Nacional de Oncologia Medica. Editorial Libro del Año, Aran, Madrid:93-104, 1993. e-Pub 1993.
246. Fraschini G, Esparza L, Booser DJ, Theriault RL, Holmes FA, Hortobagyi GN. Frontline Arterial Infusion Chemotherapy for Hepatic Metastases in Breast Cancer Patients. Proc 18th International Congress of Chemotherapy. American Society for Microbiology, 1993. e-Pub 1993.
247. Valero V, Buzdar A, Hortobágyi G. Factores Pronósticos en el Cancer de Mama. Proc Seminario Internacional Ultrasonido de la Mama y Mastografía. Aug 25-27, 1993, Mexico City, J Jellins, M Rickard, H Madjar, (Eds.), International Breast Ultrasound School, Baden, Switzerland:106-110, 1993. e-Pub 1993.
248. Hortobagyi GN. Preface. Recent Experiences with Ifosfamide in the Treatment of Breast Cancer. pmi Verlagsgruppe GmbH, Frankfurt/Main, Germany:3-5, 1993. e-Pub 1993.
249. Dhingra K Hortobagyi G. Toward an Understanding of Predisposition to Breast Cancer - The Emerging Molecular Epidemiology of Breast Cancer. Breast Dis (Editorial) 6:7-11, 1993. e-Pub 1993.
250. Hortobagyi GN. Activity of ifosfamide in breast cancer. Semin Oncol 19(6 Suppl 12):36-41, 1992. e-Pub 1992. PMID: 1485173.
251. Theriault RL Hortobagyi GN. Bone metastasis in breast cancer. Anticancer Drugs 3(5):455-62, 1992. e-Pub 1992. PMID: 1450438.
252. Booser DJ Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 19(3):278-85, 1992. e-Pub 1992. PMID: 1609294.
253. Hortobagyi GN. What is the Role of High-Dose Therapy in Breast Cancer?. Oncology Bulletin 8:4-19, 1992. e-Pub 1992.
254. Hortobagyi GN Buzdar AU. 17 Years' Experience with Anthracycline-Containing Regimens at the M.D. Anderson Cancer Center. . Anthracyclines in the Adjuvant Treatment of Early Breast Cancer. Adis International, Chester, England:19-23, 1992. e-Pub 1992.
255. Hortobagyi GN. Overview of new treatments for breast cancer. Breast Cancer Res Treat 21(1):3-13, 1992. e-Pub 1992. PMID: 1356516.
256. Theriault RL Hortobagyi GN. Investigational Drugs for Metastatic Breast Cancer. Contemporary Oncology 2:57-62, 1992. e-Pub 1992.
257. Hortobagyi GN. Local control for locally advanced breast cancer: many opinions, few facts. Int J Radiat Oncol Biol Phys 23(5):1085-6; discussion 1093, 1992. e-Pub 1992. PMID: 1639643.
258. Hortobagyi GN. (Book Review) Breast Diseases, 2nd Edition, JR Harris, S Hellman, IC Henderson, DW Kinne, (Eds.), J.B. Lippincott, Philadelphia, 1991, 928 pp. J Natl Cancer Inst 84:639-640, 1992. e-Pub 1992.
259. Hortobagyi GN. Tratamento Complementar. Sociedade Brasileira de Mastologia - Regional Sao Paulo. Atividades Cientificas do Trienio 1989/1992:102-105, 1992. e-Pub 1992.
260. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol 18(4 Suppl 5):11-5, 1991. e-Pub 1991. PMID: 1925624.
261. Hortobagyi GN. The role of mitomycin C in the treatment of metastatic breast cancer. Mitomycin C in Cancer Chemotherapy Today T Taguchi and KR Aigner (Eds)., Excerpta Medica, Tokyo:1-9, 1991. e-Pub 1991.
262. Hortobagyi GN. (Book Review) Detection and Treatment of Early Breast Cancer. I Fentiman (Ed.), J. B. Lippincott, Philadelphia, 1990, 256 pp. Cancer Bull 43:591-592, 1991. e-Pub 1991.
263. Hortobagyi GN, Singletary SE, Buzdar AU, McNeese MD, Ross MI, Holmes FA, Strom E, Theriault RL, Sneige N. Primary Chemotherapy for Breast Cancer - M.D. Anderson Experience. Proc 3rd Int Congress on Neo-Adjuvant Chemotherapy, P Banzet, JF Holland, D Khayat, M Weil (Eds.), Springer-Verlag, Paris:146-148, 1991. e-Pub 1991.
264. Spitzer G, Huan S, Dunphy F, Dicke K, Wallerstein R, Hortobagyi G, Buzdar A, Holmes F, Yau J, Deisseroth A. Double High-Dose Therapy in Human Solid Tumors - An Emphasis on Breast Cancer. New Strategies in Bone Marrow Transplantation. Champlin RE, Gale RP, (Eds.) Wiley-Liss, Inc:437-445, 1991. e-Pub 1991.
265. Haynie TP, Kim EE, Wong WH, Yang DJ, Tilbury RS, Hortobagyi G, Podoloff DA, Singletary S, Misra LK, Zermeno A. Evaluation of Breast Cancer by Positron Emission Tomography using 18F-fluorodeoxyglucose. Nuclear Medicine: Nuclear Medicine in Research & Practice. Schmidt HAE and Hofer R (Eds.), Proc Eur Assoc Nuclear Med Congress 1991, Vienna, Schattauer, Stuttgart:677-680, 1991. e-Pub 1991.
266. Hortobagyi GN. The Duggan article reviewed. Oncology 5:74-79, 1991. e-Pub 1991.
267. Buzdar AU, Hortobagyi GN, McNeese MD, Frye D, Holmes FA, Fraschini G, Theriault RL, Singletary SE. Combined Modality Approach in Treatment of Inflammatory Carcinoma of the Breast - M.D. Anderson Cancer Center Experience. Proc 3rd Int Congress on Neo-Adjuvant Chemotherapy, P Banzet, JF Holland, D Khayat, M Weil (Eds.), Springer-Verlag, Paris:193-195, 1991. e-Pub 1991.
268. Hortobagyi GN. Dose Intensification and Autologous Stem Cell Support in Breast Cancer. Proc 3rd Int Congress on Neo-Adjuvant Chemotherapy, P Banzet, JF Holland, D Khayat, M Weil (Eds.), Springer-Verlag, Paris:472-474, 1991. e-Pub 1991.
269. Hortobagyi GN. High-Dose Chemotherapy and Autologous Bone Marrow Transplantation. Proc 3rd Int Congress on Neo-Adjuvant Chemotherapy, P Banzet, JF Holland, D Khayat, M Weil (Eds.), Springer-Verlag, Paris:314-316, 1991. e-Pub 1991.
270. Hortobagyi GN. Multimodality therapy of locally advanced breast cancer. Educational Booklet of the 26th Annual Meeting Amer Soc Clin Oncol:28-36, 1990. e-Pub 1990.
271. Carbone PP, Nixon DW, Fennelly J, Greenberg E, Henderson IC, Hortobagyi G, Kennedy BJ, Trainin N, Scanlon EF. Adjuvant systemic therapy. Cancer 65(9 Suppl):2108-9, 1990. e-Pub 1990. PMID: 2328476.
272. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, Frye D, McNeese MD, Holmes FA, Fraschini G, Hug V, McBride CM. Combined modality therapy for locally advanced breast cancer: 14 year results. Adjuvant Therapy of Cancer VI. S.E. Salmon (Ed.), W.B. Saunders Co., Philadelphia:254-261, 1990. e-Pub 1990.
273. Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Hug V, Gutterman JU, McNeese MD, Singletary SE, Ames F. Doxorubicin-containing adjuvant therapy for patients with stage II breast cancer: M.D. Anderson Cancer Center experience. Adjuvant Therapy of Cancer VI. S.E. Salmon (Ed.), W.B. Saunders Co., Philadelphia:210-215, 1990. e-Pub 1990.
274. Holmes FA, Buzdar AU, Kau SW, Fraschini G, Hug V, Smith T, Theriault RL, Singletary ES, Ames F, McNeese MD, Hortobagyi GN. Isolated visceral recurrences of breast cancer: Ten-year results of a combined modality approach. Adjuvant Therapy of Cancer VI. S.E. Salmon (Ed.), W.B. Saunders Co., Philadelphia:262-268, 1990. e-Pub 1990.
275. Hortobagyi GN. The Importance of dose-response in cytotoxic therapy for breast cancer. Advances in Breast Cancer Treatment, IC Henderson (Ed), Mediscript, London:47-69, 1990. e-Pub 1990.
276. Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, Buzdar AU. Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol 13 Suppl 1:S54-6, 1990. e-Pub 1990. PMID: 2291460.
277. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Holmes F, Horwitz LJ, Yau JC, Spinolo JA, Jagganath S, Dicke KA. High-Dose Chemotherapy Intensification With Bone Marrow Support for Hormone-Receptor Negative or Hormonal-Refractory Relapsing Breast Cancer. Dev Oncol 58:125-131, 1990. e-Pub 1990.
278. Cady B, Glick JH, Hortobagyi GN. Adjuvant Therapy for Breast Cancer. Patient Care 24:43-59, 1990. e-Pub 1990.
279. Hortobagyi GN. Breast Cancer Screening. Patient Care 24:11, 1990. e-Pub 1990.
280. Hortobagyi GN, McLelland R, Reed FM. Your key role in breast cancer screening. Patient Care 24:82-113, 1990. e-Pub 1990.
281. Hortobagyi GN. Prognostic factors in breast cancer: Today`s needs and challenges for tomorrow. Proceedings of Developments in Cancer Diagnostics and Therapeutics: Factors Impacting Global and Domestic Market Share. Biomedical Business International, Section 3, 1990. e-Pub 1990.
282. Buzdar A, Hortobagyi G, Kau S, Patel H, Hug V, Holmes F, Fraschini G, Singletary S, Ames F. Evaluation of risk and benefits of doxorubicin-containing (FAC) adjuvant chemotherapy in breast cancer - M.D. Anderson Cancer Center experience. Proceedings of the 16th International Congress of Chemotherapy, June 1989, Israel:781.1-781.2, 1990. e-Pub 1990.
283. Hortobagyi GN, Dunphy F, Buzdar AU, Spitzer G. Dose intensity studies in breast cancer--autologous bone marrow transplantation. Prog Clin Biol Res 354B:195-209, 1990. e-Pub 1990. PMID: 2236166.
284. Hortobagyi GN Ragaz J. Treatment of locally advanced and inflammatory breast cancer. Oncology Update - Focus on Breast Cancer:6-7, 1989. e-Pub 1989.
285. Hortobagyi GN. Neoadjuvant chemotherapy for patients with stage III breast cancer. OncoLog 34(4):8, 1989. e-Pub 1989.
286. Hortobagyi GN. Breast Cancer Consultation: For which patients should I consider flow cytometry?. Primary Care & Cancer:20, 1989. e-Pub 1989.
287. Buzdar AU Hortobagyi GN. Treatment of early and advanced breast cancer. Syllabus American College of Physicians 1989-1990 Postgraduate Courses Course (#906), 1989. e-Pub 1989.
288. McGuire WL, Abeloff MD, Hortobagyi GN, Swain SM. Treatment of stage III breast cancer. A panel discussion. Breast Cancer Res Treat 13(3):225-35, 1989. e-Pub 1989. PMID: 2758112.
289. Hortobagyi GN. Endocrine Therapies in Breast and Prostate Cancer. C.K. Osborne (Ed), Martinus Nijhoff Publishers, Dordrecht, The Netherlands, 1988. J Natl Cancer Inst 81(1):68, 1989. e-Pub 1989.
290. Theriault RL Hortobagyi G. When breast cancer complicates pregnancy: What options are available?. Primary Care and Cancer 9(2):27-29, 1989. e-Pub 1989.
291. Hortobagyi GN. Stage III Breast Cancer: Prognostic Factors and Therapy. Oncology Overview, National Cancer Institute, 1988. e-Pub 1988.
292. Dunphy FR, Spitzer G, Dicke KA, Buzdar AU, Hortobagyi GN. Tandem high-dose chemotherapy as intensification in stage IV breast cancer. Bone Marrow Transplantation: Current Controversies. UCLA Symposia on Molecular and Cellular Biology [New Series] Gale RP, Champlin E, (Eds.) 87:245-251, 1988. e-Pub 1988.
293. Brown GR, Askew RE, Gallager HS, Hortobagyi GN, Montague ED, Neff LE, Osborne CK, Race GJ, Salem RJ, Townsend CM, Jr, et al. Breast cancer. Breast Oncology Workgroup, Legislative Task Force on Cancer in Texas. Tex Med 83(9 Pt 2):81-96, 1987. e-Pub 1987. PMID: 3672409.
294. Buzdar A, Hortobagyi G, Frye D, Ames F, Singletary S, McNeese M, Montague E. Inflammatory carcinoma of the breast: Preliminary results of combined modality approach. Proceedings of the 15th International Congress of Chemotherapy, Istanbul, Turkey:438-439, 1987. e-Pub 1987.
295. Hortobagyi GN. Salvage chemotherapy for metastatic breast cancer. Semin Hematol 24(2 Suppl 1):56-61, 1987. e-Pub 1987. PMID: 3589709.
296. Hortobagyi GN. Is cisplatin useful for breast cancer?. Eur J Cancer Clin Oncol 23(2):119-21, 1987. e-Pub 1987. PMID: 3327695.
297. Hortobagyi GN. Tratamiento de cancer de mama localmente avanzado. Revisiones en Cancer 1(2):69-75, 1987. e-Pub 1987.
298. Hortobagyi GN. (The Article Reviewed) Dowden RV: The current approach to breast reconstruction. Oncology 1:29-38, 1987. e-Pub 1987.
299. Hortobagyi GN, Tomasovic SP, Nicolson GL. Breast cancer metastasis. Cancer Bulletin 39:210-215, 1987. e-Pub 1987.
300. Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Hug V, Campos LT, Ames FC, Martin RG. Breast cancer adjuvant therapy trials of M. D. Anderson Hospital: Results of three studies. Adjuvant Therapy of Cancer V, S.E. Salmon (Ed.), Grune & Stratton, New York:411-418, 1987. e-Pub 1987.
301. Hortobagyi GN, Kau SW, Buzdar AU, Ames FC, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Martin RG, Montague ED. Induction chemotherapy for stage III primary breast cancer. In Adjuvant Therapy of Cancer V, S.E. Salmon (Ed.), Grune & Stratton, New York:419-428, 1987. e-Pub 1987.
302. Spitzer G, Buzdar A, Hortobagyi G, Horwitz L, Jagannath S, Smith K, Dicke K. High-dose chemotherapy intensification and autologous bone marrow transplantation with emphasis on breast carcinoma. Proceedings of the Third International Symposium of Autologous Bone Marrow Transplantation III:455-463, 1986. e-Pub 1986.
303. Hortobagyi G. Immunostimulation by BCG (Summaries & Conclusions). Proceedings of the IABS Symposium on BCG Vaccines and Tuberculins, Budapest, Hungary, September 6-9, 1983, Develop Biol Standard. S. Karger, Basel 58:759, 1986. e-Pub 1986.
304. Hortobagyi GN. Biological markers in breast cancer. Ann Immunol Hung 26:775-792, 1986. e-Pub 1986.
305. Hortobagyi GN, Buzdar AU, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand 58 ( Pt A):357-63, 1986. e-Pub 1986. PMID: 3596041.
306. Hortobagyi GN Romsdahl MM. Multidisciplinary management of patients with stage III breast cancer. M.D. Anderson Oncology Case Reports & Review 1(3):1-9, 1986. e-Pub 1986.
307. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr(1):105-9, 1986. e-Pub 1986. PMID: 3534581.
308. Hortobagyi GN. Focus on therapy for advanced breast cancer. Trends in Chemotherapy 1(4):1-2, 1986. e-Pub 1986.
309. Buzdar AU, Hortobagyi GN, Marcus CE, Smith TL, Martin R, Gehan EA. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr(1):81-5, 1986. e-Pub 1986. PMID: 3534594.
310. Hortobagyi GN. Mitomycin-C in breast cancer. Semin Oncol 12(4 Suppl 6):65-70, 1985. e-Pub 1985. PMID: 3936183.
311. Buzdar AU, Smith TL, Blumenschein GR, Hortobagyi GN. Pre- and post-operative combination chemotherapy in breast cancer - M. D. Anderson experience. Proceedings of International Symposium of Senology, Evaluation of the risk of breast cancer primary chemotherapy, Liege-Belgium:287-295, 1985. e-Pub 1985.
312. Hortobagyi GN Fritsche HA. Carcinoembryonic antigen in breast cancer. Cancer Bulletin 37:58-60, 1985. e-Pub 1985.
313. Fritsche HA, Trujillo JM, Hortobagyi GN. Tumor markers in the clinical laboratory. Cancer Bulletin 37:54-58, 1985. e-Pub 1985.
314. Hortobagyi GN. Consulting reviewer - Postoperative adjuvant therapy of breast cancer. Oncology Overview, 1984. e-Pub 1984.
315. Holmes FA, Yap HY, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol 11(3 Suppl 1):28-31, 1984. e-Pub 1984. PMID: 6385262.
316. Blumenschein GR, Buzdar AU, Hortobagyi GN. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. Recent Results Cancer Res 96:129-132, 1984. e-Pub 1984. PMID: 6528087.
317. Buzdar, AU, Smith TL, Marcus CE, Hortobagyi GN, Blumenschein GR. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. Recent Results in Cancer Research 63:141-147, 1984. e-Pub 1984.
318. Buzdar AU, Smith TL, Blumenschein GR, Hortobagyi GN, Marcus CE, Hersh EM, Martin RG, Gehan EA, Freireich EJ. Breast cancer adjuvant therapy trials of M.D. Anderson Hospital: Results of two studies. Adjuvant Therapy of Cancer IV, S.E. Jones, S.E. Salmon (Eds.), Grune & Stratton, Inc., New York:217-225, 1984. e-Pub 1984.
319. Blumenschein GR, Pinnamaneni K, Buzdar AU, Hortobagyi GN, Yap HY, Montague ED, Ames FC. Combined regional and systemic therapy in breast cancer patients with an isolated metastases with or without chemotherapy. Adjuvant Therapy of Cancer IV, S.E. Jones, S.E. Salmon (Eds.), Grune & Stratton, Inc., New York:311-318, 1984. e-Pub 1984.
320. Hortobagyi GN. Hormone preparations. Clin Chemo - Antineoplastic Chemo:234-244, 1984. e-Pub 1984.
321. Yap HY, Esparza L, Blumenschein GR, Hortobagyi GN, Bodey GP. Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer. Cancer Treat Rev 10 Suppl B:53-5, 1983. e-Pub 1983. PMID: 6661735.
322. Legha SS, Benjamin RS, Ewer M, Mackay B, Wallace S, Hortobagyi GN, Freireich EJ. Continuous intravenous infusion of Adriamycin. Evaluation of its efficacy and toxicity. Proceedings of the International Symposium on Adriamycin. Japan, 1983. e-Pub 1983.
323. Chawla SP, Benjamin RS, Ewer MS, Hortobagyi GN, Legha SS, Mackay B, Ali MK, Carrasco CH, Wallace S, Haynie III TP, Freireich EJ. High cumulative dose Adriamycin beyond the conventional limits of 500 mg/m2 and reduction of cardiotoxicity by continuous infusion schedule. Proc. of the Thirteenth International Congress of Chemotherapy. KH Spitzy and K Karrer (Eds.), Verlag H, Egermann, Vienna (Austria):546-550, 1983. e-Pub 1983.
324. Chawla SP, Benjamin RS, Legha SS, Ewer MS, Ali ML, Mackay B, Carrasco CH, Hortobagyi GN, Wallace S, Haynie III TP, Freireich EJ. Role of cardiac biopsy and radionuclide scan in monitoring of Adriamycin-induced cardiotoxicity. Proc. of the Thirteenth International Congress of Chemotherapy. KH Spitzy and K Karrer (Eds.), Verlag H, Egermann, Vienna (Austria):490-492, 1983. e-Pub 1983.
325. Hortobagyi GN. Current status of chemotherapy and hormonal therapy for breast cancer. Cancer Bulletin 35:80-84, 1983. e-Pub 1983.
326. Hortobagyi GN, Schultz P, Cailleau R, Samaan N, Blumenschein GR. In vitro prostaglandin production by metastatic breast cancer. Prostaglandins and Cancer: First International Conference, Vol. 2, T.J. Powles, R.S. Bockman, K.V. Hohn, P. Ramwell (Eds.), Alan R. Liss, Inc., New York:567-572, 1982. e-Pub 1982.
327. Legha SS, Wang YM, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, Ali MK. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann N Y Acad Sci 393:411-8, 1982. e-Pub 1982. PMID: 6959564.
328. Bodey GP, Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU. A randomized comparative study of vinblastine, vindesine, and vincristine in patients with refractory metastatic breast cancer. Drugs Exp Clin 8:559-564, 1982. e-Pub 1982.
329. Hortobagyi GN, Blumenschein GR, Buzdar AU, Yap HY. Combination chemotherapy for metastatic breast cancer - The M.D. Anderson Hospital Experience. Treatment of Disseminated Breast Cancer (Part 2), Adria Laboratories, Inc., Columbus, Ohio:12-16, 1982. e-Pub 1982.
330. Blumenschein GR, Hortobagyi GN, Buzdar AU, Yap HY. Poor prognosis breast cancer - is cure possible?. Proceedings II International Conference on Immunology of Cancer, Cancer (Sect. IV):175-181, 1982. e-Pub 1982.
331. Hortobagyi GN. Levamisole in breast cancer. Proceedings of the International Symposium on Levamisole, November 8, 1979, Athens, Janssen Pharmaceutica S.A.C.I:94-98, 1981. e-Pub 1981.
332. Buzdar AU, Smith TL, Blumenschein GR, Hortobagyi G, Hersh EM, Gehan EA. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC) for stage II or III breast cancer: 5 year results. Adjuvant Therapy of Breast Cancer III, S.E. Salmon, S.E. Jones (Eds.), Grune & Stratton, New York:419-426, 1981. e-Pub 1981.
333. Blumenschein GR, Buzdar AU, Hortobagyi GN, Yap HY. Adjuvant chemoimmunotherapy of regionally treated stage IV breast cancer patients: A five year follow-up. Adjuvant Therapy of Cancer III, S.E. Salmon, S.E. Jones (Eds.), Grune & Stratton, New York:427-434, 1981. e-Pub 1981.
334. Blumenschein GR, Yap HY, Hortobagyi GN, Buzdar AU, Legha SS. Interaction between vinca alkaloids in breast carcinoma. Current Chemotherapy and Immunotherapy; Proceedings of the XII International Congress of Chemotherapy, Washington, D.C., American Association of Microbiology, P. Periti, G. Grassi (Eds.), 1981. e-Pub 1981.
335. Fraschini G, DiStefano A, Yap HY, Barnes BC, Buzdar AU, Hortobagyi GN, Blumenschein GR. Chemotherapy with dibromodulcitol, Adriamycin, cyclophosphamide for metastatic breast cancer. Current Chemotherapy and Immunotherapy; Proceedings of the XII International Congress of Chemotherapy, Washington, D.C., American Association of Microbiology, P. Periti, C.G. Grassi (Eds.):1485-1487, 1981. e-Pub 1981.
336. Buzdar AU, Powell KC, Legha SS, Hortobagyi GN, Blumenschein GR. Trioxifene mesylate in the treatment of advanced breast cancer: A phase I-II study. Current Chemotherapy and Immunotherapy; Proceedings of the XII International Congress of Chemotherapy, Washington, D.C., American Association of Microbiology, P. Periti, C.G. Grassi (Eds.):1472-1473, 1981. e-Pub 1981.
337. Hortobagyi GN. Cancer de mama. Rev Argent Cancerol 18:3-6, 1980. e-Pub 1980.
338. Buzdar AU, Blumenschein GR, Gutterman JU, Hortobagyi G, Campos L, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan E. Adjuvant therapy with 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) for stage II or III breast cancer. Adjuvant Therapy of Cancer II, S.E. Jones, S.E. Salmon (Eds.), Grune & Stratton, New York:277-284, 1979. e-Pub 1979.
339. Blumenschein GR, Buzdar AU, Hortobagyi GN, Tashima C. Adjuvant chemoimmunotherapy following regional therapy for initial solitary metastases of breast cancer (stage IV NED). Adjuvant Therapy of Cancer II, S.E. Jones, S.E. Salmon (Eds.), Grune & Stratton, New York:303-310, 1979. e-Pub 1979.
340. Buzdar AV, Gutterman JU, Blumenschein GR, Tashima CK, Hortobagyi GN, Yap HY, Hersh EM, Gehan EA. Adjuvant therapy of stage II, III breast cancer. Recent Results Cancer Res 68:123-8, 1978. e-Pub 1978. PMID: 379930.
341. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Wheeler W, Gehan E, Freireich EJ, Hersh EM. Adjuvant chemoimmunotherapy following regional therapy in breast cancer. Adjuvant Therapy of Cancer, S.E. Salmon, S.E. Jones (Eds.), Elsevier North-Holland Publishing Co., Amsterdam:139-146, 1977. e-Pub 1977.
342. Blumenschein GR, Buzdar AU, Tashima CK, Hortobagyi GN, Gutterman JU. Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer. Adjuvant Therapy of Cancer, S.E. Salmon, S.E. Jones (Eds.), Elsevier North-Holland Publishing Co., Amsterdam:147-152, 1977. e-Pub 1977.
343. Hortobagyi GN. Immunotherapy of human solid tumors. Cancer Bulletin 28:23-27, 1976. e-Pub 1976.
344. Morrow, PK, Hortobagyi GN. Breast Cancer, Primary Invasive. BMJ Point of Care Monographs.

Manuals, Teaching Aids, Other Teaching Publications

1. Picavet V. A Review of the Charter and its Impact with Co-Founder of the Charter: Professor Gabriel Hortonagyi. Paris Charter Against Cancer, 2024.
2. Hortobagyi GN. How Best to Use Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in HR+/HER2− Early Breast Cancer. JNCCN, 2024.
3. Hortobagyi GN. How Best to Use Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in HR+/HER2− Early Breast Cancer. JNCCN 360 Breast Cancer, 2024.
4. Hortobagyi GN. Expert Perspective on the MONALEESA-2 Findings for HR-Positive, HER2-Negative Breast Cancer. JNCCN Spotlights, 2021.
5. Hortobagyi GN. Advanced Breast Cancer Treated With Endocrine Therapy and Ribociclib. The ASCO Post Newsreels, 2021.
6. Hortobagyi GN. The MONALEESA-2 Trial. ESMO2021, 2021.
7. Hortobagyi GN. Frontline Endocrine Therapy for Postmenopausal HR+, HER2- mBC: MONALEESA-2 Trial. VuMedi - eCancer, 2021.
8. Hortobagyi GN. Progress in Management of Hormone-Receptor-Positive Breast Cancer. 7th Annual USC Multidisciplinary Breast Cancer Symposium, 2020.
9. Hortobagyi GN. Highlights of the 2018 San Antonio Breast Cancer Symposium. Promenade Medical Communications – Congress Report, 2018.
10. Hortobagyi GN. Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer. Medscape Williams S, 2018.
11. Hortobagyi GN. Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer. ecancer conferences, 2016.
12. Hortobagyi GN. Cáncer mamario triple negative. Ecancertv. Ecancertv, 2015.
13. Hortobagyi GN. What is the rationale behind the S1207 clinical trial testing hormonal therapy with and without everolimus in high risk breast cancer patients?. Talk About Health, 2014.
14. Hortobagyi GN. If I would like to participate in the S1207 clinical trial testing hormonal therapy with and without everolimus for breast cancer. Where is more information?. Talk About Health, 2014.
15. Hortobagyi GN. What have been the results of using everolimus (Afinitor) to treat metastatic breast cancer?. Talk About Health, 2014.
16. Hortobagyi GN. What is the current status of using everolimus (Afinitor) to treat early stage breast cancer?. Talk About Health, 2014.
17. Hortobagyi GN. 5.Breast Cancer News TV – Review of the 2012 San Antonio Breast Cancer Symposium. Television Program: Dutch Oncology TV/European Breast Cancer TV, 2012.
18. Hortobagyi GN. Internet Internet Conferences: Talk About Health, 2012.
19. Hortobagyi GN, Pritchard K. Internet Publication: Everolimus in Postmenopausal Hormone-Receptor-Positive Breast Cancer. PraeMedica Ltd, 2012.
20. Hortobagyi GN, Carey L, Rugo HS. Internet Publication: BOLERO-2: Everolimus Thwarts Resistance to Hormonal Therapy in Advanced Breast Cancer. ASCO Post, 2012.
21. Baselga J, Hortobagyi GN, Pritchard K. CD-ROM: Breast Cancer Disease Awareness and the Significance of the BOLERO-2 Study. Praemedical Digital, 2011.
22. Melhem-Bertrand A, Hortobagyi GN. Internet Publication: Primary Invasive Breast Cancer. Epocrates Online, 2011.
23. Hortobagyi, GN. Podcast: Role of Bone-Modifying Agents in Metastatic Breast Cancer. J Oncol Practice, 2011.
24. André F, Hortobagyi GN, Perez E, Rugo H. Interactive Internet Conference: Exploring Pathways to Progress in Breast Cancer management. Expert Commentary on Breast Cancer Management: Daily Roundtable Discussions from the 5th Annual International Breast Cancer Conference. 5th Annual International Breast Cancer Conference, 2011.
25. Hayes DF, Allred C, Anderson BO, Anderson S, Ashley P, Barlow W, Berry D, Carlson RW, Gelman R, Hilsenbeck S, Hortobagyi GN, Kattan M, Lester SC, Morrow M, Ravdin PM, Solin LJ, Tabbara SO, Thor A, Tripathy D, Viale G, Weaver DL, Whelan T. Audio Cassette: Part VII - Breast, IN: AJCC Cancer Staging Manual (CD-Rom included). Springer, 2010.
26. Hayes DF, Allred C, Anderson BO, Anderson S, Ashley P, Barlow W, Berry D, Carlson RW, Gelman R, Hilsenbeck S, Hortobagyi GN, Kattan M, Lester SC, Morrow M, Ravdin PM, Solin LJ, Tabbara SO, Thor A, Tripathy D, Viale G, Weaver DL, Whelan T. Part VII – Breast, IN: AJCC Cancer Staging Manual (CD-ROM included). Springer, 2010.
27. Carlson RW, Anderson BO, Bleiweiss IJ, Edge S, Hortobagyi GN, Ibarra JA. Internet Publication: Identifying and Addressing Interdisciplinary Gaps in Systemic Treatment of Breast Cancer. IN: Ensuring Optimal Interdisciplinary Breast Care in the United States – Proceedings of a Colloquium. ASBD website, 2009.
28. Hortobagyi, GN. Interactive Internet Conference: Selection of Optimal Treatment for Primary Breast Cancer Based on Molecular Markers, 2009.
29. Hortobagyi GN. Interactive Internet Conference: Clinical and Biological Data in the Management of Metastatic Breast Cancer. Access to Knowledge, Breast Cancer Private Lectures, 2009.
30. Hortobagyi GN, Arun B, Naik L, Bruera E, Cristofanilli M, McKenzie J, Demark-Wahnefried, Morrow PK. Interactive Internet Conference: Breast Cancer Course, 2009.
31. Morrow PK, Hortobagyi GN. Internet Publication. Primary Invasive Breast Cancer, 2008.
32. Hortobagyi, GN. DVD: State of the Art Lecture: Progress in the Management of Breast Cancer. In: ASCPT 2007 Annual Meeting Highlights. American Society for Clinical Pharmacology and Therapeutics, 2007.
33. Hortobagyi GN. Interactive Internet Conference: People Living with Cancer Ask the ASCO Expert Series-Chat: Breast Cancer Basics and Beyond, 2006.
34. Hortobagyi GN, Buchholz TA. Interactive Internet Conference: Ask-The-Expert Online Conference: Inflammatory Breast Cancer. breastcancer.orgg, 2006.
35. Hortobagyi GN, Marty M, Slamon D. DVD: Healthy Body Healthy Mind Show #610: Breast Cancer. Information Television Network, Carlos Pagan (Host), 2006.
36. Hortobagyi GN, Goldberg RM, Maiello E, de Marinis F, Bunn PA, Hudis C, Zagonel V, Bukowski RM, Venturini M. Interactive Internet Conference: Associazione Italiana di Oncologia Medica Commenta ASCO. Associazione Italiana di Oncologia Medica Commenta ASCO, 2006.
37. Brinker N, Ganz P, Harros J, Hortobagyi G, Page D, Tabar L, Veronesi U. DVD: Pathfinder Lectures - 30th Anniversary Symposium ASBC. American Society of Breast Disease, 2006.
38. Chlebowski R, Gradishar W, Hortobagyi GN, Jordan VC, Morrow M, van’t Veer L. CD-ROM: The Best of the 7th Annual Lynn Sage Breast Cancer Symposium. Northwestern University, Robert H. Lurie Comprehensive Cancer Center, PeerPoint Medical Education Institute, LLC, 2005.
39. Hortobagyi GN. La W Radio Miami – Herceptin and other Targeted Therapies for Breast Cancer, 2005.
40. Hortobagyi GN, Pronzato P, Conte PF, de Laurentis M. CD-ROM: Challenge the Expert. Accademia Nazionale di Medicina, 2005.
41. Hortobagyi, G. CD-ROM: Trastuzumab: Dramatic Benefit in Adjuvant Therapy. ASCO-Audio Journal of Oncology, 2005.
42. Hortobagyi GN. CD-ROM: Progress in Adjuvant Systemic Therpay of Breast Cancer. Accademia Nazionale di Medicina-Controversie in Oncologia, 2005.
43. Hortobagyi GN. Radio Program: Prevenir es Salud Radio Show. Broadcast from the Orlando Convention Center, 2005.
44. Baum M, Blum JL, Buzdar AU, Chang JC, Gradishar WJ, Henderson IC, Hortobagyi GN, Howell A, Hudis C, Jakesz RV, Muss HB, Osborne CK, Pegram MD, Peto R, JFR: R. CD-ROM: Best of Breast Cancer Update, Conversations with Oncology Research Leaders -Bridging the Gap between Research and Patient Care. 22nd Annual Miami Breast Cancer Conference- Research to Practice, 2005.
45. Hortobagyi GN. Radio Program: The Group Room® Cancer Talk Radio Show Broadcast from the 2nd Interamerican Breast Cancer Conference. 2nd Interamerican Breast Cancer Conference, 2004.
46. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Stmmans WF, Pusztai L, Hortobagyi GN. Internet Publication: Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell Proteomics, 2004.
47. Hortobagyi GN. Audio/Teleconference: The Group Room® Cancer Talk Radio Show Broadcast from the 2nd Interamerican Breast Cancer Conference, Cancun, Mexico, July 25, 2004, 2004.
48. Singletary SE, Robb GL, Hortobagyi GN. CD-ROM: Advanced Therapy of Breast Disease, Second Edition, BC Decker, Inc. Publisher, Hamilton, Ontario, 2004.
49. Hortobagyi GN, Pegram MD, Miller KD. Audio Cassette: Breast Cancer Update, Conversations with Clinical Research Leaders (Bridging the Gap between Research and Patient Care), BCU, Love N (Ed.), NL Communications, Inc. Miami, FL, 2004, 2004.
50. Margolese RG, Hortobagyi GN, Buchholz TA. CD-ROM: Section 31: The Breast, Chapter 121: Neoplasms of the Breast. In: Cancer Medicine 6th Edition, Kufe DW, Pollock, RE, Weichselbaum RR, Bast Jr., RC, Gansler TS, Holland JF, Frei III, E, (Eds. ) B.C. Decaer, Inc., Hamilton, Ontario (Canada), 2003, pp. 1879-1970, 2003.
51. Giordano SH Hortobagyi GN. Internet Publication: Inflammatory Breast Cancer: Clinical Progress and the Main Problems that Must be Addressed, 2003.
52. Theriault, RL, Gwyn, KMEH, Hortobagyi GN. CD-ROM: Section 20: Multidisciplinary Mangement, Chapter 74: Cancer and Pregnancy. In: Cancer Medicine, 6th Edition, Kufe DW, Pollock RE, Weichselbaum RR, Bast Jr., RC, Gansler TS, Holland JF, Frei III, E, (Eds.) B.C. Decaer, Inc., Hamilton Ontario (Canada), 2003. pp. 1085-1091, 2003.
53. Giuliano A, Hortobagyi G, Margolese R, Love S. Audio Cassette: Breast Cancer Update, Conversations with Clinical Research Leaders (Bridging the Gap Between Research and Patient Care), BCU Surgeons, Love N (Ed.), NL Communications, Inc. Miami, FL 2003, 2003.
54. Norton L, Hortobagyi, G, Dvidson NE. Audio Cassette: Breast Cancer Update, Conversations with Oncology Leaders (Bridging the Gap Between Research and Patient Care), Love N (Ed.), NL Communications, Inc., Miami, FL 2003, 2003.
55. Giuliano A, Hortobagyi G, Margolese R, Love S. CD-ROM: Breast Cancer Update, Conversations with Clinical Research Leaders (Bridging the Gap Between Research and Patient Care), BCU Surgeons Volume 2, Issue 1, 2003, Love N (Ed.), NL Communications, Inc, 2003.
56. Norton L, Hortobagyi, G, Davidson NE. CD-ROM: Breast Cancer Update, Conversations with Oncology Leaders (Bridging the Gap Between Research and Patient Care), Volume 2, Issue 1, 2003, Love N (Ed.), NL Communications, Inc, 2003.
57. Hortobagyi GN, Janjan N, Matthew P. Internet Publication: Understanding Skeletal Complications of Cancer. In: New Developments In Cancer Treatments, 2002.
58. Hortobagyi GN, Lyerly HK, Miles DW, Morse MA, Perou CM. Interactive Internet Conference: Breast Cancer Immunotherapy Update, San Antonio, TX, December 13, 2002, Meniscos Educational Institute, 2002.
59. Hortobagyi GN. Internet Publication: A Site is Born! The Coming of Age of a New Society. In: The Burgundy Club Website. October 2002, 2002.
60. Rosen L Hortobagyi GN. Internet Publication: Bone Complications in Breast Cancer. In: Advances in Oncology. Healthology.com, August 5, 2002, 2002.
61. Hortobagyi GN, Janjan N, Berenson J. Internet Publication: Bone Medications Help Cancer Patients. In: New Developments In Cancer Treatments. Healthology.com, May 2002, 2002.
62. Arun B, Bonneterre J, Cardenas J, Crump M, Dickler MN, Espinosa E, Goss PE, Hortobagyi GN, Jones SE, Kuemmel S, Leonard RCF, Lonning PE, Luck HJ, Mamounas T, Marchetti P, Mortimer JE, Muss HB, Pritchard KI, Rao S, Razis E, Wachters B. Audio Cassette: Update 2002 - Breast Cancer Treatment Using Epirubicin and Exemestane. Physicians Audio News®, Suwanee, GA, March 2002, 2002.
63. Hortobagyi GN. CD-ROM: An Evidence-Based Review of Epirubicin and Doxorubicin in the Adjuvant Treatment of Breast Cancer. Monograph. Philips Group Oncology Communications (Pharmacia Oncology), 2002.
64. Pritchard KI, Hortobagyi GN, Muss HB, Goss PE, Mamounas TP. CD-ROM: Optimal Therapy for Primary and Metastatic Breast Cancer: Emerging Standards and New Approaches. BC Symposium, Jersey City, NJ, Sponsored by Seton Hall Univeristy, March 2002, 2002.
65. Hortobagyi GN. CD-ROM: Treatment of Locally Advanced Breast Cancer. Section 5, In Surgery, Version 1.0 for Windows 95, 98 & 2000, Corson J, Williamson R (Eds.) Mosby, 2001.
66. Hortobagyi GN. Audio Cassette: Neoadjuvant Chemotherapy for Breast Cancer. In: Lohrisch C, Piccart MJ, Trudeau M, Bonneterre ME, Namer M, Dixon JM, Hortobagyi G: Clinical Findings - Breast Cancer Treatment Today Using Epirubicin and Exemestane. Physicians Audio News®, Suwanee, GA, May 2001, 2001.
67. Hortobagyi G, Dixon JM, Buzdar A, Ganz P, Petrek JA. Videocassette: Breast Cancer Update, Conversations with Oncology Leaders (Bridging the Gap between Research and Patient Care), Program 3, 2001, Love N (Ed.), NL Communications, Inc, 2001.
68. Hortobagyi G, Dixon JM, Buzdar A, Ganz P, Petrek JA. Audio Cassette: Breast Cancer Update, Conversations with Oncology Leaders (Bridging the Gap between Research and Patient Care), Program 3, 2001, Love N (Ed.), NL Communications, Inc. Miami, FL, 2001, 2001.
69. Hortobagyi G, Dixon JM, Buzdar A, Ganz P, Petrek JA. CD-ROM: Breast Cancer Update, Conversations with Oncology Leaders (Bridging the Gap Between Research and Patient Care), Program 3, 2001, Love N (Ed.), NL Communications, Inc, 2001.
70. Hortobagyi GN, Burris III, H, Goldstein L, Gradishar W, Hudis C, Livingston R, Martino S, Miller K, Mortimer J, Seidman A, Sparano J, Theodoulou M, Tripathy D, Yardley D. Slide Set: Recent Developments and Future Directions on the Use of Chemotherapy and Targeted Therapy for Metastatic Breast Cancer. The Center for Biomedical Continuing Education, Irving, TX, August 2001, 2001.
71. Hortobagyi GN. Interactive Internet Conference: Recent Developments and Future Directions on the Use of Chemotherapy and Targeted Therapy for Metastatic Breast Cancer, The Center for Biomedical Continuing Education, Irving, TX. June 8, 2001 , 2001.
72. Hortobagyi GN, Burris III, H, Goldstein L, Gradishar W, Hudis C, Livingston R, Martino S, Miller K, Mortimer J, Seidman A, Sparano J, Theodoulou M, Tripathy D, Yardley D. Audio/Teleconference: Recent Developments and Future Directions on the Use of Chemotherapy and Targeted Therapy for Metastatic Breast Cancer. The Center for Biomedical Continuing Education, Irving, TX, August 2001 - August 2002, 2001.
73. Hortobagyi GN. Videocassette: Neoadjuvant Therapy for Primary Breast Cancer: Current Status and Future Directions. 25th Annual Meeting of the American Society of Breast Disease, April 28-29, 2001, New York, NY, M2 Communications, 2001.
74. Hortobagyi GN. CD-ROM: Neoadjuvant Therapy for Primary Breast Cancer: Current Status and Future Directions. 25th Annual Meeting of the American Society of Breast Disease, April 28-29, 2001, New York, NY, M2 Communications, 2001.
75. Hortobagyi GN, Nabholtz JM, Russell C. Slide Set: 23rd San Antonio Breast Cancer Symposium Roundup. Southern California Academy of Clinical Oncology, Los Angeles, CA, January 10, 2001, 2001.
76. Hortobagyi GN. Internet Publication: Progress and Controversies in Adjuvant Systemic Therapies for Early Breast Cancer. In: ASCO Grand Rounds Lectures. January 2001, 2001.
77. Hortobagyi GN. Interactive Internet Conference: Charles G. Moertel, M.D. Memorial Lecture: “New Therapeutic targets in Breast Cancer” at Breast Cancer Management: Current Status and Future Research Directions, Mayo Clinic Cancer Center & North Central Cancer Treatment Group , Rochester, MN April 26, 2001, 2001.
78. Hortobagyi GN Hinestrosa C. Interactive Internet Conference: “Cancer de Seno” Hispanic New Radio, Houston, TX. October 2, 2001, 2001.
79. Weiner LM, Czuczman MS, Dillman RO, Hortobagyi GN, Johnson DH, Slamon DJ. CD-ROM: Integrating Monoclonal Antibody Therapy Into Cancer Therapy Strategies: Recent Insights and Prospects for Oncology in the 21st Century.A Satellite Symposium to the 36th Annual Meeting of the American Society of Clinical Oncology, Friday, May 19, 2000, New Orleans, LA. M2 Communications, Inc, 2000.
80. Margolese RG, Fisher B, Hortobagyi GN, Bloomer WD. CD-ROM: Section 32, Chapter 118: Neoplasms of the Breast. In Cancer Medicine, 5th Edition, Bast Jr., RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei III, E, (Eds.) B.C. Decker, Inc., Hamilton, Ontario, 2000.
81. Hortobagyi PL. Interactive Internet Conference: Medical Management of Breast Cancer: Advanced Course. University of Texas MD Anderson Cancer Center. The Virtual Lecture Hall, March 8, 2000, 2000.
82. Kenan S Hortobagyi GN. CD-ROM: Section 40, Complications of Cancer and Its Treatment, Chapter 145, Skeletal Complications. In Cancer Medicine, 5th Edition, Bast Jr., RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei III, E, (Eds.) B.C. Decker, Inc., Hamilton, Ontario, 2000.
83. Hortobagyi GN. Internet Publication: Progress in Chemotherapy. In: National Institutes of Health Consensus Development Conference: Adjuvant Therapy of Breast Cancer. October 31-November 3, 2000, 2000.
84. Silverstein M, Baum M, Hortobagyi G, Norton L. Audio Cassette: Breast Cancer Update, An Audiotape Review Journal For Surgeons, Program 2, 1999, Love N (Ed.), NL Communications, Inc., Miami, FL, 1999. , 1999.
85. JrGW S, Hortobagyi GN, Ravdin PM, Hudis CA. Audio/Teleconference: Use of HER2 Testing in the Treatment of Breast Cancer Patients - Interactive Telesession - Course # 266, Oncology Live, Produced by Indiana University School of Medicine’s Division of Continuing Medical Education, and the Department of Medicine, Division of Oncology, October 1999 - October 2000. , 1999.
86. Hortobagyi GN. Videocassette: Conference Report ASCO >98. PharMa International Inc. May 21, 1998, Tokyo, Japan, 1998.
87. Burris III HA, Gianni L, Hortobagyi GN, Hudis CA, Seidman AD, Sikov WM, JrGW S. Audio Cassette: Taxanes in the Treatment of Breast Cancer. The Center for Research and Education, The Sarah Cannon Cancer Center, Nashville, TN, 1998, 1998.
88. Burris III HA, Gianni L, Hortobagyi GN, Hudis CA, Seidman AD, Sikov WM, JrGW S. Videocassette: Taxanes in the Treatment of Breast Cancer. The Center for Research and Education, The Sarah Cannon Cancer Center, Nashville, TN, 1998, 1998.
89. Hortobagyi GN, Blayney DW, Lipton A, Osborne CK, Theriault RL. Audio/Teleconference: Bone Metastases - Protection and Treatment. Sponsored by the Strategic Institute for Continuing Health Care Education, Vienna, VA. March 12 - May 22, 1998, 1998.
90. Hortobagyi GN, Blayney DW, Lipton A, Osborne CK. Audio/Teleconference: Current Concepts in Breast Cancer: Practical Approaches to Bone Metastases - A Case-Based Review. Sponsored by the Strategic Institute for Continuing Health Care Education, Vienna, VA. September 16 - November 20, 1998, 1998.
91. Hortobagyi GN, Nabholtz JM, Sparano J, Slamon D, Ravdin P, Costa S, Sledge G. Audio Cassette: Taxotere Investigators’ Meeting, San Antonio, TX Dec 12, 1998, 1998.
92. Cheson BD, Mason BA, Appelbaum FR, Baker LH, Bosl GJ, Haller DG, LeBeau MM, Hortobagyi GN, Johnson DH, Ozer H, Scher HI, Williams SD. CD-ROM: Oncology - Medical Knowledge Self-Assessment Program. Second Edition. American College of Physicians-American Society of Internal Medicine-American Society of Clinical Oncology, Philadelphia, PA, 1998, 1998.
93. Hortobagyi GN, Blayney DW, Lipton A, Osborne CK, Theriault RL. Slide Set: Bone Metastases - Protection and Treatment. The Strategic Institute for Continuing Health Care Education, Vienna, VA. March 12, 1998, 1998.
94. Hortobagyi GN, Blayney DW, Lipton A, Osborne CK. Slide Set: Current Concepts in Breast Cancer: Practical Approaches to Bone Metastases - A Case-Based Review. Sponsored by the Strategic Institute for Continuing Health Care Education, Vienna, VA. September 16, 1998, 1998.
95. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Internet Publication: Impact of Selection Process on Response Rate and Long-Term Survival of Potential High-Dose Chemotherapy Candidates Treated with Standard-Dose Doxorubicin-Containing Chemotherapy in Patients With Metastatic Breast Cancer. In ASCO OnLine Journal Club Reviews, January 1998, 1998.
96. Hortobagyi GN. Videocassette: Recent Advances in Medical Management of Breast Cancer. Michiana Breast Cancer Symposium, South Bend, IN, October 30, 1998, 1998.
97. Hortobagyi GN. Videocassette: A Pan European Interactive Forum on Taxol: Putting the Evidence into Practice. Gibbs Associates Ltd., June 28, 1997, Lisbon, Portugal, 1997.
98. Bakemeier RF, Blayney DW, Hortobagyi GN, Lipton A, Osborne CK. Audio/Teleconference: Managing Bone Metastases - A Focus on Breast Cancer. Sponsored by the University of Colorado School of Medicine, Office of Continuing Medical Education. June 25 - December 31, 1997, 1997.
99. Hortobagyi GN. Interactive Internet Conference: Internet Tumor Board (Faculty), 1997 - Present, 1997.
100. Hortobagyi GN. Interactive Internet Conference: Managing Bone Metastases - A Focus on Breast Cancer (Moderator), 1997 - Present, 1997.
101. Bakemeier RF, Blayney DW, Hortobagyi GN, Lipton A, Osborne CK. Slide Set: Managing Bone Metastases - A Focus on Breast Cancer. Strategic Implications International. June 25, 1997, 1997.
102. Sledge JrGW Hortobagyi GN. Audio Cassette: Phase III Trial of Doxorubicin Versus Paclitaxel Versus Doxorubicin+Paclitaxel as First-line Therapy for Metastatic Breast Cancer: An Intergroup Trial. American Society of Clinical Oncology, May 1997, 1997.
103. Hortobagyi GN, Osborne CK. Audio Cassette: Pamidronate: New Approaches to Skeletal disease in Breast Cancer. The University of South Dakota, 1996.
104. Hortobagyi GN. Television Program: The Art of Survival – Today’s Health. Five Star, NBC-TV, Host: Faith Daniels (Show No. 318, Segment No. 3035), 1996.
105. Hortobagyi GN, Osborne CK, Raszkowski RR. Audio/Teleconference: Pamidronate: New Approaches to Skeletal Disease in Breast Cancer. Sponsored and Accredited by The University of South Dakota School of Medicine. October 29 and 30, 1996, 1996.
106. Shpall EJ, Doroshow JH, Holland JF, Hortobagyi GN, Jones RB, Ragaz J, Swain SM. Slide Set: Breast Cancer. Solid Tumor Oncology Education Foundation. Physicians World Communications Group. November 1996, 1996.
107. Hortobagyi GN. Audio/Teleconference: Cures for Metastatic Breast Cancer?, 1996.
108. Hortobagyi GN, Holmes FA, Norton L, Ravdin P, JrGW S, Valagussa P. Videocassette: Clinical Perspectives: Paclitaxel in the Management of Breast Cancer. Bios Communications, Inc., April 29, 1996, 1996.
109. Henderson IC, Dieras V, Ellis G, Fumoleau P, Hochster HS, Hortobagyi GN, O’Rourke M, Vogel CL, Weber BL, Winer E. Audio Cassette: Recent Advances in Refractory Advanced Breast Cancer. Center for Bio-Medical Communication, Inc. May, 1996, 1996.
110. Vogel C, Hortobagyi GN, Beck T. Videocassette: Cancer Update: Breast Cancer. Medivision, MedEdNet Satellite Network, Houston, TX, January 11, 1996, 1996.
111. Hortobagyi GN. Audio/Teleconference: Breast Cancer. Sponsored and Accredited by Solid Tumor Oncology Education Foundation, Inc. November 13, 1996, 1996.
112. Hortobagyi GN, Singletary SE, Stelling C. Videocassette: The Art of Survival - Today’s Health, Host: Faith Daniels (Show No. 318, Segment No. 3035), Five Star, April 19, 1996, 1996.
113. Hortobagyi GN. Television Program: Breast Cancer: A Quest for Answers - Every Woman’s Story. Produced by Patricia Burd. KUHT-TV Channel 8 (Houston PBS), 1995.
114. Hortobagyi GN, Singletary SE, Stelling CE. Television Program: Buddy Check 2. KPRC-TV, Channel 2: Hosted by Linda Lorelle, 1995.
115. Jordan VC, Hortobagyi GN, Morrow M. Videocassette: Disease Management: Breast Cancer. MedEdNet Satellite Network, Houston, TX, March 8, 1995, 1995.
116. Henderson IC, Ellis G, Hortobagyi GN, Vogel C, Winer E. Audio Cassette: Recent Advances in Refractory Advanced Breast Cancer. Center for Bio-Medical Communication, Inc. October, 1995, 1995.
117. Hortobagyi GN, Stelling CB, Singletary SE, Foxhall LE. Videocassette: Cancer Update for Primary Care Physicians: Breast Cancer. U.T. M.D. Anderson Cancer Center T.V. - Continuing Medical Education Series, April 19, 1995, 1995.
118. Hortobagyi GN. Videocassette: Primary Chemotherapy in Treatment of Breast Cancer: Current Status and Future Directions. U.T. M.D. Anderson Cancer Center T.V. - Continuing Medical Education Series, April 8, 1994, 1994.
119. Hortobagyi GN. Slide Set: Prognostic Factors in Early Breast Cancer. The Upjohn Company. March 1992, 1992.
120. Hortobagyi GN, Durant JR, Love RR, Redmond CK, Wolmark N, Wolter JM, Yates JR. Audio Cassette: Disease-Free Survival - Establishing Clinical Endpoints for Patients with Breast Cancer. ICI Pharma Audioconference, February 2nd, 1991, 1991.
121. Hortobagyi GN. Videocassette: The dose-response relationship in breast cancer. An interactive video disc programme. Gardiner-Caldwell Communications LTD. Tim Kelly (Ed.). Presented at the 15th International Cancer Congress, Hamburg, FRG. August 1990, 1990.
122. Ames FC, Paulus D, Singletary E, Balch CM, McNeese M, Kroll S, Hortobagyi GN. Videocassette: Controversies in early stage breast cancer. Satellite Teleconference (program # 920-1-89), December 6, 1989. Presented by Anderson Satellite Teleconference Network, 1989.
123. Hortobagyi GN, Ames FC, McNeese MD. Videocassette: Managing primary breast disease. The Network for Continuing Medical Education (NCME #532), October 10, 1988, 1988.
124. McGuire WL, Abeloff MD, Swain S, Hortobagyi GN. Audio Cassette: Treatment of stage III breast cancer. Bristol-Myers Oncology Division Audioconference, October 31, 1988, 1988.
125. Hortobagyi GN. Videocassette: Breast Cancer - Screening and Diagnosis. UT TV, 1986.
126. Hortobagyi GN. Audio Cassette: Clinical applications of tumor markers: CEA in Breast Cancer. SMA CME Tape 019, 1986.
127. Hortobagyi GN. Videocassette: Breast Cancer - Treatment. UT TV, 1986.
128. Ames F, Paulus D, Hortobagyi G, Martin R, Staff N, Station. Videocassette: ACS Core Curriculum Breast Series: Treatment of Breast Cancer. The University of Texas MD Anderson Cancer Center, 1985, 1985.
129. Ames F, Paulus D, Hortobagyi G, Staff N, Station. Videocassette: ACS Core Curriculum Breast Series: Rehabilitation of Breast Cancer. The University of Texas MD Anderson Cancer Center, 1985.
130. Hortobagyi GN. Videocassette: CEA in breast cancer. For Department of Laboratory Medicine, M.D. Anderson Hospital (Dr. Fritsche), 1985, 1985.
131. Hortobagyi GN. Audio Cassette: Chemotherapy of breast cancer. Dial Access Tape A-6, 1982.
132. Hortobagyi GN. Audio Cassette: Chemoimmunotherapy of early and advanced breast cancer. Dial Access Tape A-24, 1982.
133. Leon Galindo MA, Rubiano-Groot Ribon H, Hortobagyi GN, Leon Galindo J, Prada Gomez A, Niet Paez R. Slide Set: Algunos Rasgos Epidemiologicos del Aborto en Colombia. Universidad Nacional de Colombia, February 1969, 1969.
134. Hortobagyi GN. Internet lecture: Selection of optimal treatment for primary breast cancer based on molecular markers. Access to Knowledge, Breast Cancer Private Lectures.
135. Hortobagyi GN. Internet lecture: Clinical and biological data in the management of metastatic breast cancer. Access to Knowledge, Breast Cancer Private Lectures.

Other Articles

1. Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat 193(2):253-264, 2022. PMID: 35347549.
2. Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol 39(35):3938-3958, 2021. PMID: 34324366.
3. Hester RH, Hortobagyi GN, Lim B Inflammatory breast cancer: early recognition and diagnosis is critical. Am J Obstet Gynecol 225(4):392-396, 2021. PMID: 33845027.
4. Jiang Z, Hsu JL, Li Y, Hortobagyi GN, Hung MC Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. Front Oncol 10:1197, 2020. PMID: 32775303.
5. Franzoi MA, Hortobagyi GN Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol 135:85-94, 2019. PMID: 30819451.
6. Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol 18(4):e228-e232, 2017. PMID: 28368261.
7. Hortobagyi GN, El-Saghir NS, Cufer T, Cazap E, de Guzman R, Othieno-Abinya NA, Sanchez JA, Pyle D The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine. J Clin Oncol 34(1):76-82, 2016. PMID: 26578614.
8. Gagliato DM, Jardim DL, Marchesi MS, Hortobagyi GN Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. PMID: 26824988.
9. Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH Comparison of cardiac events associated with Liposomal Doxorubicin, Epirubicin, and Doxorubicin in breast cancer; a Bayesian network meta-analysis. Eur J Cancer 51(16):2314-20, 2015. PMID: 26343314.
10. Hortobagyi GN Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2. Neoplasia 17(3):279-288, 2015. PMID: 25810012.
11. Carlson RH, Hortobagyi GN Zoledronic Acid: Less-frequent Dosing Proven to have Comparable Efficacy. Oncology Times 36(14):48-49, 2014.
12. Alvarez RH, Gong Y, Ueno NT, Alizadeh PA, Hortobagyi GN, Valero V Metastasis in the breast mimicking inflammatory breast cancer. J Clin Oncol 30(22):e202-6, 2012. PMID: 22734030.
13. Austin JM, Balch CM, Hortobagyi GN Patient Resource Women's Cancer Guide. PRP Patient Resource Publishing, LLC, 2012.
14. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH Retrospective Review of Male Breast Cancer Patients: Analysis of Tamoxifen-related Side Effects. Ann Oncol 23(6):1471-4, 2012. PMID: 22085764.
15. Laino C, Hortobagyi GN, Litton JK, Perez EA, Liu MC, Huober JB Breast Cancer: Everolimus Extends Progression-Free Survival after Failed Hormonal Treatment. Oncology Times:23-24, 2012.
16. Litton JK, Arun BK, Brown PH, Hortobagyi GN Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother 13(3):325-31, 2012. PMID: 22242911.
17. Hortobagyi GN, Carey L, Rugo HS BOLERO-2 Everolimus Thwarts Resistance to Hormonal Therapy in Advanced Breast Cancer. ASCO Post 3(1):1-7, 2012.
18. Goodman A, Hortobagyi GN, Baker LH Novel Initiative to Address Oncology Drug Crisis. ASCO Post 3(8):92-93, 2012.
19. Fehrenbacher L, Hortobagyi GN, Pusztai L Uncertainty Rules Adjuvant Chemo for Tiny HER2 Breast Tumors. The Oncology Report:11-13, 2011.
20. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 1218:47-54, 2011. PMID: 20946574.
21. Morrow PK, Mattair DN, Hortobagyi GN Hot flashes: a review of pathophysiology and treatment modalities. Oncologist 16(11):1658-64, 2011. PMID: 22042786.
22. Hortobagyi, GN Updated Guidelines on Bone-Modifying Agents in Metastatic Breast Cancer. ASCO Post 2(7):44, 2011.
23. Hortobagyi, GN Breakthroughs in Breast Cancer: Management Approaches, Treatment, Recommendations and Future Outlook. Foundations of Clinical Cancer Research 10(1):27-28, 2011.
24. Alvarez RH, Valero V, Hortobagyi GN Emerging targeted therapies for breast cancer. J Clin Oncol 28(20):3366-79, 2010. PMID: 20530283.
25. Hortobagyi GN, Balch CM Patient Resource Breast Cancer Guide - HER2+ & ER/PR+ Personalized Therapy Options. PRP Patient Resource Publishing, LLC. Kansas City, MO, 2010.
26. Balch CM, Hortobagyi GN Patient Resource Breast Cancer Guide. PRP Patient Resource Publishing, LLC. Kansas City, MO, 2010.
27. Hortobagyi GN, Balch CM Patient Resource Cancer Guide - Metastatic Breast Cancer. PRP Patient Resource Publishing, LLC. Kansas City, MO, 2010.
28. Hortobagyi, GN Personalized Oncology: The New Holy Grail. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances (CITA). JW Covenant 8(1):1-8, 2010.
29. Hortobagyi, GN The Best Treatments for Breast Cancer Today, Tomorrow and Beyond: an ASCO Expert's Perspective. Foundations on Clinical Cancer Research 9(1):16-18, 2010.
30. Jiralerspong S, Liu S, Palla SL, Mills GB, Hortobagyi GN, Gonzalez-Angulo AM Correlation of Snail Expression and Survival in Patients with Early-stage Triple-negative Breast Cancer (TNBC). 2010 ASCO Annual Meeting Abstracts. J Clin Oncol 28(7s)(Poster Discussion presentation), 2010.
31. Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27(28):4798-808, 2009. PMID: 19687331.
32. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 6(7):387-94, 2009. PMID: 19468291.
33. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT Imaging bone metastases in breast cancer: update on imaging techniques and recommendations for diagnosis. Lancet Oncol 10(6):606-14, 2009. PMID: 19482249.
34. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4):320-68. PMID: 19346299.
35. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN Ductal Carcinoma In Situ: State of the Science and Roadmap to Advance the Field. J Clin Oncol 27(2):279-88, 2009. PMID: 19064970.
36. Morrow PK, Hortobagyi GN Management of Breast Cancer in the Genome Era. Annu Rev Med 60(22):153-165, 2008. PMID: 19630569.
37. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK Staging of breast cancer in the neoadjuvant setting. Cancer Res 68(16):6477-81, 2008. PMID: 18701468.
38. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420-32, 2008. PMID: 17906299.
39. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26(5):814-9, 2008. PMID: 18258991.
40. Moulder S, Hortobagyi GN Advances in the treatment of breast cancer. Clin Pharmacol Ther 83(1):26-36, 2008. PMID: 18091763.
41. Hortobagyi, GN From Freireich to FAC and Beyond: New Approaches to Breast Cancer Treatment. Foundations of Clinical Cancer Research 6(1):19-21, 2008.
42. Hortobagyi GN Newsletter: Integrating Translational Research into the ASCO Annual Meeting. ASCO News & Forum:15, 2007.
43. Hortobagyi GN Newsletter: New Thematic Meetings, Resources, Emphasize Clinical Integration of Translational Research and Biomarkers. ASCO News & Forum January:6, 2007.
44. Hortobagyi, GN Targeted Therapies are Here to Stay. OncoLog 52(9):8, 2007.
45. Andre F, Mazouni C, Hortobagyi GN, Pusztai L DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. Biochim Biophys Acta 1766:197-204, 2006. PMID: 16962247.
46. Baptista MZ, Prieto VG, Chon S, Hortobagyi GN, Esteva FJ Tamoxifen-related vasculitis. J Clin Oncol 24(21):3504-5, 2006. PMID: 16849770.
47. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 24(18):2910-6, 2006. PMID: 16782931.
48. Esteva FJ Hortobagyi GN Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. The Breast 15:301-12, 2006. PMID: 16230014.
49. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 24:2113-22, 2006. PMID: 16648513.
50. Hortobagyi GN Newsletter: The Globalization of Oncology. ASCO News & Forum July:6-7, 2006.
51. Hortobagyi GN Newsletter: ASCO Promotes Global Cancer Prevention through Tobacco Control. ASCO News & Forum October:11, 2006.
52. Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F, Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi GN Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer 6(5):412-20, 2005. PMID: 16381624.
53. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O'Shaughnessy JA, Shen ZZ, Albain KS The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6(5):391-401, 2005. PMID: 16381622.
54. Hortobagyi GN Treatment of Locally Advanced and Metastatic Breast Cancer, University of Modena, September 26-27, 2005. Academia Nazionale di Medicine, Sezione di Oncologia, Bologna, Italy, 2005.
55. Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 16(8):1289-96, 2005. PMID: 15890665.
56. Hortobagyi GN Newsletter: Effect of Breast Cancer and Treatment on Bone Density. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 4(3):1-3, 2005.
57. Hortobagyi GN Newsletter: The Fate of Great Ideas. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 4(1):1-8, 2005.
58. Hortobagyi, GN Born Agian Drugs-Platins as Phoenix?. M.D. Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 4(2):1-2, 2005.
59. Hortobagyi, GN Effect of Breast Cancer and Treatment on Bone Density. M.D. Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 4(3):1-3, 2005.
60. Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer 101(7):1482-9, 2004. PMID: 15378476.
61. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT Bone imaging in metastatic breast cancer. J Clin Oncol 22(14):2942-53, 2004. PMID: 15254062.
62. Schwartz GF, Hortobagyi GN, Masood S, Palazzo J, Holland R, Page D Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA. (Monograph). Hum Pathol 35(7):781-4, 2004. PMID: 15257539.
63. Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN Pharmacogenomics. Adv Anat Pathol 11(4):211-20, 2004. PMID: 15220824.
64. Schwartz GF, Hortobagyi GN Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. (Monograph). Cancer 100:2512-32, 2004. PMID: 15197792.
65. Green MC, Esteva FJ, Hortobagyi GN Neoadjuvant chemotherapy. Breast Dis 21:23-31, 2004. PMID: 15687719.
66. Esteva FJ Hortobagyi GN Prognostic molecular markers in early breast cancer. Breast Cancer Res 6(3):109-18, 2004. PMID: 15084231.
67. Love N, Borgen P, Carlson R, Fox K, Grana G, Hortobagyi G, Ravdin P, Singletary E, Tripathy D, Weiss MC Breast Cancer Patient Perspectives Project - Special Report. N Love (Ed.). Miami, FL, January 2004. Breast Cancer Update, 2004.
68. Schwartz GF Hortobagyi GN, Conference Committee TC Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast, April 26-28, 2003, Philadelphia, PA. (Monograph). The Breast J, 2004.
69. Hortobagyi GN, Buzdar AU, Gallagher JC, Ravdin PM, Stuenkel CA, Van Poznak CH Management of Osteoporosis in Women With Early-Stage Breast Cancer. In Press. Discovery International, 2004.
70. Hortobagyi GN, Goss PE, Gradishar WJ, Mortimer JE, Vogel VG The Role of Anti-Aromatase Agents in New Treatment Strategies for Breast Cancer. Skillman, NJ, April, 2004. Seton Hall University School of Graduate Medical Education, American Academy of CME, Inc, 2004.
71. Hortobagyi GN Newsletter: Developing Markers of Minimal Residual Disease. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 3(2):1, 2004.
72. Hortobagyi GN Newsletter: Plus ça change, plus c’est la même chose. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 3(3):1-2, 2004.
73. Hortobagyi GN Newsletter: The Positive Side of the Law of Unintended Consequences. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 3(4):1, 2004.
74. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN Male Breast Cancer Cases Steadily Climbing. Geriatrics 59(8):15-16, 2004.
75. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN HER-2/neu testing in breast cancer. Am J Clin Pathol 120 Suppl:S53-71, 2003. PMID: 15298144.
76. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 98(6):1150-60, 2003. PMID: 12973838.
77. Hortobagyi GN Newsletter: Incremental Progress in Adjuvant Therapy of Breast Cancer. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 2(3):1, 2003.
78. Hortobagyi GN Newsletter: The Challenge of Too Many Therapeutic Options. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 2(4):1-2, 2003.
79. Hortobagyi GN Newsletter: Uncommon Situations in Breast Cancer. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 3(1):1, 2003.
80. Hortobagyi GN Newsletter: Improving Quality of Life: A continuous Process. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 2(2):1, 2003.
81. Hortobagyi GN Arteaga CL Diagnosis and treatment of HER2-Positive Metastatic Breast Cancer. Houston, TX, October 2003. The University of Texas M.D. Anderson Cancer Center, 2003.
82. Hortobagyi GN Newsletter: Evolution vs. Revolution: Our First Steps into the 21st Century. MD Anderson Beast Medical Oncology Clinical Issues & therapeutic Advances 2(1):1, 2003.
83. Giordano SH, Buzdar AU, Hortobagyi GN Breast cancer in men. Ann Intern Med 137(8):678-87, 2002. PMID: 12379069.
84. Cristofanilli M, Charnsangavej C, Hortobagyi GN Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov 1(6):415-26, 2002. PMID: 12119743.
85. Meric F, Hung MC, Hortobagyi GN, Hunt KK HER2/neu in the management of invasive breast cancer. J Am Coll Surg 194(4):488-501, 2002. PMID: 11949754.
86. Hortobagyi GN Newsletter: 24th Annual San Antoino Breast Cancer Symposium. ASCO News April-June 2002:22, 2002.
87. Hortobagyi GN Newsletter: Clinical Research in a Molecular Environment. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 1(1):1-2, 2002.
88. Hortobagyi GN Newsletter: Multidirectional Resarch for a Heterogeneous Disease. MD Anderson Breast Medical Oncology Clinical Issues & Therapeutic Advances 1(2):1-2, 2002.
89. Hortobagyi GN An Evidence-Based Review of Epirubicin and Doxorubicin in the Adjuvant Treatment of Breast Cancer. Phillips Group Oncology Communications (Pharmacia), 2002.
90. Buzdar AU, Berk GI, Campos M, Chlebowski RT, Elledge RM, Gradishar WJ, Grana G, Havlin K, Henderson IC, Hortobagyi, GN, Hudis C, Hyams DM, Ingle JN, Kuter I, Mamounas EP, Pritchard KI, Ravdin PM, Robert NJ, Swain SM, Vogel CL, Waisman Hormonal Agents in the Treatment of Breast Cancer: Current Status. Highlights from and Expert Opinion Forum. Deerfield, IL. Nov 1, 2002. Discovery International, 2002.
91. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25(3):235-7, 2001. PMID: 12040279.
92. Gradishar WJ Hortobagyi GN Emerging Data on UFT + LV in the Treatment of Metastatic Breast Cancer. In Press. Clinical Insights, 2001.
93. Hortobagyi GN Management of Bone Metastases in Patients with Breast Cancer. Monograph, Sevilla Meeting, November 28, 2001, 2001.
94. Hortobagyi GN Khayat D Charter of Paris Against Cancer (Charte de Paris Contre le Cancer) Sous le haut patronage de Monsieur Jacques Chirac, President de la Republique, Palis de l’Elysee, le 4 Fevrier 2000. YD Print, Paris, France, November 2001. Service d’Oncologie Medicale Pitie Salpetriere, Paris, France and The University of Texas MD Anderson Cancer Canter, 2001.
95. Green MC, Murray JL, Hortobagyi GN Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 26(4):269-86, 2000. PMID: 10913382.
96. Major PP, Lipton A, Berenson J, Hortobagyi G Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 88(1):6-14, 2000. PMID: 10618600.
97. Hung MC, Hortobagyi GN, Ueno NT Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol 465:171-80, 2000. PMID: 10810625.
98. Hortobagyi GN 1999 Herceptin Investigators Meeting Highlights. South San Francisco, CA, 2000. Genentech, Inc, 2000.
99. Hortobagyi GN Norton L Assessing Risk and Optimizing Outcomes in the Adjuvant Therapy of Node-Positive Breast Cancer. Princeton, NJ, 2000. Bristol-Myers Squibb Co, 2000.
100. Gianni L, Hortobagyi GN, Perez EA, Jr S, GW Paclitaxel and Doxorubicin Combination Therapy in Breast Cancer. An Expert Panel review. Princeton Junction, NJ, 2000. Academy of Medicine of New Jersey, 2000.
101. Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treat Rev 25(5):271-7, 1999. PMID: 10544071.
102. Pivot X, Asmar L, Hortobagyi GN The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). Int J Oncol 15(2):381-6, 1999. PMID: 10402251.
103. Ueno NT, Hortobagyi GN, Champlin RE Allogeneic peripheral blood progenitor cell transplantation in solid tumors. Cancer Treat Res 101:133-56, 1999. PMID: 10800648.
104. Albain KS, Hortobagyi G, Ravdin P, Slamon D HER2 Overexpression in Breast Cancer. Genentech, Inc, 1999.
105. Hortobagyi GN, Hudis CA, Mamounas EP, Perez EA, Jr S, GW, Winer EP Significant Advances in Adjuvant Therapy for Breast Cancer. Princeton, NJ, 1999. Bristol-Myers Squibb Oncology Medical Services, 1999.
106. Hortobagyi GN, Perez EA, Seidman AD Semisynthetic Taxol (paclitaxel) Injection and Trastuzumab: A New Option for the Treatment of Metastatic Breast Cancer. Princeton, NJ, 1999. Bristol-Myers Squibb Oncology Medical Services, 1999.
107. Hortobagyi GN Treatment of breast cancer. N Engl J Med 339(14):974-84, 1998. PMID: 9753714.
108. Buzdar AU, Hortobagyi G Update on endocrine therapy for breast cancer. Clin Cancer Res 4(3):527-34, 1998. PMID: 9533518.
109. Buzdar AU Hortobagyi GN Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16(1):348-53, 1998. PMID: 9440763.
110. Hortobagyi GN Buzdar AU Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management. Cancer Invest 16(6):385-90, 1998. PMID: 9679529.
111. Cheson BD, Mason BA, Appelbaum FR, Baker LH, Bosl GJ, Haller DG, LeBeau MM, Hortobagyi GN, Johnson DH, Ozer H, Scher HI, Williams SD Oncology - Medical Knowledge Self-Assessment Program. Second Edition. (Also available in CD-ROM format). Philadelphia, PA, 1998. American College of Physicians-American Society of Internal Medicine-American Society of Clinical Oncology, 1998.
112. Burris III HA, Gianni L, Hortobagyi GN, Hudis CA, Seidman AD, Sikov WM, JrGW S Taxanes in the Treatment of Breast Cancer. Nashville, TN, 1998. The Center for Research and Education, The Sarah Cannon Cancer Center, 1998.
113. Albain KS, Hortobagyi G, Ravdin P, Slamon D HER2 Overexpression in Breast Cancer. Genentech, Inc, 1998.
114. Hortobagyi GN Consultation: FAC or Taxane/Doxorubicin in Advanced Breast Cancer: One Investigator’s Perspective. Oncology News International 7(1):10-17, 1998.
115. Hortobagyi GN Newsletter: The Role of HER-2/neu in Prognosis and Treatment of Breast Cancer. ASBD Advisor, Fall Fall, 1998:2, 1998.
116. Buzdar AU Hortobagyi GN Consultation: Should Community Oncologists Give High-Dose Chemotherapy Requiring G-CSF?. Oncology Rounds, Oncology News International 6(3):48, 1997.
117. Hortobagyi GN Consultation: Any Adjuvant Treatment for this Woman Following Bilateral Mastectomies?. Oncology Rounds, Oncology News International 6(6):52-53, 1997.
118. Hoff PM, Valero V, Holmes FA, Whealin H, Hudis C, Hortobagyi GN Paclitaxel-induced pancreatitis: a case report. J Natl Cancer Inst 89(1):91-3, 1997. PMID: 8978416.
119. Anderson CM, Walters RS, Hortobagyi GN Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. Am J Clin Oncol 19(6):566-8, 1996. PMID: 8931672.
120. Johnson SA, Harper P, Hortobagyi GN, Pouillart P Vinorelbine: an overview. Cancer Treat Rev 22(2):127-42, 1996. PMID: 8665565.
121. Hortobagyi GN Newsletter: 9th International Congress on Breast Diseases. ASBD Advisor Fall Fall, 1996:1, 1996.
122. Elie G, Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB Recent advances in the application of gene therapy to human disease. Am J Med 99(5):537-552, 1995. PMID: 7485213.
123. Dhingra K, Hittelman WN, Hortobagyi GN Genetic changes in breast cancer--consequences for therapy?. Gene 159(1):59-63, 1995. PMID: 7607573.
124. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13(2):513-29, 1995. PMID: 7844613.
125. Hortobagyi GN, Dombernowsky P, Gelmon KA, Gianni L, Seidman AD, Sledge Jr GW First-Line Treatment of Metastatic Breast Cancer: Taxol (paclitaxel) for Injection Concentrate - Clinical Studies. Princeton, NJ 1995. Bristol-Myers Squibb Oncology Medical Education Services, 1995.
126. Hortobagyi GN The M.D. Anderson Cancer Center Historical Experience and Current Strategies with Taxol7 (Paclitaxel) for Injection Concentrate for Breast Cancer. IN: Current Clinical Experience in Breast Cancer: Taxol. Princeton, NJ 1995. Bristol-Myers Squibb Oncology Medical Education Services, 1995.
127. Hortobagyi GN, Gelmon KA, Gianni L, Seidman AD, Sledge Jr GW, Winer E Therapy of Recurrent Metastatic Breast Cancer: Taxol (paclitaxel) for Injection Concentrate - Clinical Studies. Princeton, NJ 1995. Bristol-Myers Squibb Oncology Medical Education Services, 1995.
128. Hortobagyi GN Consultation: Is Tamoxifen Appropriate for this Woman Following Mastectomy?. Primary Care & Cancer 16(1):3, 1995.
129. Peters GN, Kardinal CG, Robidoux A, Hortobagyi GN Consultation: Inflammatory Breast Cancer: What is the Appropriate Therapy for Patients Who Have a Clinical Response to Induction Chemotherapy?. Sem Oncol 22(5)(XIV, XXI, XXVI, XXXII), 1995.
130. Canetta R, Gelmon KA, Hortobagyi GN, Hudis CA, Sledge GW The Current Role of Taxol7 (paclitaxel) in the Treatment of Metastatic Breast Cancer. Princeton, NJ, 1994. Bristol-Myers Squibb Co, 1994.
131. Dhingra K, Vogel V, Sneige N, Sahin A, Aldaz M, Hortobagyi GN, Hittelman W Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials. J Cell Biochem Suppl 17G:37-43, 1993. PMID: 8007707.
132. Hortobagyi GN Consultation: How would you manage this asymptomatic man with rising CEAs three years after treatment for breast cancer?. Oncology Rounds, Oncology News International 2(6):27, 1993.
133. Hortobagyi GN Consultation: What Treatment for this Woman with Breast Cancer and Multiple Fixed Nodes?. Oncology Rounds, Oncology News International 2(8):25-26, 1993.
134. Voravud N, Theriault R, Hortobagyi G Vertebral osteomyelitis mimicking bone metastasis in breast cancer patients. Am J Clin Oncol 15(5):428-32, 1992. PMID: 1524044.
135. Jaiyesimi IA, Buzdar AU, Hortobagyi G Inflammatory breast cancer: a review. J Clin Oncol 10(6):1014-24, 1992. PMID: 1588366.
136. Hortobagyi GN Consultation: Does tamoxifen interact adversely with slow-acting antiarthritic agents?. Primary Care & Cancer 12:10, 1992.
137. Hortobagyi GN Consultation: Diagnostic Breast Imaging. JAMA 268:1926, 1992.
138. Fritsche HA, Mitchell MS, Abbate I, Ceriani RL, Chan DW, Crombach G, de Hertogh R, Hortobagyi G, Kan-Mitchell J, Longenecker BM, MacLean G, McEwan AJB, McKenzie IFC, McPherson TA, Nisselbaum J, Noujaim AA, Oehr P, Reddish M, Schwartz M, Segers M, Silver H, Wu J The Role of Tumor Markers in Breast Cancer. HA Fritsche, MS Mitchell (Eds.). Edmonton, 1992. Biomira Inc. and ADI Diagnostics, 1992.
139. Voravud N, Dimopoulos M, Hortobagyi G, Ross M, Theriault R Breast cancer and second primary ovarian cancer in dermatomyositis. Gynecol Oncol 43(3):286-90, 1991. PMID: 1752501.
140. Hug V, Kau S, Hortobagyi GN, Jones L Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone. Br J Cancer 63(3):454-6, 1991. PMID: 1825919.
141. Hortobagyi GN Comprehensive management of locally advanced breast cancer. Cancer 66(6 Suppl):1387-91, 1990. PMID: 2205369.
142. Hortobagyi GN Consultation: Breast Cancer Screening. Patient Care 24:11, 1990.
143. Vanek N, Hortobagyi GN, Buzdar AU Radiotherapy enhances the toxicity of aminoglutethimide. Med Pediatr Oncol 18(2):162-4, 1990. PMID: 2154663.
144. Carbone PP, Nixon DW, Fennelly J, Greenberg E, Henderson IC, Hortobagyi G, Kennedy BJ, Trainin N, Scanlon EF Adjuvant systemic therapy. Proceedings of the Workshop on The Management of Limited Breast Cancer. American Cancer Society, 1990.
145. Hortobagyi G Metastatic Breast Cancer - The Use of Non-Cross-Resistant Chemotherapy. Bristol-Myers Squibb Company, 1990.
146. Lerner HJ, Baker RR, Hortobagyi GN, Kinne DW, Love SM, Romsdahl MM, Sutherland CM Surgical management of breast cancer. Insights into Current Practices and Treatment Options. ICI Americas Inc, 1990.
147. Givens SS, Ellerbroek NA, Butler JJ, Libshitz HI, Hortobagyi GN, McNeese MD Angiosarcoma arising in an irradiated breast. A case report and review of the literature. Cancer 64(11):2214-6, 1989. PMID: 2680051.
148. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, et al Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62(12):2507-16, 1988. PMID: 3056604.
149. Hortobagyi GN The role of high-dose chemotherapy with autologous bone marrow transplantation in the treatment of breast cancer. Bone Marrow Transplant 3(6):525-30, 1988. PMID: 3063320.
150. Hortobagyi GN Buzdar AU Management of locally advanced breast cancer. Am J Clin Oncol 11(5):597-601, 1988. PMID: 2845771.
151. Hug V, Hortobagyi GN Unusual toxicity of doxorubicin infusion. Am J Med 85(3):447-8, 1988. PMID: 3414741.
152. Hortobagyi GN Consultation: Should this woman have contra lateral needle biopsies? How risky would pregnancy be?. Primary Care & Cancer 8(10):9-10, 1988.
153. Hortobagyi GN Consultation: What further treatment would you recommend for this woman with a four inch carcinoma of the breast?. Primary Care & Cancer 5:34, 1985.
154. Hortobagyi GN Leukonychia striata associated with breast carcinoma. J Surg Oncol 23(1):60-1, 1983. PMID: 6843133.
155. Stein W, III, Hortobagyi GN, Blumenschein GR Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol 22:45-6, 1983. PMID: 6823117.
156. Spanos WJ, Jr, Montague ED, Hortobagyi GN, Schell S Multimodal treatment of advanced breast cancer. Prog Clin Cancer 8:237-43, 1982. PMID: 6818613.
157. Ross MB, Buzdar AU, Hortobagyi GN, Lukeman JM Spontaneous regression of breast carcinoma: follow-up report and literature review. J Surg Oncol 19(1):22-4, 1982. PMID: 7057640.
158. Krutchik AN, Tashima CK, Hortobagyi GN Periodontal disease: predisposing factor to chemotherapy-induced stomatitis. South Med J 72(8):1020-1, 1979. PMID: 472801.
159. DiStefano A, Tashima CK, Yap HY, Hortobagyi GN Bone marrow metastases without cortical bone involvement in breast cancer patients. Cancer 44(1):196-8, 1979. PMID: 455244.
160. Hortobagyi GN, DiStefano A, Legha SS, Buzdar AU, Blumenschein GR Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep 63(4):539-41, 1979. PMID: 221118.
161. Hortobagyi GN, Richman SP, Dandridge K, Gutterman JU, Blumenschein GR, Hersh EM Immunotherapy with BCG administered by scarification: standardization of reactions and management of side effects. Cancer 42(5):2293-303, 1978. PMID: 363257.
162. Jaimes A, Hortobagyi GN, Henao GM, Leon PJ, Leon MA Diagnostico del Enterobius Vermicularis por el Método de la Cinta Adhesiva. Reportes de Parasitología. Universidad Nacional de Colombia. June 1969, 1969.
163. Leon Galindo MA, Rubiano-Groot Ribon H, Hortobagyi GH, Leon Galindo J, Prada Gomez A, Nieto Paez R Algunos Rasgos Epidemiologicos del Aborto en Columbia. Universidad Nacional de Colombia. February 1969, 1969.